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   Balloon angioplasty was the first non-surgical therapeutic modality for coronary artery 
disease introduced in 1977. It was related with high rates of acute complications and restenosis 
that limited its application to a minority of patients with coronary artery disease with relatively 
simple lesion morphology. Continuous developments during the next decade led to the 
introduction of stents in 1986. They were proven extremely efficient in reducing acute 
complications, dramatically expanding the indications for percutaneous interventions. In 
addition they were associated with favourable outcome in reducing restenosis compared to 
balloon angioplasty but they were also limited by the development of in-stent restenosis. In-
stent restenosis remained a therapeutic challenge for almost a decade and many mechanistic 
and pharmacological attempts failed to solve it. Ionic forms of radiation (radioactive stents and 
localised catheter based intracoronary radiation therapy) were introduced. Radioactive stents 
showed no benefit compared to conventional stenting. However intracoronary brachytherapy, 
which was first applied in human coronaries in 1995, was proven effective for the treatment of 
in-stent restenosis (secondary prevention of restenosis). Its efficiency for treatment of de novo 
lesions (primary prevention of restenosis) especially in combination with the use of stents is 
limited. In 2001 drug eluting stents were introduced into clinical practice and they 
revolutionised the treatment of coronary artery disease. They are the first therapeutic modality 
in interventional cardiology expected to show equal or superior results in comparison to 
coronary artery by pass surgery. 
   In Europe were conducted the majority of the human trials with radioactive stents and 
pioneering and exploratory studies with intracoronary radiotherapy with catheter based systems 
mainly with beta emitters for de-novo lesions. This thesis addresses issues central to both of 
these therapeutic modalities. 
It consists of two parts:  
Chapter 1  Is the introduction and overview of the thesis. 
In Part I (chapters 2-15) we present our experience with intracoronary radiation therapy with 
catheter based systems. 
Chapter 2  Is an introduction to the principles of radiation and summarises our and the 
international experience with this therapeutic modality. 
Chapter 3  Describes the developments in Quantitative Coronary Angiography necessary to 
describe the implications of edge restenosis and relocation of the minimal 
luminal diameter observed after intracoronary radiation therapy which occurs in 
a significantly higher incidence compared to standard techniques.  
Chapter 4  Reports on our initial experience with intracoronary radiation therapy with the 
Beta Radiation In Europe registry. This was the registry that introduced 
brachytherapy in Europe. Both the problems of edge restenosis and late vessel 
occlusion became evident in this registry. The sponsoring company organised a 
randomised trial in USA without waiting for the results of this registry which 
resulted in the negative Beta-Cath trial. 
Chapter 5 Is a case report describing the application of beta radiation under challenging 
anatomical conditions. 
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Chapter 6 Summarises our experience and the outcome of unselected patients treated with 
intracoronary radiation therapy in a routine fashion (RENO registry). 
Chapter 7 Is a detailed angiographic analysis of patients enrolled in the BRIE registry with 
focus on the concept of geographical miss. We found a strong association with 
geographical miss and edge restenosis. 
Chapter 8 The same angiographic analysis described in the previous chapter was 
performed in patients treated according to the protocol of the Dose Finding study. 
No association between geographical miss and edge restenosis was documented 
in this study. 
Chapter 9 Summarises the differences between the BRIE and Dose Finding studies 
explaining the differential outcome in relation to geographical miss and gives a 
final answer for its strong association not only with edge restenosis but also with 
the overall angiographic outcome of patients treated with beta radiation therapy. 
Chapter 10 Describes the intravascular ultrasound finding of the “black hole”, an echo 
lucent tissue, as a limitation of intracoronary brachytherapy. 
Chapter 11 Describes the unfavourable long term outcome of patients treated with 
intracoronary beta radiation therapy in our institution. 
Chapter 12 Is a case report describing a total occlusion 5 years after intracoronary 
brachytherapy in a patient treated according to the BERT protocol. 
Chapter 13 Reports on the high incidence of late total occlusion observed after intracoronary 
beta radiation therapy and the unfavourable clinical outcome of these patients. 
Late silent or thrombotic occlusion remains the main and unfortunately 
unresolved limitation of brachytherapy. 
Chapter 14 Describes the long term clinical outcome of patients treated with percutaneous 
interventions after brachytherapy failure. 
Chapter 15 Reports on the modest efficiency of sirolimus eluting stents to treat 
brachytherapy failures in a small cohort of patients. 
In Part II (chapters 16-18) we present our experience with radioactive stents. 
Chapter 16 Is an intravascular ultrasound analysis that unravels the mechanism of restenosis 
after cold-end radioactive implantation, a modification that failed to eliminate 
the problem of edge restenosis observed after conventional radioactive stents. 
Chapter 17 Reports on the mid term outcome of patients after radioactive stent implantation 
and the problem of delayed restenosis observed with this therapeutic modality. 
Chapter 18 Presents the long term outcome of patients after radioactive stent implantation 
which despite the early failure of this treatment is not associated with long term 
irreversible sequealae. 
Chapter 19 Summarises the thesis and quotes the conclusions 
CHAPTER 2 
Sianos G, van der Giessen W, de Feyter P, Smits P, Hofma S, Mc 
Fadden E, Serruys PW 
Intracoronary Radiation Therapy 
Marco J, Serruys PW, Biamino G, Fajadet J, de Feyter P, Morice MC 
(Eds): The Paris course on revascularisation. Paris: Europa 
edition.2003. ISBN 2-913628-12-5, pages 243-264 
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Introduction
Following coronary balloon angioplasty, restenosis of the
dilated segment occurs in 30% to 50% of patients and results
from elastic recoil, neointima formation, and negative remod-
elling1,2. The advent of coronary stenting reduced restenosis
to 15% in certain type of lesions3,4, but introduced the even
more difficult to treat in-stent restenosis5. Brachytherapy has
been introduced as a promising technique for primary and
secondary prevention of restenosis.
Most of the randomized clinical trials were conducted in the
U.S.A. In Europe, experience has been gained with beta-radiation
with pilot studies and registries, while gamma radiation has been
used in a few centers and few patients. Important reasons are the
strict regulatory requirements regarding shielding, storage and
transportation of these sources.
A number of points have become evident in coronary application
of radiation. First, radioactive stents do not show overall
beneficial therapeutic effect. Second, beta-radiation therapy
seems to be as effective as gamma in the mid-term follow-up.
Third, vascular brachytherapy is effective for the treatment of
in-stent restenosis, but its effectiveness in de novo lesions with
new stent implantation is ambiguous. For the coming years, the
questions regarding the duration of anti-thrombotic treatment,
the long-term outcome and the benefit in de-novo lesions in
patients at very high risk for restenosis have to be answered.
This chapter summarizes the clinical experience and gives an
overview of the current practice.
Definition
Brachytherapy is derived from the Greek "EUDF cX9" (brachy)
meaning short and "THUDSHcLD" (therapy) meaning treatment
to describe the application of radioactivity by a sealed source
at a very short distance to the target tissue, e.g. by intracav-
itary or interstitial source placement. Recently, the term
vascular brachytherapy has been introduced to describe
endovascular radiation therapy.
Rationale
Radiotherapy has been proven successful in the treatment of
hypertrophic scars, keloids6, ophthalmic pterygia7, hetero-
topic bone formation8 and solid malignancies9. In non-
malignant diseases, radiation inhibits efficiently fibroblastic
activity, without influencing the normal healing process, and
without causing significant morbidity during long term
follow-up of up to 20 years. Brachytherapy has the physical
benefit that very high doses of radiation can be delivered
directly or almost directly to the target.
Basic radiation physics
Radioactivity
Radioactivity is the spontaneous process in which an unstable
nucleus, which has either too many or too few neutrons, turns to a
stable state (ground state) whereby superfluous energy is released.
The release of energy is called radiation, which can be in the
form of electromagnetic waves, like gamma radiation, or of
particle rays, like alpha, beta and neutron rays. This process
is often called the "disintegration" of an atom.
The activity (A) can be expressed by the quotient of the
number of disintegrations (dN) within a time interval (dt).
The mathematical expression for the activity is:
A = -dN/dt with the unit bequerel (Bq) according to the inter-
national system (SI) for units. This unit replaces the formerly
used unit curie (Ci) whereby 1Ci = 37 1010 Bq.
Decay
For most atoms the activity is proportional to the number of
nuclei (A=ON). The proportionality constant is called the
decay constant. This leads to the decay law: At=A0exp(-Ot),
and O=ln2/T1/2 whereby T1/2 is called the "physical half-life
time", being the time that the original activity of a nuclide
has been reduced with a factor two. The physical half-life
time is characteristic for nuclids (distinct nuclear species)
and isotopes (various forms of an element).
Biological half-life
Biological half-life is used for the time needed by the body to
eliminate one-half of an administered amount of any
substance by regular process of elimination.
This time is approximately the same for both, stable and
unstable isotopes of the same element.
Effective half-life
In case radioactive material is ingested in the human body,
both, physical and biological half-live, have to be considered.
Combination of both half-lives gives the effective half-life,
which can be expressed by 1/T1/2eff = 1/T1/2phy + 1/T1/2biol.
Half-lives can be replaced by the physical and biological
decay constants: Oeff = Ophy + Obiol.
Absorption - radiation dose
The released energy during transformation of an unstable
atom into a stable atom is absorbed in tissue. The quantity of
absorbed energy in a tissue is called the "dose" with the SI
unit Gray (Gy=J/kg). The dose is strongly dependent of the
type of radiation (activity and decay) and the time span, also
called "dwell time".
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Radiation dose rate
Dose rate is the dose of radiation per time (delivered or
received). The dose rate delivered by a source depends on the
activity of the source and the radionuclide that it contains.
Currently, all vascular brachytherapy sources deliver energy at
high dose rate.
Dose
Biological effects of the absorbed radiation are dependent on
the type of radiation and the type of tissue, which is
irradiated. The unit of the dose is joules per kilogram (Jkg-1)
and is called Sievert (Sv).
Radiation weighting factor (WR)
A correction factor that indicates the harmfulness of the type
of radiation involved.
Tissue weighting factor (WT)
The tissue-weighting factor indicates the sensitivity of an
organ/tissue to radiation.
Equivalent dose (HT)
The equivalent dose is a quantity used for radiation
protection purposes. It takes into account the probability of
effects. It is defined as the product of the averaged absorbed
dose in a specified organ or tissue (DT) and the radiation-
weighting factor (WR).
HT = WRDT.
Effective dose (HE)
The sum of the products of the equivalent dose to the organ
or tissue (HT) and the tissue weighting factor (WT) applicable
to each of the body organs or tissue that are irradiated.
HE = ¦WRWTDT.
Isodose
Descriptive of a locus at every point of which the absorbed
dose is the same.
Isotopes
The most important physical properties of currently used
isotopes in vascular brachytherapy are listed below:
Isotope Emission Max. Energy Av. Energy Half-life
192Ir gamma 612 keV 375 keV 74 days
90Sr/90Y beta 2270 keV 565 keV 28 years
32P beta 1710 keV 690 keV 14 days
90Y beta 2270 keV 970 keV 64 hours
188Re beta 2130 keV 780 keV 69 days
Other potential candidates are the following:
Isotope Emission Max. Energy Av. Energy Half-life
106Rh beta 923 keV 307 keV 2.2 hours
48V positron 696 keV 144 keV 16 days
125I X-ray 35 keV 28 keV 60 days
103Pd X-ray 21 keV 21 keV 19 days
These isotopes show important physical differences. Basically,
gamma radiation consists of photons, beta radiation of electrons.
Gamma radiation
Gamma rays are photons originating from the nucleus of a
radionuclide, which take the form of electromagnetic
radiation. A heavy unstable nucleus will emit an alpha
(heavyweight charged particle, which can travel only very
short distances within tissues) or beta particle followed by
gamma radiation. Gamma rays may have either 1 or 2 discrete
energy values or a broad spectrum of many energy values.
They penetrate deeply within tissues.
X-ray radiation
X-rays are comparable to gamma radiation. Their physical
characteristics are similar, however, their origin is different.
While the photons of gamma radiation originate from the
nucleus, the photons of x-rays originate from the electron
orbit. X-rays used in catheterization laboratories have an
energy level of maximal 125 kVp.
Beta radiation
Beta particles are lightweight high-energy electrons, with
either positive or negative charge. When beta particles, which
can travel only finite distances within tissues, are slowed
down by nuclei interactions, they give rise to high
penetration X-rays, called Bremsstrahlung.
Major differences between
gamma and beta radiation
The interaction of photons with other material is much lower
than the interactions with electrons. That means, the energy
transfer to other material is less intensive for gamma than for
beta radiation. In the setting of brachytherapy, this has two
major consequences.
1. Dwell time: to obtain a defined dose in a tissue at a
certain distance from a source, gamma sources require
much higher activities or much longer dwell times in
comparison to beta sources.
2. Radiation exposure: the exposure to the staff inside and -
because of deep tissue penetration- outside the catheteri-
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zation laboratory is much higher during treatment with
gamma radiation than beta radiation. In consequence,
staff should leave the catheterization laboratory during
radiation treatment and additional shielding facilities
have to be implemented.
The clinically and practically most relevant advantages and
disadvantages are as follows:
Gamma radiation
Pro's:
• Deep tissue penetration (ideal for large vessel diameters)
• No attenuation of Ir -192 gamma radiation by stent struts
(ideal for in-stent restenosis)10,11
Con's:
• Extensive shielding required (25mm lead)
• High radiation exposure for patient and staff
• Staff has to leave catheterization laboratory
• Long dwell times (8-20 min)
Beta radiation
Pro's:
• Simple shielding by means of thick plastics
• Short dwell times (3-10 min)
• Radiation exposure to the patient only local
• Radiation exposure to staff is negligible
• Staff can remain in the catheterization laboratory
Con's:
• Probable not able to treat vessels with diameters >4 mm
(with existing devices)
• Inhomogeneity of the dose (potentially centering device
required)
• Partially shielded by stents and calcified plaques
• Dose distribution calculations of beta emitters are more
complicated.
Mechanisms of action
Cell biological effects
Absorbed radiation can cause damage in a tissue either
directly by ionization or indirectly by interacting with other
molecules to produce free radicals, which will subsequently
damage the critical target. Approximately 80% of the radiation
damage is caused by these free radicals. The most critical
target is DNA12. In consequence, early and late toxic effects in
normal tissue are mainly caused by cell death.
These biological effects are independent of the radiation type
(gamma, beta or X-rays) whereas total radiation dose and dose
rate are of major importance, since damage caused by
radiation can be repaired between fractionated doses or
during low dose rate exposure13. Furthermore, there seems also
to be an inverse dose rate effect in human cells most probably
by blocking cells in the mitosis (G2) phase of the cell cycle at
low dose rate (approx. 6 mGy/min), which is known to be more
radiosensitive, thereby causing more cell death.
Experiments with human cells addressed long-term effects of
radiation. Human aortic cells show a significant decrease in
their clonogenic potential after radiation. Modulation of the
subsequent repopulation of the surviving cells under the
assumption that the repopulation kinetics were similar to
those in non-irradiated cells, revealed a delay by factors of
approximately 6 to 8. This would shift the time to restenosis
from a median of 6 months in non-radiated cells to median
values from 36 months (for 13Gy) to 43 month (for 15 Gy)14.
Experimental data
In injured vascular tissue, radiation doses of 12-20 Gy appear
to be efficacious in inhibiting neointimal formation in various
animal restenosis models15-17. The local mechanisms of action
and time course are complex, dose dependent and poorly
understood. Possible high dose radiation effects include an
anti-angiogenic effect18 and decrease of smooth muscle
cells19 on the adventitia, selective inactivation of smooth
muscle cells20 and myofibroblasts21, or complete elimination
of their proliferative capacity at doses >20 Gy. Application of
lower dose could mean that restenosis would only be delayed
for the period of time necessary for the population of smooth
muscle cells to regenerate.
Furthermore, low dose radiation even promotes cellular
growth. Low dose radiation (±2 Gy) has been shown to poten-
tiate cellular metabolic activities22 and hormesis (immuno-
logic response) in various tissues (splenocytes23,
thymocytes24, macrophages25 and hematopoietic cells26).
Furthermore, in experimental studies of endovascular
brachytherapy it was shown that relatively low-doses (±10Gy)
caused a paradoxical increase in tissue response27,28.
Long-term experiments in normal porcine coronary arteries
after balloon injury and beta radiation showed that
neointima formation is not inhibited at 6-month follow-
up29,30. Un-resorbed thrombus was an important contributor
of augmented neointima formation. The adventitia showed
thickening with substantial collagen accumulation29. Fatal
subacute and late thrombosis was seen at 5 days, 7 days,
3 months and 4 months after the index procedure. The animals
had received the combination of aspirin and ticlopidin for
30 days after the index procedure and continued aspirin
therapy until sacrifice30.
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In a balloon injury porcine restenosis model intracoronary
radiation was related with increased thrombogenicity in a
dose-dependent manner. This was more often a non-
obstructive non luminal thrombus rather than an luminal
thrombus and its morphology appeared to be less organized
than the pattern of thrombosis observed in non irradiated
injured arteries indicating that might not related with
compromise the of the lumen volume31.
In a porcine model, balloon injury and intracoronary
radiation therapy altered the passive mechanical properties
of the arterial wall. Furthermore, receptor operated release
of endothelium-derived nitric oxide and endothelial hyper-
polarising factor were reduced by brachytherapy and injury
alone and completely prevented by their combination32. In
a rat model endothelial function was fund to be impaired up
to six months after irradiation without concomitant
injury33.
There is increased evidence in animal models that radiation is
related with delayed and incomplete endothelalisation18 and
that the new endothelium might be dysfunctional. An
example is given in figure 1.
Clinical trials
Over the last years, radiation has been applied in various ways
to human coronary arteries, using different sources and mode
of applications. This includes catheter-based line sources,
radioactive stents, radioactive wires, liquid filled balloons34.
The latter have been used in few patients only, whereas there
is considerable clinical experience with catheter-based line
sources and radioactive stents.
Catheter-based line sources
Clinical trials (Figure 2) have been completed for both,
gamma (Table 1) and beta radiation (Table 2), and for
different lesion types.
Figure 1.
An example of incomplete endothelialisation with exposed stent struts 3 months after stentimplantation and brachytherapy (15Gy) in a
porcine coronary artery.
Figure 2.
Overview over clinical brachytherapy trials with catheter-based
line sources.
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Table 1. Results of gamma radiation trials
Study No pts Dose (Gy) Lesion length Source Restenosis rate MACE %
SCRIPPS 53 8-30* <30 Ir-192 17 15
Placebo 54 48
WRIST-gamma 130 15** <47 Ir-192 22 35
Placebo 60 68
Long WRIST 120 15** 36-80 Ir-192 46 32
Placebo 78 63
Long WRIST HD 120 18** 36-80 Ir-192 N/A 23 (1m plavix)
17 (6m plavix)
SVG WRIST 120 14-15*** <47 Ir-192 21 32
Placebo 44 63
WRIST PLUS 120 14** <80 Ir-192 34 23 at 6m
35.8 at 15m
WRIST 12 120 14 <80 Ir-192 N/A 13.4 at 6m
20.8 at 15m
GAMMA-1 252 8-30* <45 Ir-192 33 28
Placebo 55 44
GAMMA-2 125 14** <45 Ir-192 34 30
MACE = major adverse cardiac events, N/A = not available, No pts = number of patients,
*to the external elastic membrane, **at 2 mm from the source, ***at 2-2.4 mm from the source depending on the vessel size.
Table 2. Results of beta radiation trials
Study No pts Dose (Gy) Lesion length Source Restenosis rate % MACE %
Geneva 15 18* <20 Y-90 40 33
BERT 20 12,14,16** <15 Sr/Y 90 15 15
BERT 1.5 35 12,14,16** <20 Sr/Y 90 11 11
BRIE 149 14** <22 Sr/Y 90 34 34
Dose Finding 181 9,12,15,18† <15 Y-90-9Gy all 29
Y-90-18Gy all 15 15
Y-90-9Gy balloon 28
Y-90-18Gy balloon 4
Beta-Cath 1455 16,20** <15 Sr/Y 90 balloon 31 14
Placebo balloon 36 21
Sr/Y 90 stent 44 28
Placebo stent 34 17
PREVENT 96 16,20,24‡ <22 P-32 22
Placebo 50 32
START 30 396 18,23** <20 Sr/Y 90 29 19
Placebo 45 29
START 40 207 18,23** <20 Sr/Y 90 25 19
INHIBIT 332 20 Gy‡ <47 P-32 26 24
Placebo 52 34
Beta WRIST 50 20.6 <47 Y-90 34 34
Placebo+ 71 76
BRITE 32 20† <24 P-32 9 3
MACE = major adverse cardiac events, N/A = not available, No pts = number of patients,
* at the inner arterial surface, ** at 2 mm from the source, † at 1mm from the balloon, ‡ at 1mm into the vessel wall, + control group from gamma-WRIST.
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Safety and feasibility studies
Human coronary arteries were treated for the first time by
Condado in 1995 in Venezuela. De novo lesions where treated
by balloon angioplasty followed by gamma-radiation (Ir 192).
No restenosis was observed after 6 months35.
The GRANITE registry is the only multicenter gamma radiation
trial conducted in Europe. A low-dose iridium-192 source was
used 96 in patients undergoing percutaneous revascular-
ization for in-stent restenosis. At six month, event-free
survival was 70%, the angiographic restenosis rate 32%.
Three-year follow-up is pending36.
In 1997, Verin reported the feasibility of beta sources after
balloon angioplasty37. The BERT trial used beta-radiation
(90Sr/90Y) in 23 patients after successful balloon angioplasty.
Follow-up quantitative coronary angiography at 6month showed
a late loss of 0.05mm and a restenosis rate of 15%38.
BRIE was the registry that introduced beta radiation in
Europe. In total 149 patients were enrolled and received 14Gy
at 2mm from the source with restenosis rate of 34% and MACE
of 34%39. It was one of the first trials who unravelled the
problem of edge restenosis and correlated it with the
geographical miss40.
BRITE was the safety and feasibility study with the beta
emitting, P-32 balloon source for in-stent restenosis;
32 patients received 20 Gy with very low restenosis rate
(9.7%) and MACE (3%)41.
Efficacy trials
Randomized, double blind, placebo-controlled trials or non
randomised trials using for comparison the placebo arms of compa-
rable randomised trials, have been completed for both gamma and
beta radiation, and for different lesion types (Figure 3).
Gamma radiation trials
The SCRIPPS trial demonstrated first the effectiveness of 192-
Ir gamma therapy for the treatment of de-novo and in-stent
restenotic lesions in 55 randomized patients42.
The gamma-WRIST was the first randomised trial (130 patients)
with gamma radiation for in-stent restenosis; the irradiated
patients had improved angiographic and clinical outcome43.
The GAMMA-1 multi-center randomised trial (252 patients),
with IVUS based dosimetry reconfirmed the beneficial effect
of gamma radiation in the treatment of in stent restenosis,
but it was limited by the high incidence of stent thrombosis,
5.3%44. The GAMMA-2 trial with simpler no IVUS based
dosimetry gave the same good results as the GAMMA-1 trial.
The efficacy of gamma radiation for the treatment of long
restenotic lesions (up to 80 mm) was confirmed in the LONG WRIST
randomised trial, but a very high incidence of 15% late total
occlusion was observed. The higher dose and the prolonged
antiplatelet treatment prescribed in the LONG WRIST high dose
registry, further improved the angiographic parameters and elimi-
nated the problem of the late thrombosis and occlusion.
The efficacy of gamma radiation for the treatment of in-stent
restenosis in the vein-grafts was proved the SVG-WRIST
randomised trial45.
Beta radiation trials
• De novo lesions
The PREVENT trial used a centered beta-emitting (32) P
source wire. Patients with de novo or restenotic lesions
received 0 (control), 16, 20, or 24 Gy. The clinical and angio-
graphic outcome was better in the irradiated patients46.
In the Dose Finding study 181 patients randomly assigned to
receive 9, 12,15,18 Gy at 1mm from the centering balloon
Figure 3.
Outcome of randomized brachytherapy trials at 6-month follow-up. a. Angiographic restenosis b. Major adverse cardiac events (MACE).
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surface. Restenosis was reduced in a dose related manner with
better angiographic outcome for the patients received the
higher dose. An important observation was that patients
treated with balloon angioplasty alone had the best outcome
with a restenosis rate of 3.9% at 18 Gy47.
The Beta-cath trial was the largest randomised trial of beta-
radiation for de-novo lesions (1455 patients). It failed to show
any difference in the primary end point, the target vessel
failure, in the combined radiation arms compared to the
placebo arms48. In the balloon group the reduction in binary
restenosis observed with radiation in the lesion segment was
not maintained in the vessel segment analysis. Even worse in
the stent group the significant reduction in the stented
segment inverted to a significant increment in the analysis
segment with worse outcome in the radiation group. The late
vessels thrombosis, the edge restenosis and the incompatibility
of radiation with the use of stent for de novo lesions were the
main lessons learned from this negative study.
In the multicenter BRIDGE randomized the concept of direct
stenting followed by irradiation in combination with IIb-IIIa
antagonists and prolonged antiplatelet up to 11 months was
addressed, aiming to eliminate the two major problems of the
combination of radiation with stenting; the edge restenosis and
the late vessel occlusion/thrombosis49. In total 112 patients
randomised and 58 received 20Gy at 1mm in the vessel wall with
a centred P-32 wire. The restenosis rate was 9% (15% in the
control group) without edge restenosis but the problem of late
thrombosis was not solved (10% in the radiation group).
• In stent restenosis
The beta-WRIST registry examined the beta-emitter 90-
yttrium for the prevention of recurrent in-stent restenosis in
50 consecutive patients, which underwent PTCA, laser angio-
plasty, rotational atherectomy, and/or stent implantation
followed by radiation with a 90-yttrium centered source. At
6 months, the binary angiographic restenosis rate was 34%,
the target vessel revascularization rate and MACE were 34%50.
The START 30 trial was a multicenter randomized, placebo-
controlled, trial, with the Beta-Cath System using Sr-90 in
476 patients with recurrent ISR following successful coronary
intervention51. The restenosis rate within the vessel segment
was reduced by 36%, MACE was reduced by 31%; target vessel
revascularization was reduced by 34%. The positive results
observed in the START 30 were confirmed in the START 40
registry with the longer source52.
The INHIBIT was the randomised trial used a centered P-32
beta emitting source for the treatment of in-stent restenosis;
332 patients received 20 Gy. Significant reduction in the
restenosis rate and the MACE was observed53.
Routine use registries
The RENO registry is a large post marketing surveillance registry.
At 47 centers in Europe and Israel 1032 patients were prospec-
tively included for treatment with standard angioplasty (balloon,
stent, laser, rotational and/or directional atherectomy) followed
by beta-radiation therapy (90-Sr/Y source). At 6-month follow-
up, the MACE rate was 18.7% (with 1.9% death, 2.6% AMI (Q or
non-Q), 16.3% target vessel revascularization) and the
composite endpoint of late thrombosis 5.4%54.
Clinical observations
Positive vessel remodelling
Balloon angioplasty followed by irradiation predominantly
shows an increase in minimal lumen diameter at the treated
segment at follow-up35. This is in contrast to standard balloon
angioplasty, where late lumen loss caused by neointimal
growth and vessel shrinkage is the usual response55. Irradiation
inhibits neointimal growth56, may prevent shrinkage after
balloon angioplasty57 and even promote positive remodelling at
the treated segments58. Promotion of positive vessel remod-
elling is dose dependent47 and has been well documented with
IVUS observations indicating increment of the total vessel
volume and subsequently the lumen.
Late stent malapposition
The positive remodelling and tissue erosion around a previ-
ously well deployed stent combined with irradiation, will lead
to late stent malapposition with blood flow behind the
struts59. An example is presented in figure 4.
Persistent dissections
Healing is the natural history of post-angioplasty dissections.
Radiation appears to change the normal healing process
resulting in unhealed dissection. An incidence of 40%
persistent dissections has been reported at 6 months after
irradiation60,61.
Late occlusion
Early in the clinical phase, a new phenomenon became
apparent, that of late occlusion62. Possibly causes are
increased thrombogenicity, delayed endothelialisation,
persistent dissections, late stent malapposition. There are
two forms depending on the clinical presentation:
a. Late total occlusion, usually asymptomatic, related with
accelerated formation of restenotic tissue (figure 5).
b. Late thrombotic occlusion, always related with related with
acute thrombosis leading to an acute coronary syndrome.
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Figure 4.
(A) Longitudinal view of 3-D intravascular ultrasound (IVUS) image reconstruction at baseline; (A') schematic model of 3-D IVUS image
reconstruction at baseline; (B) longitudinal view of 3-D IVUS image at follow-up (arrowhead indicates the site of positive remodelling and
malapposition). (B') schematic model of 3-D reconstruction IVUS image at follow up; (C) post-procedure IVUS cross-sectional image at the
site where stent mallaposition appeared at follow up; (C') schematic model of IVUS cross sectional image at baseline; (D) IVUS cross-
sectional image at follow up (the arrowhead indicates a space behind the stent at 2-5 o'clock-positive remodelling leading to stent malap-
position). (D') schematic model of IVUS cross sectional image at follow-up; (E) graphic of external elastic membrane (EEM) and stent areas
at baseline (upper line: EEM area, lower line: stent area); (F) graphic of EEM area and stent area at follow up (upper line: EEM area, lower
line: stent area) (arrowhead indicates the local EEM increased from nearly 20mm2 to more than 25 mm2; positive remodelling).
An overview of the incidence of late occlusion/thrombosis in
various clinical trials is presented in figure 6. Initial clinical
trials prescribed a combined antithrombotic treatment
(aspirin and clopidogrel or ticlopidin) of 2 or 4 weeks after
the index procedure. The first observation was that most of
the acute events were presenting after discontinuation of the
double antiplatelet treatment. In consequence, prolonged
combined antithrombotic treatment was recommended. Two
trials addressed the issue of prolonged antiplatelet treatment
for the prevention of late occlusion/thrombosis. In the WRIST
PLUS63 trial clopidogrel and aspirin were prescribed for
6 months and in the WRIST 1264 for 12 months. Both showed
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good results at 6 months follow up, but at 15 months the
incidence of occlusion/thrombotic rates were unacceptably
high; 15.9% in the WRIST PLUS and 13.5% in the WRIST 12.
The second observation was that new stent implantation was
related with late thrombosis both for de novo48 and restenotic
lesions65.Therefore at least for the treatment of in-stent
restenosis it is recommended to be avoided.
The evolving clinical important question is the duration of
platelet inhibition and whether or when to stop clopidogrel
prescription. Current data suggest that combined antithrom-
botic medication for 12 months might be inadequate and
probably should be prescribed indefinitely following intra-
coronary radiation treatment.
Edge restenosis and geographical
miss
Restenosis at the edges of the irradiated segment is the
second major limitation of brachytherapy. It was first
described after radioactive stent implantation named as
"candy wrapper" or "edge effect"66. An example after
catheter based beta radiation is presented in figure 7. In
almost all the brachytherapy trials reported, there is a 10-
15% increment in the restenosis rate observed between the
segment that received radiation and the total analysed
segment. This was a new phenomenon in interventional
cardiology, the edge restenosis, and changed the way we
interpret and report the results of brachytherapy trials in
comparison with historical trials. By IVUS, edge restenosis, is
Figure 6.
Incidence of late total and late thrombotic occlusion after
catheter based intracoronary radiation therapy.
Figure 5.
Clinical example of late total occlusion after balloon dilatation and beta radiation in the left anterior descending coronary artery. The
patient was enrolled in the BERT trial and brachytherapy was performed with the 90Sr/90Y beta source. The vessel remained patient without
restenosis at 3 years and occluded 5 years after the index procedure.
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a combination of increase in plaque volume without adaptive
remodelling56,67,68.
In concordance with known cell biological effects and animal
data, low dose radiation at the extremities of the source and
angioplasty induced vessel injury, referred as "geographical
miss" seems to play a key role in edge restenosis and
treatment failure for beta69,40 and gamma70,71 brachytherapy
(figure 8). This is conformed by experimental studies which
could demonstrate that the edge effect is associated with the
combination of periprocedural vessel injury and radioactive
dose fall-off at the extremities of the source72. The fall-off the
dose at the source edges is a inherent characteristic of all the
sources, beta or gamma, and must be taken into account
during application of radiation (figure 9).
Safety margins
The safety margins after brachytherapy for avoidance of
geographical miss and subsequently edge restenosis have not
yet been defined. Many factors such as the extent of the
perivascular injury, which can extent up to 10 mm away from
the microscopic injury73, the barotrauma caused by the
balloons which can be up to 2.5mm away from the actual
stent margins74, the source displacement during the cardiac
cycle (up to 5.4 mm)75, and the fall-off the dose at the
margins of each source must be taken into account.
It was proposed that for an 18mm lesion treated with a 20mm
balloon, a 39 mm Iridium source should be used76. In an
animal model a safety margin of 14.5 mm was sufficient to
eliminate edge restenosis77. Recently a 10mm safety margin
per vessel found to have 95% specificity for avoidance of
GM71. As a general simple rule a ratio of one to two for the
lesion to source length is advised. The availability of longer
sources and stepping application of radiation will help for the
elimination of geographical miss. In recently conducted trials
such as the BRIDGE and BRITE in which the problem was
known and prevented by protocol, edge restenosis was not an
issue.
Beta versus gamma radiation:
efficacy, impact of vessel size,
lesion length and failure modes.
From meta-analysis of trials for in-stent restenosis the
following have been observed:
a. Gamma and beta radiation have similar efficacy at dose
tested in clinical trials. Beta radiation is more effective for
inhibiting restenosis in the stent but it is associated with
greater incidence of edge failures (figure 10).
b. When failing, both modalities change the pattern of
restenosis at more focal lesions. The more diffuse the
lesion is at baseline the greater the reduction of lesion
length at follow up.
c. Gamma brachytherapy appears to have a consistent
treatment effect at all vessel sizes and lesion lengths
d. Beta brachytherapy appears to have greater treatment
effect the larger the vessel size and the longer the baseline
lesion length.
Figure 7.
A clinical example of bilateral edge restenosis or "candy wrapper" effect. a) Baseline angiogram of a large, diffusely diseased intermediate
branch with a focal subtotal lesion. The patient was treated with stent implantation and beta radiation according the BRIE study protocol
(Beta-cath 90Sr/90Y source). b) at 6 months follow-up significant lumen narrowing at the proximal and at the distal extremities of the stent,
referred as "edge effect" or "candy wrapper", was observed. The difference in the pattern of stenosis, as a result of radiation is obvious.
28
Chapter 2
Long-term outcome
Progressively, long-term follow-up data of patients, which
had received intracoronary brachytherapy, are becoming
available. Major concerns are possible late catch-up with
increased lumen loss at the treatment site, delayed restenosis
and delayed major adverse clinical events.
The three-year follow-up of the SCRIPPS trial demonstrated an
decrease in mean minimal luminal diameter between 6months
and 3 years from 2.49±0.81mm to 2.12±0.73 mm in the
irradiated patients, whereas the minimal lumen diameter was
unchanged in placebo patients. This angiographic finding,
however, was not associated with clinical events. The target-
lesion revascularization was significantly lower in the (192) Ir
group (15. 4% versus 48.3%) as was the restenosis rate (33%
versus 64%)78. At five years follow up of the same study the
target lesion revascularisation increased to 23.1% in the
irradiated patients while remained unchanged in the placebo
group and there was no more difference between the two groups
in any revascularisation or the composite end point of death,
myocardial infarction of target vessel revascularisation79.
A two-year follow-up is available of the (192) Ir WRIST and
BETA-WRIST patients. Irradiated patients had significantly
lower rates of target vessel revascularizations than the
placebo WRIST patients at 2 years. Beta and gamma radiation
were independent predictors of event-free survival at 2 years.
However, between 6 months to 2 years, significant rates of
target vessel revascularization (14%) were noted in both
radiation groups, yet no revascularization was required in
placebo WRIST patients (p <0.05)80.
We followed 302 patients treated with brachytherapy in
Thoraxcenter since 1997. The mean duration was 38.7 months.
At six months the event free survival rate was 75%, but at
4 years only 42% (figure 11). The same progression was also
noticed in the target lesion revascularisation, 8.3% at six
months, 19.9% at 12 months, 23.8% at 24 months and 28.5%
at 4 years, indicating that brachytherapy delays rather than
inhibits the restenosis process81.
Radioactive stents
The results of radioactive stents were disappointing and could
not be favourably influenced by modification in design and
activity66,82,83,84,85. The outcome at 6 months showed a high
rate of clinical events and restenosis (up to 50%), preferably
at the edges of the stent66, called the "candy wrapper".
Moreover delayed restenosis was also observed at longer follow
up86 and their use never found a place in routine practice.
Figure 8.
A clinical example of geographical miss leading to edge
restenosis. At baseline a significant lesion in the proximal part
of the left anterior descending coronary artery can be seen. The
patient was treated with stent implantation and beta radiation
with the Beta-cath 90Sr/90Y source. The proximal part of the
injured vessel (stent implantation) was not completely covered
by the radiation source and consequently received inadequate
dose, leading to geographical miss (GM) as indicated by the red
dotted lines. The coloured vertical lines are confirming the
correct alignment of the frames; blue for the carina, yellow for
the balloon markers and green for the radiation delivery
catheter markers. At six months a focal stenosis at the part of
the vessel that was injured and received low dose (geographical
miss) can be seen (edge restenosis).
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Radiation protection and
safety considerations
Radioactive material cannot be turned off. Therefore, secure
control of the radioactive inventory and surveillance of staff
and patients is of special concern.
Figure 9.
Fall-off the dose and its relation with geographical miss (GM). Right side: dosimetric characteristics of the 90Sr/90Y beta-cath source. At
the last 2.5mm at the edge of the source the dose drops by 50% and at the end of the radiopaque gold marker (RGM) is almost negligible.
Angiographic, the drawing corresponds to the insert in the left corner of the left image which is a magnification of the proximal part of
the source in frame (d). It is important to realise that dose starts to drop 2.5mm within the length of the active source (red line) which
is almost 7-8mm away from the delivery catheter marker (DCM), usually used for the positioning of the source. Left side: Angiographic
example of GM. a) tandem lesion in the proximal left anterior descending coronary artery. b,c) balloon dilatations. d) The radiation
delivery catheter and radiation source 30mm in length. The source is short to cover the long injured segment by the sequential balloon
inflations causing GM as indicated by the green vertical lines. The mismatch at the proximal edge is obvious (gross GM). At the distal edge
it corresponds exactly at the fall-off of the dose zone, the last radioactive seed and distal radiopaque gold marker, as indicated by the
arrowheads (subtle GM).
Figure 10.
Comparative efficacy of beta and gamma radiation therapy
versus placebo for in-stent restenotic lesions.
Regulatory considerations
For transportation, storage and handling of nuclear sources,
European countries require various licenses according to
individual nuclear laws.
In general, the institute or hospital needs a license for using
radioactive material. Within the institute or hospital a local
permission has to be obtained which is mostly linked to
specific room conditions and expertise of the personnel.
Mandatory key personnel include a radiation oncologist, a
medical physicist, a radiation safety officer and a cardiol-
ogist. Clinical responsibility lies with the radiation oncol-
ogist, though he may delegate practical aspects to others.
Practical safety considerations
In Europe, standards for the protection of patients,
health workers and the public against exposure to
radiat ion have been specified in two direc t ives
(96/29/EURATOM: 97/3/EURATOM)87,88 and are now being
incorporated into national laws. Radiation protection is
determined by two principles: exposure must be justified
by showing that it confers more benefit than detriment
and exposure should be as low as reasonable achievable
(ALARA principle).
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Monitoring
Individual personnel dosimeter badges allowing for effective
dose equivalent reading are mandatory in controlled areas like
catheterization laboratories. Radioactivity can be further
assessed by two basic instruments, the portable Geiger-Müller
counter and the ionization chamber survey meter.
Source
Every source must be inspected on receipt, which involves
visual inspection in the shielding, calibration to verify the
exact level of activity and, in line-sources, checking the
number and activity of sources.
Storage
Sources must be stored securely and held under lock and key.
Storing facilities must be provided with sufficient shielding,
taking into account that 90Sr/90Y sources from the Beta-
cath system produce Bremstrahlung. Pre-treatment checks
and calibrations of the source are mostly performed in the
storing facilities. 32P has a half-life of 14 days only. In
consequence, 32P sources have to be exchanged every four
weeks. 90Sr/90Y sources require a yearly check especially for
the mechanical condition of the source. The time necessary
to transfer the source in a special delivery device to the
laboratory must be taken into account by treatment
protocols.
Catheterization laboratory design
and equipment
Actual shielding requirements are catheterization laboratory
specific depending on size and configuration of the procedure
room and the adjacent rooms. The radiation levels of the X-
rays require approximately 4mm lead shielding in the walls.
Beta radiation requires no additional specific shielding of the
catheterization laboratory or adjacent rooms.
Gamma radiation requires special shielding (minimum
thickness 25mm lead) of the procedure room and the control
room to block the gamma rays (e.g. mobile shields of approx.
200kg positioned close to the patient). Outside the
laboratory, the level of exposure must be estimated and
regularly monitored in adjacent rooms.
Patient safety
PRINCIPAL RISKS RELATED TO INTRACORONARY
RADIATION INCLUDE:
• Damage to the artery wall with consecutive perforation
and/or aneurysm formation. This risk seems to be dose
related (>30Gy) and low35,38,89,90.
• Accelerated coronary artery disease as known side effect
of high dose radiation (>35 Gy) for the treatment of
neoplasms91,92. Intermediate doses (30-40 Gy) have shown
a low risk of cardiac disease during long term follow-up93.
• Radiation-induced carcinogenesis. This risk appears to be
low at least in beta radiation as the dose beyond the
immediate target lesion is low and the exposed tissues
(e.g., arteries, veins, cardiac muscle, and pericardium)
have a low spontaneous carcinogenicity rate.
TECHNICAL RISK RELATED TO INTRACORONARY
RADIATION
The main technical risks related to intracoronary radiation is
the failure to smoothly deploy and retrieve the source.
Therefore, proper source passage into the target coronary
artery should be routinely tested by deploying and retrieving
a dummy source. A dummy source allows also for control of
the treatment position within the coronary artery and reposi-
tioning of the delivery catheter if necessary.
Figure 11.
(a) Major adverse cardiac events (MACE) free survival curve. (b)
Target lesion revascularisation (TLR) free survival curve. Both
curves are consisting of three distinct segments. Up to six
months a relapse is clearly visible followed by a sharp decrease
related to the angiographic control in the majority of the
patients as mandated by the study protocols that they partici-
pated. From six months up to 4 years a second gradual and
continue relapse can be noted.
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STAFF SAFETY
Every source is brought into the catheterization laboratory in
a shielding device. The shielding device can be a source of
radiation. The operator's hand dose can be reduced by not
touching the shielding device. During delivery into the
coronary artery and retrieval, the source is unshielded for a
few seconds. Again, the operator's dose is reduced by not
touching the treatment catheter and keeping distance. Direct
finger contact with a high dose rate source is hazardous.
During treatment with gamma radiation, all personnel with
exception of the radiation oncologist must leave the catheter-
ization laboratory in order to limit their exposure to radiation.
Procedure performance
Intravascular radiation treatment requires a substantial
commitment and collaboration between the interventional
cardiologist and the radiation oncologist. Prior to every
brachytherapy procedure, the radiation oncologist and the
medical physicist have to be informed. The radiation oncol-
ogist must be able to review the patient's anamnesis and
physical condition for proper treatment planning, the medical
physicist guarantees secure source transportation.
Patient selection
INDICATIONS
Based on the outcome of the randomized clinical trials FDA
approval is limited to the treatment of in-stent restenosis in
the U.S. The findings of several clinical trials point to a
possibly elevated risk for thrombotic events in patients
receiving radiation therapy in newly implanted stents.
Potential indications in all circumstances with elevated risk
for restenosis after conventional catheter based intervention
such as long lesions, sapheneous vein grafts, small coronary
arteries, diabetic patients and renal insufficiency patients
still need to be established.
CONTRAINDICATIONS
Contraindications are previous radiotherapy of the chest,
previous intracoronary brachytherapy, pregnancy, genetic
radiation sensitivity disorders (e.g. ataxia-telangiectasia).
Patient preparation - medication
Pre-procedural treatment requires no particular medication
for brachytherapy other than antiplatelet regimen for routine
angioplasty procedures: Aspirin (75mg-300mg) and ticlopidin
or clopidogrel must be started at least 24h before the
procedure, whereby we prescribe a loading dose of 750mg,
followed by 250mg twice a day for ticlopidin and a loading
dose of 300mg, followed by 75mg daily for clopidogrel. Beta-
blockers, calcium antagonist and oral nitrates should be
administered as usually prescribed.
At the begin of the procedure, we routinely administer
neuroleptics and analgesics. Repeat bolus is given during the
procedure, if needed. Furthermore, we administer 325mg
aspirin intravenously and 10 000 IU heparin immediately
after arterial sheath placement. Activated clotting time (ACT)
is checked every 30 minutes after the first bolus injection in
order to maintain ACT > 300 sec. Additional heparin is given
if necessary.
During the procedure, GP IIb-IIIa receptor blockers are given
deliberately in patients with unstable angina, periprocedural
intracoronary thrombus formation or dissection.
Equipment set-up and special
arrangements of the operating room
For the angioplasty procedure, a standard angioplasty set and
eventually additional ablative devices (e.g. atherectomy
catheter) is needed.
For brachytherapy, the catheterization laboratory must have
appropriate shielding as described. The radiation oncologist
prepares the brachytherapy device (e.g check for mechanical
integrity, flushing of the system, dummy source, etc).
We recommend for this purpose an extra sterile table and
light. A bail-out box must be in the procedure room, typically
consisting of an assortment of long-handled instruments for
grasping a source and of a shielded container (lead for gamma
radiation, plastic for beta-radiation source) to safely place
the source. Radiation detectors to survey the environment
during the procedure and contamination monitors for source
leakage are needed. At least two timers must be available to
allow for correct dwell time and to minimize treatment errors.
Access method
We prefer the standard femoral approach using a 7F sheath
and guiding catheter. Application through the radial approach
is also feasible.
Angiography
TERMINOLOGY
Brachytherapy as new treatment with complex mechanisms of
action urges detailed angiographic assessment and necessi-
tates the introduction of a new terminology (figure 12).
• Target segment. The target segment is defined by the
proximal and distal margin of the obstructed segment.
• Injured segment. The macroscopic injured segment is
defined as the segment encompassed by the most proximal
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and most distal position of the angioplasty device (e.g.
rotablator burr) or marker of the angioplasty balloon and
all visible vessel injury as assessed by flouroscopy.
• Irradiated segment. The irradiated segment is defined as
the segment encompassed by the inner edge of the
radiopaque markers of the source train.
• Effective irradiated segment is the segment receiving full
prescribed therapeutic radiation dose (100% isodose) and
it is shorter than the irradiated segment as a result of the
dose fall-off caused by the limited size of the source train.
The exact delineation of the effective irradiated segment
is complicated, as is requires the knowledge of the
individual dose-profiles for each isotope and source
design.
• Edge segments. Edge segments are the vessel segments at
the extremities of the radiation source, which do not
receive full therapeutic radiation dose. The length of the
edge segments is dependent on the isodose profile of the
individual source.
• Vessel segment. The vessel segment is the coronary
segment bordered by angiographically visible side-
branches which encompass the original lesion, all angio-
plasty devices and the radiation source.
• Geographic miss segment. In coronary brachytherapy, it
is defined as a mismatch between injured and irradiated
segment: Geographical miss is present when the entire
length of the injured segment is not completely covered by
the irradiated segment (figure 13).
Figure 13.
An schematic example of geographical miss based on the
definitions described in figure 12.
Figure 12.
Left side: Isodose rate contour map and radiation 90Sr/90Y source train (Beta cath system). Isodose rate contour map at a depth or 1.89 mm
(10 mGy/sec contour intervals) as described by NIST (The National Institute of Standard and Technology). This depth (1.89 mm) illustrates an
isodose model resembling the radius of the coronary artery wall. The longitudinal dose fall-off may be extrapolated from this graphic. The
central part of the source train (26mm) radiates approximately the full dose (100% isodose) constituting the EIRL. Right side: A diagram of
an irradiated coronary artery and the anatomical and dose-based subsegment definition. B = Balloon, EIRS = Effective irradiated segment,
INS = Injured segment, IRS = Irradiated segment, SB = Side branch, TS = Target segment, VS = Vessel segment, IRL = Irradiation length, EIRL =
Effective irradiation length.
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GENERAL REQUIREMENTS
Angiography should be done in biplane views. At the start of
the procedure, two projections are selected with more than
30degrees difference in rotation and avoiding foreshortening
and side branch overlapping. The entire procedure should be
filmed in identical projections. The meticulous documen-
tation of all angioplasty devices and the radiation source in
place with contrast medium, using the same projections, is
essential. Inadequate angiographic documentation,
hampering the identification of the irradiated and the injured
segment is seen in up to 50% of the cases enrolled in
brachytherapy trials.
PRIMARY ANGIOGRAPHY
Primary angiography identifies the culprit lesion, the "target
segment" and the "vessel segment". Basic considerations are
• vessel size (dose prescription?)
• lesion accessibility for the source (dimensions, stiffness?)
• strategy of angioplasty prior to radiation
• lesion length (source long enough to cover complete
injured segment?)
• side branches (in bifurcation lesions, only 1 side branch
can receive radiation)
Primary angiography also serves for decision on the "best
projection" to document the complete procedure.
Angioplasty
Prior angioplasty might consist in debulking (directional or
rotational atherectomy, laser), stent implantation or "simple"
balloon inflation and is performed in conventional technique.
Any instrumentation has to be filmed at the site of treatment
surrounded by contrast medium in identical projections! It is
important, that angioplasty is not stopped before reaching a
satisfactory result. Every instrumentation after radiation
therapy carries inevitably the risk of geographic miss and
subsequently edge restenosis. We strongly recommend that
radiation should be the last intervention.
Dose prescription and source
selection
The treated coronary artery is usually 2-5 cm of length, with a
diameter of 3-5 mm and a vessel wall thickness of 0.5-3 mm. The
radiation dose given to the vessel wall should target the media
as well as the adventitia delivered at 0.5-5mm from the source.
Dose prescription and source selection are performed in close
collaboration with the radiation oncologist. Dose is prescribed
in relation to the long axis of the source (e.g. at 2mm) and can
be based on the angiography or intravascular ultrasound.
Given the radioactivity and dose rate of the selected source,
dwell time is calculated in dependency of the vessel size.
The length of the source should be selected in that way, that
• the vessel segment, which has been "touched" by any
angioplasty device and
• the vessel segment which shows macroscopic injury is
completely covered
• there is sufficient safety margin at the proximal and distal
end of the source to guarantee full dose radiation of the
treated segment.
Radiation treatment
The radiation oncologist prepares the brachytherapy device.
Meanwhile it might be helpful for the operator to review the
angiograms. This allows for a precise image of the "injured
segment" relative to landmarks such as side-branches.
The guiding catheter should be correctly positioned at the
coronary ostium: if it is too deep it will obstruct flow and may
creep further into the coronary artery during the procedure, if
it is to far away, it may slip during the procedure and move the
source ribbon. Then the catheter accommodating the dummy
source is carefully advanced into the vessel. Most radiation
delivery catheters are fragile without inserted ribbon, it may
easily kink during insertion. If stented lesions are treated, it
has to be avoided, particularly in tortuous vessels, that the
catheter becomes caught on the stent struts. An angiogram
with the dummy source in place should be done. If angiog-
raphy confirms correct positioning with complete coverage of
the injured segment and safety margins, the radiation oncol-
ogist removes the dummy source, connects the afterloader
device to the catheter and delivers the source. The radioactive
source must be filmed in place with contrast medium
repeating the projections used for angioplasty. Care should be
taken to not over tighten the O-ring and Y-connector while
attempting to obtain good quality contrast injections, as this
may crimp the delivery catheter and obstruct movement. At
the end of the dwell time, the radiation oncologist removes
the source. The contrast medium should be withdrawn into the
delivery syringe prior to injection down the coronary artery
after withdrawal of the source to avoid thrombotic emboli-
sation. While removing the delivery catheter, care should be
taken not to push the guide to far distally into the vessel. A
final angiogram should confirm good angioplasty result and
the absence of dissections and/or thrombus.
How to avoid geographic miss
• Source length > lesion length!
• Select a projection without foreshortening and side
branch overlap
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• Film any instrumentation with contrast medium to allow
for anatomical orientation
• Film any instrumentation in the same projection and respi-
ratory position
• Film the dummy and active wire in the same projection
and respiratory position
• Use proximal (or distal) side branches within the vessel
segment as index anatomical landmarks to assess the
distances to the markers of the angioplasty balloon and
the radiopaque source markers
• Consider proximal and distal safety margins
• Do not perform brachytherapy before a satisfactory angio-
plasty result
• Avoid instrumentation (e.g. additional stents) after
brachytherapy
• Listen to your radiation oncologist!
Complications
Procedural complications
Procedural complications include all complications typically
linked to the angioplasty/debulking procedure. Most compli-
cations related to brachytherapy by removable sources are
caused by the relatively high profile and stiffness of the
delivery catheter:
• myocardial ischemia with angina and/or ECG changes,
which, might necessitate fractionation of the dose
(approx. 4% of the patients) and
• dissection after manipulation of the delivery catheter
(approx. 10% of lesions).
Furthermore, radiation increases local thrombogenicity31,
which promotes intracoronary thrombus formation during
active treatment (approx. 4% of lesions). In these cases,
GP IIb/IIIa inhibitors should be given deliberately.
Procedural emergencies
CATHETER BASED LINE SOURCES
Prolonged retrieval represents one of the most serious
technical events which can produce unwanted dose to the
patient and staff. In that case, the entire treatment catheter
should be withdrawn and placed into the bail-out box. If that
is not successful, an attempt should be made to move the
source into a larger diameter artery whilst calling for
emergency surgery.
BALLOON BASED FLUID OR GASEOUS SOURCES
Radioactive fluid filled balloons might leak or burst and spill
their content's into the patient's blood stream. The
radioactive material need to be physiologically cleared from
the patient before an unacceptable dose is delivered to any
tissue. Gaseous 133Xe is rapidly exhaled and presents
minimum radiation hazard to the patient.
In all cases of emergency, the physicist's responsibility is to
remain focused on safely retrieving the sources and
minimizing unnecessary exposure of patients and staff. To
allow for rapid and well directed action, contingency plans
must be made in advance, discussed and rehearsed for a
variety of likely and unlikely occurrences.
Postprocedural care
The arterial sheath is withdrawn immediately after the
procedure and the access site sealed with a closure device
(Perclose or Angioseal). In case of a difficult arterial puncture
with substantial fibrosis, the sheath is removed 6 hours after
the procedure and the artery manually compressed. All patients
must receive effective antiplatelet therapy for at least 12
months. In our institution, we prescribe aspirin indefinitely in
combination with clopidogrel (75mg daily) for 12 months. This
is essential to avoid late thrombotic occlusion.
Brachytherapy in the era of
Drug Eluting Stents
Primary prevention of restenosis
The Drug Eluting Stents have been recently introduced in our
clinical practice and proved to be very effective for the
prevention of restenosis in de novo lesions94. Most of the
limitations of brachytherapy are strongly related with the use
of stents. This incompatibility with the use of stents was the
reason that it failed to find a place in the routine practice for
de-novo lesions. Stents are the cornerstone therapeutic
modality in interventional cardiology today and that doesn't
seem to change in the near future. Any technique incom-
patible with their use will not find wide application.
Secondary prevention of restenosis
The Drug Eluting Stents have been recently reported to be
effective for the treatment of in-stent restenosis of non-
eluting stents95. The confirmation of these results in large
randomised trials and the unique application of eluting
stents, will limit brachytherapy as a specialised technique, for
the limited number of patients with failure of eluting stents,
in dedicated centers.
Limitations
Three appearing to be the main limitations of intracoronary
radiation therapy:
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1. Edge restenosis. The underline mechanism seems now well
understood. Underdosing in combination with injury. Current
data show that with appropriate application of the radiation,
taking sufficient margins, it can be eliminated.
2. Late occlusion and thrombosis. Prolongation of the antiplatelet
treatment just delayed its appearance. Life long aspirin and
clopidogrel might be warrant, with questionable efficiency.
3. Delayed restenosis. Current data are still limited but seems
that they support it. Furthermore, the treatment of these
patients is another serious challenge in interventional cardiology.
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Intracoronary -radiation to reduce restenosis after
balloon angioplasty and stenting
The Beta Radiation In Europe (BRIE) study
P. W. Serruys1, G. Sianos1, W. van der Giessen1, H. J. R. M. Bonnier2, P. Urban3,
W. Wijns4, E. Benit5, M. Vandormael6, R. Do¨rr7, C. Disco8, N. Debbas9 and
S. Silber10 on behalf of the BRIE study group
From the 1Thoraxcenter, Heartcenter, Rotterdam, Academisch Ziekenhuis Dijkzigt Rotterdam, The Netherlands;
2Catharina Ziekenhuis, Eindhoven, The Netherlands; 3Centre Hospitalier Vaudois, Lausanne, Switzerland; 4Onze
Lieve Vrouw Ziekenhuis — Cardiovascular Center, Aalst, Belgium; 5UZ Virga Jesse Ziekenhuis, Hasselt, Belgium;
6Clinique St. Jean, Brussels, Belgium; 7Klinik Weisser Hirsch, Dresden, Germany; 8Cardialysis, Rotterdam, The
Netherlands; 9Clinique Universitaire de Saint-Luc, Brussels, Belgium; 10Internistische Klinik, Munchen, Germany
Aims The BRIE trial is a registry evaluating the safety and
performance of 90Sr delivered locally (Beta-Cath TM sys-
tem of Novoste) to de-novo and restenotic lesions in
patients with up to two discrete lesions in diﬀerent vessels.
Methods and Results In total, 149 patients (175 lesions)
were enrolled; 62 treated with balloons and 113 with stents.
The restenosis rate, the minimal luminal diameter and the
late loss were determined in three regions of interest: (a) in
a subsegment of 5 mm containing the original minimal
luminal diameter pre-intervention termed target segment;
(b) the irradiated segment, 28 mm in length, and (c) the
entire analysed segment, 42 mm in length, termed the vessel
segment. Binary restenosis was 9·9% for the target segment,
28·9% for the irradiated segment, and 33·6% for the vessel
segment. These angiographic results include 5·3% total
occlusions. Excluding total occlusions binary restenosis was
4·9%, 25% and 29·9%, respectively. At 1 year the incidence
of major adverse cardiac events placed in a hierarchical
ranking were: death 2%, myocardial infarction 10·1%,
CABG 2%, and target vessel revascularization 20·1%. The
event-free survival rate was 65·8%. Non-appropriate cover-
age of the injured segment by the radioactive source termed
geographical miss aﬀected 67·9% of the vessels, and
increased edge restenosis signiﬁcantly (16·3% vs 4·3%,
P=0·004). It accounted for 40% of the treatment failures.
Conclusion The results of this registry reﬂect the learning
process of the practitioner. The full therapeutic potential of
this new technology is reﬂected by the restenosis rate at the
site of the target segment. It can only be unravelled once the
incidence of late vessel occlusion and geographical miss has
been eliminated by the prolonged use of thienopyridine, the
appropriate training of the operator applying this new
treatment for restenosis prevention, and the use of longer
sources.
(Eur Heart J, 2002; 23: 1351–1359, doi:10.1053/euhj.2001.
3153)
 2002 The European Society of Cardiology. Published by
Elsevier Science Ltd. All rights reserved.
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Introduction
Following coronary balloon angioplasty, restenosis of
the dilated segment occurs in 30% to 50% of patients and
results from elastic recoil, neointima formation, and
negative remodelling[1–4]. The advent of coronary stent-
ing reduced restenosis to 15% in certain type of
lesions[5,6], but introduced the even more diﬃcult to treat
in-stent restenosis[7]. Radiation has been shown to be
eﬀective in the management of other benign proliferative
conditions, such as keloids, heterotopic bone formation,
pterygia, and Grave’s opthalmopathy[8–11]. Endovascu-
lar radiation has been evaluated in animal balloon and
stent restenosis models and was shown to reduce
neointima formation in a dose- related manner both
Revision submitted 3 December 2001, and accepted 5 December
2001.
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with gamma and beta emitters[12–15]. Clinical feasibility
studies and randomized trials with beta and gamma
emitters have been proven to be eﬀective in reducing
restenosis after balloon angioplasty, and recurrent in-
stent restenosis[16–21]. Recent intravascular ultrasound
studies have documented the favourable mechanisms of
positive remodelling and inhibition of plaque forma-
tion[22,23] resulting in lumen enlargement after radio-
therapy of de-novo lesions. In contrast the development
of re-narrowing at the edges of the irradiated
segment — related to vascular injury non-eﬀectively
irradiated[24–26] — the late total occlusions[27,28], the de-
layed healing[29], the increased thrombogenicity[30], and
the persistent dissections[31,32] are limiting the eﬀective-
ness of this treatment. The purpose of the BRIE study
was to introduce in a registry mode this new technology
in Europe while awaiting the results of a large random-
ized trial (Beta-Cath trial), using the same source, in the
U.S.A.
Methods
Objectives
The primary clinical end-point was freedom from major
adverse cardiac events including death, CABG, myocar-
dial infarction (deﬁned as increase in the level of creatine
kinase or MB isoenzymes to more than twice the upper
limit of normal), and target vessel revascularization
assessed at 1 year. The major adverse cardiac events
were adjudicated by an independent clinical event com-
mittee. The angiographic end-point was restenosis
(diameter stenosis >50%), by quantitative coronary
angiography, at 6 months. Secondary angiographic end-
points were minimal luminal diameter and late loss.
Patient selection
Between July 1998 and June 1999, 149 patients were
enrolled in the study. Major inclusion criteria were: (1)
objective evidence of ischaemia on exercise testing, (2)
lesions located in vessels >2·7 mm and <4·0 mm in
diameter, (3) patients with up to two discrete de-novo or
restenotic lesions in diﬀerent native coronary arteries
who were eligible to undergo elective balloon (<24 mm)
angioplasty or provisional stent (<22 mm) placement.
Major exclusion criteria were (1) patients with unstable
angina or acute myocardial infarction, (2) patients with
in-stent restenosis, (3) bifurcation lesions and total
occlusions.
The Institutional Review Boards or Ethics Commit-
tees and the Radiation Safety Committees of the partici-
pating institutions approved the protocol of the study.
Written informed consent was obtained from all
patients. The study was conducted at nine clinical sites
listed in the appendix.
Procedure
Overall, 123 patients underwent single-vessel angi-
oplasty and 26 patients double-vessel angioplasty. In
total, 175 vessels were treated. In the single-vessel group
48 vessels were treated with balloon angioplasty and 75
with stenting (64 provisional and 11 rescue). In the
double-vessel group, 14 vessels were treated with balloon
angioplasty and 38 with stenting (36 provisional and two
rescue). Overall, 62 vessels were treated with balloon
angioplasty alone. In 42 of these, radiation was the last
intervention whereas additional balloon angioplasty was
necessary after radiation in the remaining 20 (32·2%). In
113 vessels, stents were implanted (100 provisional
and 13 rescue). All the stents but four (109/113, 96·4%)
were placed after radiation. In these four cases,
stenting was necessary before radiotherapy due to
threatened vessel occlusion after the initial balloon
angioplasty. Overall, post-radiation intervention was
performed in 73·7% (129/175) of the vessels treated.
Baseline patients and procedural characteristics are
presented in Table 1.
Balloon angioplasty and stent implantation was car-
ried out according to investigator’s standard practice,
with all patients receiving heparin and aspirin before the
procedure. By-protocol stenting was not discouraged.
The angiographic criteria for stent placement were
residual stenosis >30%, ﬂow-limiting dissection or
threatened vessel occlusion. After successful dilatation,
the balloon catheter was removed, with the guidewire
left in place. The radiation delivery catheter was then
inserted over the guidewire and advanced so that the two
marker bands encompassed the angioplasty site with a
margin of 3 mm, as speciﬁed in the protocol. Once
satisfactory positioning of the catheter was conﬁrmed
under ﬂuoroscopy, the transfer device was connected to
the delivery catheter, the gate of the transfer device was
opened, and the source train was hydraulically delivered
down the catheter. During the procedure, minimal press-
ure and ﬂuid ﬂow were required to maintain the source
train at the distal end of the source lumen. After
Table 1 Patients and procedural characteristics
Age (range) 60 (35–85) years
Males 111/149 (74·4%)
Diabetes 21/149 (14·1%)
Hypertension 54/149 (36·2%)
Prior MI 51/149 (34,3%)
Prior CABG 8/149 (5·4%)
LAD 65/175 (37·1%)
CFX 38/175 (21·7%)
RCA 72/175 (41·2%)
De-novo lesions 165/175 (94·3%)
Restenotic lesions 10/175 (5·7%)
Balloon angioplasty 62/175 (35·6%)
Rescue stenting 13/175 (7·4%)
Provisional stenting 100/175 (57%)
MI=myocardial infarction; CABG=coronary artery bypass graft
operation; LAD=lleft anterior descending; LCX=left circumﬂex;
RCA=right coronary artery.
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radiation therapy, the source train was returned to the
transfer device by reversal of the switching system,
which enabled injected ﬂuid to push the train back into
the transfer device. Further intervention was carried out
when necessary and after achievement of a satisfactory
result the procedure was concluded with ﬁlming of
the ﬁnal result after administration of intracoronary
nitrates.
Post-procedural antiplatelet treatment
By protocol, the recommendation of antiplatelet treat-
ment was 2 to 4 weeks. Due to the high incidence of
angiographic vessel occlusion observed in the initial
period of recruitment before 1999, prolongation of an-
tiplatelet treatment for at least 8 weeks and up to 6
months was recommended after 1999.
Radiation delivery system
The device has been described elsewhere[20,33]. In sum-
mary, it consists of three components: (1) the transfer
device which stores the radiation source train and allows
its positioning within the catheter; (2) the delivery cath-
eter, which is a 5 Fr multilumen non-centred catheter
which uses saline to send and return the radiation
source train; and (3) the radiation source train which
consists of 12 independent cylindrical seeds which
contain the radioisotope 90Sr/90Y source bounded by
two gold radiopaque markers (30 mm in length). The
longitudinal distance of the ‘full’ prescribed dose (100%
isodose) coverage, measured by radiochromic ﬁlms, is
about 26 mm[34] constituting the eﬀective irradiation
length.
Dosimetry
The prescribed dose was 14–18 Gy, at 2 mm from the
centreline of the source axis, based on the reference
diameter, by on-line quantitative coronary angiography,
which measured <3·35 mm or >3·35 mm, respectively.
Overall, 57·5% of the patients received 14 Gy and 42·5%
18 Gy. The dwelling time was on average
3·120·43 min (meanSD).
Angiographic analysis
Quantitative coronary angiography was performed oﬀ-
line by an independent Core-lab (Cardialysis, Rotterdam,
Netherlands). All angiograms were evaluated after intra-
coronary administration of nitrates. The analysis was
performed by means of the CAAS II analysis system (Pie
Medical BV, Maastricht, Netherlands). Calibration of
the system was based on the dimensions of the catheters
empty of contrast medium[35]. This method of analysis
has been previously validated[36,37].
A new methodological approach, recently reported[38],
was used in order to deﬁne accurately the eﬀect of
brachytherapy on the treated coronary arteries. In each
analysed coronary artery the following segments were
determined: The vessel segment was deﬁned as the
segment bordered by two side branches, which encom-
passed the original lesion, the angioplasty balloon and
the radiation source. The irradiated segment was deﬁned
as the segment encompassed by the two gold markers of
the radiation source train. The target segment was
deﬁned as the 5 mm subsegment containing the pre-
procedural minimal luminal diameter. In each of the
above subsegments minimal luminal diameter, reference
diameter, late loss, and restenosis-deﬁned as diameter
stenosis >50% at follow-up was determined. The seg-
ment encompassed by the most proximal and distal
markers of the angioplasty balloon-deﬁned the injured
segment. The eﬀective irradiated segment was the seg-
ment that received the full-prescribed dose and corre-
sponded to the vessel segment covered by the 26 mm
long central part of the radioactive source train. These
segments are illustrated in Fig. 1.
Geographical miss
Geographical miss was deﬁned for those cases where the
entire length of the injured segment was not fully
covered by the radioactive source. To determine whether
the edges of the eﬀective irradiated segment were
injured, we retrospectively analysed (blinded to the
presence or absence of restenosis and its location at
follow-up) all the baseline (intervention plus radiation)
angiograms. The following steps were followed: during
the procedure all the interventions (balloons or stents)
deﬂated at the site of injury and the radioactive source in
place were ﬁlmed during contrast medium injection in
identical angiographic projections. This approach
allowed us to deﬁne the location of the various subseg-
ments (eﬀective irradiated segment, injured segment,
edges) in relation to side branches and the correct
matching of the intervention and radiation angiograms
in the oﬀ-line analysis. The ECG recording was also
displayed on screen, allowing the selection of still frames
in the same part of the cardiac cycle. Multiple angi-
ographic loops and ECG matched still frames could be
displayed simultaneously, side-by-side, on the screen
using the Rubo DICOM Viewer (Rubo Medical Imag-
ing, Uithoorn, The Netherlands). By identifying the
relationship between the eﬀective irradiated segment and
its edges relative to the injured segment we determined
the geographical miss edges[26]. Computer-deﬁned sub-
segmental analysis (mean subsegment length was
5·00·3 mm) was also performed. In each subsegment
percentage diameter stenosis was also automatically
calculated. This allowed the determination of restenosis
location in relation to the edges of the eﬀective
irradiated segment.
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Statistical analysis
Patient survival curves were constructed according to
the Kaplan–Meier method. Continuous parameters are
presented as mean values and standard deviations, dis-
continuous parameters are presented as percentages.
Continuous parameters are compared using Student’s
t-test, where binary parameters are compared using
Fisher’s Exact-test. The statistical signiﬁcance of all tests
was deﬁned at the P<0·05 level.
Results
Major adverse cardiac events
In-hospital major adverse cardiac events
Three patients developed Q myocardial infarction after
the procedure. In two patients Q myocardial infarction
was due to total occlusion of the treated vessel (one
occlusive dissection and one thrombotic occlusion) re-
lated to radiotherapy. In the third case the Q myocardial
infarction was due to the occlusion of a side branch.
There were three patients with non-Q myocardial
infarction; one from occlusion of a side branch after
additional balloon dilatation following radiation,
another with distal embolization of the treated vessel,
and the third related to transient vessel occlusion, due to
type F dissection following radiation, that required three
stents to restore ﬂow.
Major adverse cardiac events up to 1 year
The major adverse cardiac events up to 1 year follow-up
are presented in Tables 2 and 3. The event-free survival
curve up to 1 year is presented in Fig. 2. The incidence of
major adverse cardiac events in the balloon group was
40% and in the stent group 30·9%. There was no
diﬀerence between the two groups (P=0·3).
Angiographic results at 6 months
Twenty asymptomatic patients refused follow-up
angiogram, leaving 129 patients with 152 lesions for
angiographic analysis. The quantitative coronary
analysis angiographic results are presented in Table 4.
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Figure 1 Left side: Isodose rate contour map and radiation source train. Isodose
rate contour map at a depth or 1·89 mm (10 mGy . s1 contour intervals) as
described by NIST (The National Institute of Standard and Technology). This depth
(1·89 mm) illustrates an isodose model resembling the radius of the coronary artery
wall. The longitudinal dose fall-oﬀ may be extrapolated from this graphic. The
central part of the source train (26 mm) radiates approximately the full dose (100%
isodose) constituting the EIRL. Right side: A diagram of an irradiated coronary
artery and the anatomical and dose-based subsegment deﬁnition. B=balloon;
EIRS=eﬀective irradiated segment; INS=injured segment; IRS=irradiated segment;
SB=side branch; TS=target segment; VS=vessel segment; IRL=irradiation length,
EIRL=eﬀective irradiation length.
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The average vessel size was 3·060·5 mm, the mini-
mal luminal diameter 1·010·31 mm, the lesion length
113·9 mm. The restenosis rate in the target segment
was always signiﬁcantly lower compared with the re-
stenosis rate in the irradiated segment and the vessel
segment in all groups of patients including or excluding
the total occlusions (P<0·001). This association was less
strong for the balloon group, including (7% vs 21·1%,
P=0·06) or excluding (5·4% vs 19·6%, P=0·04) the total
occlusions. There was no diﬀerence in the restenosis rate
between the irradiated segment and the vessel segment in
all groups of patients (P=ns). The late loss between
target segment, irradiated segment, vessel segment was
comparable in all group of patients (P=ns).
There was no diﬀerence in the restenosis rate and the
late loss in the vessel subsegments (target segment,
irradiated segment, vessel segment) when comparing the
groups with and without the total occlusions (P=ns).
Signiﬁcantly lower late loss was observed in the bal-
loon group compared with the stent group including
(target segment: 0·03 mm vs 0·44 mm, P<0·001,
irradiated segment: 0·14 mm vs 0·43 mm, P=0·004,
vessel segment: 0·12 mm vs 0·37 mm, P=0·009) (Fig. 3)
or excluding the total occlusions (target segment:
0·07 mm vs 0·33 mm, P<0·001; irradiated segment:
0·11 mm vs 0·33 mm, P=0·004; vessel segment: 0·08 mm
vs 0·28 mm, P=0·009) but there was no diﬀerence in the
restenosis rate (P=ns).
Late vessel occlusions
In 5·3% (8/152) of the treated vessels a total occlusion
was documented at the follow-up angiogram. In ﬁve of
them (four stents and one balloon) the patients were
asymptomatic (silent total occlusion). The other three
(all stents) presented with an acute coronary syndrome
(two with Q myocardial infarction and one with non-Q
myocardial infarction) 94, 59 and 80 days after the index
procedure and were revascularized successfully. The
incidence of vessel occlusion was 10·5% (six out of 57, all
stents) in the initial period of recruitment, before 1999,
when the recommendation for the duration of the an-
tiplatelet therapy was 2 to 4 weeks. It dropped to 2·1%
(two out of 95, one balloon and one stent) (P=0·02)
after 1999 with the prolongation of the antiplatelet
treatment for at least 8 weeks and up to 6 months.
One patient in the balloon group with a patent vessel
without restenosis at 6 months presented with unstable
angina 279 days after radiation. A late thrombotic
occlusion of the irradiated vessel was documented at the
angiogram. The patient was revascularized successfully.
Geographical miss and treatment failure
Geographical miss could not be determined in 25·1%
(44/175) of the treated vessels due to inadequate ﬁlming.
The geographical miss was observed in 67·9% (89/131) of
the interpretable vessels and in 41·2% (108/262) of the
edges of the eﬀective irradiated segment and resulted in
Table 2 Major adverse cardiac events at 1 year —
hierarchical ranking scale
Up to 31 days Up to 6 months Up to 365 days
n % n % n %
Death 0 0·0 3 2·0 3 2·0
MI 7 4·7 14 9·4 15 10·1
Q MI 3 2·0 8 5·4 8 5·4
Non-Q MI 4 2·7 6 4·0 7 4·7
CABG 0 0·0 2 1·3 3 2·0
TVR 0 0·0 23 15·4 30 20·1
No MACE 142 95·3 107 71·8 98 65·8
Hierarchical ranking scale considers only the worst event; i.e. if a
patient required repeat angioplasty and later coronary artery
bypass grafting the ranking scale would reﬂect only the worst
event. MI=myocardial infarction; CABG=coronary artery bypass
graft operation; TVR=target vessel revascularization; MACE=
major adverse cardiac events.
Table 3 Major adverse cardiac events at 1 year — total
count of events
Up to 31 days Up to 6 months Up to 365 days
n % n % n %
Death 0 0·0 3 2·0 3 2·0
MI 7 4·7 17 11·4 19 12·8
Q MI 3 2·0 10 6·7 11 7·4
Non-Q MI 4 2·7 7 4·7 8 5·4
CABG 0 0·0 4 2·7·3 5 3·4
TVR 0 0·0 33 22·1 46 30·9
All events reﬂects the total count of events i.e. if a patient required
repeat angioplasty an later coronary artery bypass grafting the
total count would reﬂect both events and not just the worst
occurred. MI=myocardial infarction; CABG=coronary artery
bypass graft operation; TVR=target vessel revascularization;
MACE=major adverse cardiac events.
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Figure 2 Event-free survival curve up to 1 year. This
curve consists of three distinct segments. Up to 6 months a
relapse is clearly visible followed by a sharp decrease
related to the angiographic control as mandated by the
protocol. From 6 months up to 1 year the curve remains
reasonably stable.
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a 16·3% incidence of edge restenosis, while the restenosis
at the edges without geographical miss was only 4·3%
(P=0·004)[26]. Out of the 44 vessels with restenosis at the
irradiated segment, in 24 restenosis was located at the
edges and in 18 it was related to geographical miss. This
inadequate treatment was responsible for 40% (18/44) of
the treatment failures. In 20 vessels the restenosis was
located in the eﬀective irradiated segment and they
represent the true treatment failures.
Discussion
Endovascular radiotherapy has emerged as a promising
treatment for reducing restenosis. Investigations using
animal models of restenosis demonstrate a dramatic
inhibition of neointima formation after balloon and
stent injury both after intravascular gamma and beta-
radiation[12–15]. Following these encouraging results, hu-
man feasibility studies both with beta[39] and gamma[16]
emitters showed that intracoronary brachytherapy is
feasible and safe. In two randomized trials intracoronary
gamma radiation showed a signiﬁcant reduction in an-
giographic and clinical assessment of restenosis in
patients undergoing coronary intervention for restenotic
lesions after balloon angioplasty treated with stent[19]
and in-stent restenosis[17].
Beta sources with more limited penetration may have
inherent safety advantages over gamma sources, but
conversely less eﬃcacy in preventing restenosis, particu-
larly in stented arteries[40]. King et al.[20] in a non-
controlled feasibility trial using 90Sr/90Y demonstrated a
Table 4 Angiographic results
TS (5 mm) IRS (28 mm) VS (42 mm)
Post F/UP Post F/UP Post F/UP
All patients with total occlusions (n=152 lesions)
MLD mm 2·54 2·28 2·08 1·75 1·93 1·65
Reference diameter mm 2·86 2·68 2·84 2·61 2·81 2·59
Late loss mm 0·26 0·33 0·28
Restenosis rate % 9·9 28·9 33·6
All patients without total occlusions (n=144 lesions)
MLD mm 2·58 2·41 2·08 1·84 1·93 1·73
Reference diameter mm 2·89 2·83 2·87 2·76 2·84 2·74
Late loss mm 0·17 0·24 0·20
Restenosis rate % 4·9 25·0 29·9
Balloon group with total occlusions (n=57 lesions)
MLD mm 2·20 2·23 1·97 1·83 1·88 1·76
Reference diameter mm 2·55 2·65 2·71 2·66 2·73 2·66
Late loss mm 0·03 0·14 0·12
Restenosis rate % 7·0 21·1 24·6
Balloon group without total occlusions (n=56 lesions)
MLD mm 2·20 2·27 1·97 1·86 1·87 1·79
Reference diameter mm 2·55 2·70 2·70 2·71 2·72 2·71
Late loss mm 0·07 0·11 0·08
Restenosis rate % 5·4 19·6 23·2
Stent group with total occlusions (n=95 lesions)
MLD mm 2·77 2·33 2·13 1·70 1·94 1·57
Reference diameter mm 3·05 2·70 2·93 2·59 2·86 2·55
Late loss mm 0·44 0·43 0·37
Restenosis rate % 11·7 33·7 38·9
Stent group without total occlusions (n=88 lesions)
MLD mm 2·82 2·49 2·16 1·83 1·97 1·69
Reference diameter mm 3·10 2·91 2·98 2·80 2·92 2·75
Late loss mm 0·33 0·33 0·28
Restenosis rate % 4·6 28·4 34·1
MLD=minimal luminal diameter; TS=target segment; IRS=irradiated segment, VS=vessel segment.
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Figure 3 Diﬀerence in the late loss in the target segment
(TS), the irradiated segment (IRS) and the vessel segment
(VS) between patients treated with balloon angioplasty
( ) and stent implantation ( ).
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low late lumen loss and late loss index compared with
historical controls in patients with de novo lesions
treated with balloon angioplasty followed by radiation
with a non-centred source. Using the 32P as a beta-
emitter reduced the restenosis rate and improved
clinical outcome, as reported in a small randomized
trial[21]. Recently beta radiation was proved to be as
eﬀective as gamma in reducing in-stent restenosis in a
non-randomized trial[18].
Evidence of treatment eﬃciency
The angiographic end-points in the current study sug-
gest eﬀective inhibition of restenosis (9·9%) within the
target segment in patients receiving radiotherapy com-
pared with historical cohorts[5,6] treated with balloon
angioplasty or stents. Excluding the late total occlusions,
which have a diﬀerent pathophysiology from that of the
restenotic process, binary restenosis in the same segment
is as low as 4·9%. This result is comparable with the
3·9% restenosis observed in the balloon group that
received 18 Gy in the Dose Finding study[41]. The target
segment represents the subsegment in which inappropri-
ate radiation is technically excluded since this corre-
sponds to the treatment target and is always
appropriately covered by the radiation source and thus
receives the prescribed dose. The restenosis rate in this
segment reﬂects the full therapeutic potential of this
treatment. Late lumen loss in this segment was also
substantially lower compared with historical trials with
similar angiographic and demographic characteris-
tics[5,6]. Most importantly, in patients treated with bal-
loon angioplasty alone, a negative late loss is observed in
the target segment with enlargement of the vessel lumen
at follow-up. A similar result was reported in the bal-
loon group that received 18Gy in the Dose Finding
study. The vessel expansion in the target segment
resulted in comparable minimal luminal diameters
between the balloon and the stent group at the 6 months
follow-up angiogram (2·23 mm and 2·31 mm, respect-
ively) and no diﬀerence in the restenosis rate (7% and
11·7%, respectively, P=0·41). This conﬁrms previous
observations made with intravascular ultrasound[22] in-
dicating positive remodelling with enlargement of the
total lumen and vessel volume 6 months after intracoro-
nary beta radiation in vessels treated with balloon
angioplasty. Radiotherapy is the ﬁrst therapeutic
modality achieving such a beneﬁcial eﬀect.
Edge restenosis and treatment failures
Edges restenosis, the so-called ‘edge eﬀect’, observed
both after radioactive stent implantation[25] and
catheter-based radiotherapy[24] limits considerably the
positive results observed at the site of the target segment,
increasing binary restenosis from 9·9% to 28·9% at the
irradiated segment. Careful retrospective analysis of all
the procedural ﬁlms revealed the aetiology of this fail-
ure. The combination of low dose radiation with injury,
the so-called geographical miss, was responsible for 75%
(18/24) of the edge failures or 40% (18/44) of the
restenosis observed in the irradiated segment. Our igno-
rance of the microscopic extent of the perivascular injury
(up to 10 mm away from the macroscopic injury)[42], of
the proliferative eﬀect of low dose radiation on the
injured tissue[43,44], and the actual length of the eﬀective
radiation source account for this phenomenon. Beta
radiation due to low penetration in the tissue results in
acute fall-oﬀ of the dose delivered at the edges of the
sources in the axial direction. This in an inherent prop-
erty of all beta sources. For the current source this
fall-oﬀ area was 2 mm on each side of the source. as
measured with radiochromic ﬁlm[34] limiting the eﬀective
radiation length to 26 mm, as opposed to the 30 mm
distance between the gold markers which were used as
guides for proper positioning of the source. For achiev-
ing a suﬃcient margin of eﬀectively irradiated vessel at
the edges of the injured segment a balloon to source
ratio of one to two is advised. The use of longer sources
up to 60 mm in length, which are now available, will
allow treatment of lesions up to 30 mm.
In 73·8% of the vessels treated post-radiation inter-
vention was performed. This was responsible for 53% of
the incidence of geographical miss[26]. To avoid this
complication, radiation therapy should be planned as
the last intervention.
All the edge restenotic lesions were new non pre-
existing lesions. In seven vessels the minimal luminal
diameter was located outside the irradiated segment but
inside the analysed vessel segment increasing binary
restenosis from 28·9% (irradiated segment) to 33·6%
(vessel segment). These were pre-existing lesions (ﬁve
vessels), unmasked after the treatment of the target
segment, or progression of the disease (two vessels)
non-related to brachytherapy, which has proved to be
safe in non-injured vessels both with beta[34] and
gamma[45] emitters.
The edge restenosis phenomenon and the positive
vascular remodelling observed after brachytherapy
increased the incidence of relocation of minimal luminal
diameter compared to the standard treatments[38]. This,
in conjunction with the increment in the mean length of
the analysed vessel segment, 42 mm in our study com-
pared to the 28 mm in the Benestent I trial[5], made the
interpretation of the results in brachytherapy trials more
complex and any direct comparison with historical trials
unfair. New methodological approaches in the quantita-
tive coronary analysis, such as the one used in the
present study with reports of the angiographic par-
ameters for the stenotic, the irradiated and the total
analysed segment will improve our understanding of the
results of brachytherapy.
In 20 patients the restenosis was located in the eﬀec-
tive irradiated segment representing the true failures of
the treatment. Dose inhomogeneity, since our system
is not centred or inappropriate dose, are possible
explanations for these failures.
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Chapter 4
Clinical thrombosis and late angiographic
occlusion
Eight patients (5·3%) presented with late total occlusion.
Seven of the patients had a stent implanted during the
index procedure and one was treated with balloon
angioplasty alone. The incidence of occlusion in the
stent group was 7·3% and in the balloon group 1·7%
(P=0·1). An incidence of 9·1%28] for in-stent restenotic
lesions and 6·6%[27] for non-restenotic lesions has been
recently reported with higher prevalence in patients
treated with stent implantation. Various causes such as
delayed healing[29], persistent dissections[31,32], late stent
malaposition[46], and increased radiation induced throm-
bogenicity[30] have been hypothesized to be the reasons.
In our study a signiﬁcant decrement in the incidence of
vessel occlusion was observed with the prolongation of
the antiplatelet treatment up to 6 months (10·5% vs
2·1%, P=0·02). Reduction in the incidence of the total
occlusion and the late thrombosis was recently reported
with the use of clopidogrel for 6 months in combination
with aspirin after intracoronary -radiation for the treat-
ment of in-stent restenosis[47]. Further randomized trials
are necessary to evaluate the eﬃcacy and the duration of
antiplatelet treatment for the prevention of late vessel
occlusion after intracoronary radiation therapy.
Recently drug eluting stents have been introduced for
the prevention of restenosis. Preliminary results indicate
that restenosis may be completely abolished by the
sirolimus drug-eluting stents[48], and if conﬁrmed could
have a drastic impact on the use of brachytherapy for de
novo lesions.
Study limitations
This in not a placebo-controlled study and the number
of patients included is limited. Further randomized
placebo-controlled studies are warranted to validate the
eﬃcacy of 90Sr radiotherapy for prevention of restenosis.
Conclusions
The results of this registry reﬂect the learning process of
the practitioner. The full therapeutic potential of the
brachytherapy with strontium 90, potentially reﬂected
by the restenosis rate in the target segment, can only be
unravelled once the incidence of the late vessel occlusion
and geographical miss has been eliminated. Probably
this report will herald some of the results of the large
randomized trial undertaken in the U.S.A. using the
same source (Beta-Cath trial).
Appendix
The participating centres and investigators of the BRIE
group are listed along with the number of included
patients in parenthesis.
Catharina Ziekenhuis, Eindhoven, The Netherlands (40):
H. Bonnier, MD, M. Lybeert, MD, I. L. O. Schmeets,
MD, W. J. F. Dries, MD, HP. C. M. Heijmen, MD.
Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland (22): P. Urban, MD, P. Coucke, MD, J. J.
Goy, MD.
Onze Lieve Vrouw Ziekenhuis-Cardiovascular Center,
Aalst, Belgium (20): W. Wijns, MD, L. Verbeke, MD, B.
de Bruyne, MD, G. R. Heyndrickx, MD, M. Piessens,
PhD, J. de Jans, PhD.
UZ Virga Jesse Ziekenhuis, Hasselt, Belgium (20): E.
Benit, MD, M. Brosens, MD.
Clinique St. Jean, Brussels, Belgium (18): M. Vandor-
mael, MD, R. Burette, MD, S. Latinis, RN.
Academisch Ziekenhuis Rotterdam Dijkzigt, Thorax-
center, Rotterdam, The Netherlands (11): P. W. Serruys,
MD, PhD, V. L. M. A. Coen, MD, P. Levendag, MD.
Klinik Weisser Hirsch, Dresden, Germany (10): R. Do¨rr,
MD, Th. Herrmann, MD.
Clinique Universitaire de Saint-Luc, Brussels, Belgium
(5): N. Debbas, MD, P. Scalliet, MD.
Internistische Klinik, Munich, Germany (4): S. Silber,
MD, R. von Rotkay, MD, I. Krischke, MD.
Data co-ordinating centre: Lincoln, Paris, France (D. de
Segonzac, J. Paget, S. Crethien).
Angiographic core-laboratory and data analysis:
Cardialysis, Rotterdam, The Netherlands (C. Disco,
MSc, M-a. Morel, BSc, C. v.d. Wiel).
Monitoring: Lincoln, Paris, France (D. de Segonzac).
Angiographic committee: P. W. Serruys, MD, PhD, P.
Urban, MD, R. Bonan, MD.
Clinical Events Committee: C. Lefeuvre, MD, M-L.
Lachurie, MD, R. Bonan, MD.
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Application of -irradiation through the struts of
a previously deployed stent
Georgios Sianos1, I Patrick Kay1, Stephane G Carlier1, Jurgen MR Lighart1, Alexander J Wardeh1, Veronique
LMA Coen2, Peter C Levendag2, Patrick W Serruys1
Introduction
In-stent restenosis affects 15−20% of patients undergoing
balloon angioplasty (BA) and stenting for de novo
lesions1,2 and can occur in up to 40−60% of stents
implanted in long lesions in small vessels.3,4 Landmark
studies have shown that γ-radiation is effective for the
treatment of in-stent restenosis.5−7 Preliminary studies with
β-radiation demonstrated feasibility for in-stent restenosis
and results comparable with those of γ-radiation.8−10
However, most of the large-scale studies (START, START
40/20, INHIBIT) are still ongoing in order to determine
the efﬁcacy of β-radiation. The application of radiation in
patients with complex anatomy such as the involvement of
a major bifurcation or those whose native coronary
anatomy has been greatly modiﬁed by previous interven-
tions may be technically very challenging.
Case report
This is the ﬁrst case in which the 5 F. delivery catheter of
the Beta-Cath™ System (Novoste Corp., Norcross, GA) was
advanced through the struts of a stent, previously deployed
in an adjacent branch, so as to deliver radiation to the
target vessel. An 83-year-old man with a longstanding
history of coronary artery disease was admitted to another
hospital with an inferolateral myocardial infarction and
was successfully thrombolized with streptokinase without
rise in creatine phosphokinase.
Coronary artery bypass grafting (CABG) had been per-
formed in 1979 with venous conduits to the left anterior
descending artery (LAD) and right coronary artery (RCA).
Balloon angioplasty at the ostium of an intermediate
branch was performed in 1993 and stent implantation
(NIR 2.5 × 9 mm; Boston Scientiﬁc, Scimed, Medinol,
Jerusalem, Israel) in a repeat procedure of the same lesion
in 1997. Repeat balloon angioplasty was undertaken again
in 1998 for in-stent restenosis at the same site. Angioplasty
of the proximal and distal left circumﬂex artery (LCX) and
stent implantation (NIR 3 × 16 mm) was performed
during the same procedure, because of progression of the
disease in that vessel.
Eighteen months later, the patient presented with an
inferolateral infarction. Seven days after admission an
exercise tolerance test was performed, which was positive
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the treatment of in-stent restenosis. This
is the ﬁrst case in which the 5 F. delivery
catheter of the Beta-Cath™ system was
advanced through the struts of a stent,
previously deployed in an adjacent
branch, so as to deliver radiation to the
target vessel. (Int J Cardiovasc Intervent
2000; 3: 121-125)
Keywords: brachytherapy − restenosis
74
Chapter 5
with 3 mm ST depression in leads II, III, AVF  and V4-V6 at
the electrocardiogram. For this reason, cardiac catheteriza-
tion was undertaken. The coronary angiogram revealed a
severe stenosis, 83%, by quantitative coronary angiogra-
phy (QCA) (CAAS II analysis system; Pie Medical BV,
Maastricht, The Netherlands) in the distal part of the
saphenous vein graft (SVG) to the LAD, and severe in-stent
restenosis in both stents implanted in the proximal (76%)
and distal (87%) LCX (Figure 1(A)). The intermediate
branch was occluded because of severe in-stent restenosis.
This stent had been placed with signiﬁcant encroachment
into the proximal LCX artery (Figure 1(B)). Left ventricule
(LV) function was preserved (ejection fraction 62%).
The patient was referred to the authors’ hospital for
further treatment. After surgical consultation he was
graded as a high-risk patient for repeat CABG and a deci-
sion to undertake further percutaneous intervention was
taken. After detailed information and a written consent
form had been obtained he was enrolled in the RENO reg-
istry. This is a prospective, multicenter, multinational sur-
veillance registry for assessing the clinical event rate of
90Sr/90Y source (Beta-Cath system) combined with
approved PTCA techniques in patients with coronary
artery disease (native or bypass grafts).
Medication at the time of the intervention included
beta-blockers, calcium antagonists, nitrates and aspirin.
One hour before the intervention the patient received
300 mg clopidogrel. After intravenous administration of
7500 iu heparin and 250 mg acetylsalicylic acid the
ostium of the SVG to the LAD was cannulated with an 8 F.
JR4 guiding catheter (Vista Brite Tip; Cordis, Miami, FL) to
accommodate the 5 F. radiation delivery catheter. After
crossing the lesion with the guidewire (PT Graphix Inter-
mediate, Boston Scientiﬁc, Galway, Republic of Ireland)
direct stent implantation (Multi-Link Duet 3.5 × 13 mm;
Guidant, ACS, Temecula, CA) was performed with a very
good ﬁnal angiographic result. Subsequently intracoronary
radiation was performed (prescribed dose 16 Gy at 2 mm
from the center of the source).
After engagement of the Left Main stem (LM) with an 8 F.
AL2 guiding catheter (Vista Brite Tip; Cordis, Miami, FL) the
procedure continued with the treatment of the LCX. A PT
Graphix Intermediate 0.014″, 185 cm-long guidewire
(Boston Scientiﬁc) was advanced with difﬁculty through the
struts of the stent and placed at the ostium of the intermedi-
ate branch. The restenotic lesions in the proximal and distal
LCX were crossed with the wire. The distal lesion was dilated
with a 2.5 × 20 mm balloon (Worldpass; Cordis Europa,
Roden, The Netherlands) with pressures up to 20 atm with a
good angiographic result. The proximal lesion, which
included the proximal struts of the stent implanted in the
intermediate branch, was dilated sequentially with 2.5,
3.0 × 20 mm and 3.5 × 10 mm Worldpass balloons with
pressures up to 20 atm. Full expansion of the balloons was
not achieved due to strut compression (Figure 2(A)), but
with an acceptable angiographic result.
According to the RENO study protocol β-radiation was
aimed to be delivered in both dilated segments. The 5 F.
nontapering delivery catheter was advanced, with difﬁ-
culty, through the dilated struts of the stent in the interme-
diate branch. This procedure was made more difﬁcult by
the acute angulation between the left main stem and the
LCX. The catheter was carefully placed at the distal lesion
so as to cover the whole length of the injured area (Figure
2(B)), and to avoid geographical miss.11 Subsequently, the
delivery catheter was pulled back and placed in the proxi-
mal lesion without difﬁculty (Figure 3). In order to avoid
overlapping and excessive radiation of a part of the vessel
Figure 1
(A) The initial angiogram showing the two
sites of in-stent restenosis in the proximal
and distal left circumﬂex artery (LCX) and
the acute angulation between the left main
and LCX arteries. The distal part of the stent
previously deployed in the totally
occluded intermediate branch is also
visible. (B) The relationship between the
three stents is clearly visible (arrowheads
pointing to the edges). Note the gap
between the proximal LCX stent and the
intermediate branch stent which is com-
pressed in the middle and protrudes into
the lumen of proximal LCX.
(A) (B)
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the initial cine image of the radiation source in position in
the distal lesion was projected over the real time
roentgenographic image of the proximal lesion. By apply-
ing simultaneous roentgenographic overprojection and
ensuring that the image was acquired in the same phase of
the respiratory and cardiac cycle, excessive radiation to
areas of the coronary artery was avoided. With a three-
minute dwell time, 16 Gy, at 2 mm from the center of the
radiation source, was also delivered to the proximal lesion.
After completion of the irradiation, the source and the
delivery catheter were withdrawn without difﬁculty, but a
ﬁlling defect was noticed in the proximal irradiated
segment with the angiographic appearance of thrombus
(Figure 2(C)). An 8.5 ml bolus dose of intracoronary
ReoPro (abciximab) was administered followed by a
2.2 ml per hour intravenous infusion. The activated clot-
ting time at that moment was 343 seconds with a
maximum value during the procedure of 362 seconds.
Figure 2
(A) A 3.5 × 20 mm Worldpass balloon
inﬂated to 20 atm. Despite the high pres-
sure the balloon is clearly not fully
deployed in the center because of strut
compression. (B) The radiation source in
place in the distal lesion after successful
balloon angioplasty. (C) Presence of an
intraluminal ﬁlling defect with the appear-
ance of thrombus in the proximal part of
the proximal left circumﬂex artery lesion.
(D) Final angiographic result after stent
placement.
Figure 3
The delivery catheter, with its proximal and
distal markers (black arrowheads) and the
radiation source, with the proximal and
distal gold markers (white arrowheads) in
place, in the proximal left circumﬂex lesion
through the struts of the proximal part of
the stent deployed in the intermediate
branch.
A B
C D
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After a 15-minute wait it was apparent that there was no
improvement in the angiographic appearance and the
lesion was stented with a Multi-Link Tristar 3.5 × 13 mm
stent with a good ﬁnal angiographic result (Figure 2(D)).
At the end of the procedure the patient was transferred
back to the referring hospital. The same day he developed
neurological symptoms and the diagnosis of intracerebral
bleed at the left frontal lobe was made by means of a com-
puterized tomography scan. Despite optimal medical treat-
ment the patient died four days later.
Device description
The Novoste Beta-Cath device consists of three components:
(1) the transfer device which stores the radiation source
train and allows the positioning of these sources within the
catheter; (2) the delivery catheter, which is a 5 F. multilu-
men over-the-wire noncentered catheter which uses saline
solution to send and return the radiation source train; and
(3), the radiation source train consisting of a series of 12
independent cylindrical seeds which contain the radioiso-
tope 90Sr sources and which is boundaried by two gold
radiopaque markers separated by 30 mm.12
Discussion
This paper reports the ﬁrst case of intracoronary irradiation
with the use of the Beta-Cath system, in which the delivery
catheter crossed the struts of a stent previously deployed in
another vessel, for the delivery of radiation in the target
vessel. Although feasible, one must always keep in mind
the risks of complications, such as thrombus formation,
because of prolonged positioning of bulky devices in the
coronary circulation. From animal studies there is evidence
that radiation induces dose-dependent thrombosis.13 Also
to be considered is the potential risk of kinking of the
delivery catheter leading to entrapment of the radiation
source and inability to retrieve the device, with subsequent
potentially deleterious effects. Balloon entrapment during
side-branch angioplasty through a stent has been
described.14 New 3 F. delivery catheters are currently under
development (Novoste, personal communication, 2000).
This will make the application of β-radiation with this
system easier, safer and applicable in smaller vessels.
Dose perturbations caused by stents, especially for the
-radiation, which has a ﬁnite range in the tissue (typically
a few millimeters) is an important issue for the manage-
ment of in-stent restenosis. In a balloon liquid-ﬁlled
model the average dose reduction varied from 4% to 14%
in the presence of nine different types of stents, depending
on stent mass, geometry, strut thickness and composi-
tion.15 For the NIR stent this attenuation was found to be
in the area of 4%. If this shielding effect proves to be clini-
cally important, dose adjustments may be required to use
β-sources effectively for treatment of restenotic lesions that
have previously been stented, particularly when there are
multiple or overlapping stents. Additionally, stents with
low attenuation may be used for primary stenting before
radiation whereas others should be reserved for postradia-
tion stenting.
The deformation of various types of stents with simu-
lated side-branch dilation in phantom vessels has been
recently reported.16 When the struts of an NIR stent were
dilated with a 3.5 mm balloon at 6 atm the minimal
lumen diameter at the side-branch ostium, which corre-
sponds to the deformation of the struts, was 1.7 mm. This
diameter is slightly bigger than the diameter of a 5 F.
(1.65 mm) catheter. In the era of intracoronary
brachytherapy, where bulky delivery catheters might need
to cross stent struts, the selection of a stent with the bigger
cell dimensions when fully deployed might be an impor-
tant issue. Under these circumstances a seven-cell NIR
stent, for example with a cell diameter of 1.1 mm when
fully deployed, is more suitable than the nine-cell design
of the same stent with a cell diameter of 0.6 mm.
Restenosis rate after balloon angioplasty is higher at a
bifurcation site.17 Various techniques for stenting bifur-
cated lesions have been reported for better acute outcome
and to reduce restenosis.18 True bifurcational stents have
also been described with promising results,19 but resteno-
sis remains a signiﬁcant limitation. Brachytherapy usage is
most compelling for the treatment of recurrent in-stent
restenosis.11 Because of this, interventional cardiologists
will face the challenge of crossing the struts of stents with
radiation delivery catheters for irradiation of side-branches
or bifurcation lesions.
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Routine intracoronary beta-irradiation
Acute and one year outcome in patients at high risk for recurrence
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Aims Intracoronary radiation is a promising therapy
potentially reducing restenosis following catheter-based
interventions. Currently, only limited data on this treat-
ment are available. The feasibility and outcome in daily
routine practice, however, is unknown.
Methods and Results In 100 consecutive patients, intra-
coronary beta-radiation was performed with a 90Strontium
system (Novoste Beta-Cath) following angioplasty.
Predominantly complex (73% type B2 and C) and long
lesions (length 24·315·3 mm) were included (37% de
novo, 19% restenotic and 44% in-stent restenotic lesions).
Radiation success was 100%. Mean prescribed dose was
19·82·5 Gy. A pullback procedure was performed in 19%
lesions. Geographic miss occurred in 8% lesions. Peri-
procedural thrombus formation occurred in four lesions,
dissection in nine lesions. During hospital stay, no death,
acute myocardial infarction, or repeat revascularization
was observed. Major adverse cardiac events occurred
predominantly between 6 and 12 months after the index
procedure with major adverse cardiac event-free survival of
66% at 12 months (one death, 10 Q-wave myocardial
infarctions, 23 target vessel revascularizations; ranked for
worst event).
Conclusion Routine catheter-based intracoronary beta-
radiation therapy after angioplasty is safe and feasible with
a high acute procedural success. The clinical 1-year
follow-up showed delayed occurrence of major adverse
cardiac events between 6 and 12 months after the index
procedure.
(Eur Heart J, 2002; 23: 1038–1044, doi:10.1053/euhj.2001.
3045)
 2002 The European Society of Cardiology. Published by
Elsevier Science Ltd. All rights reserved.
Key Words: Brachytherapy, angioplasty, safety, radio-
isotopes.
See page 999, doi:10.1053/euhj.2001.3176 for the Editorial
comment on this article
Introduction
Although balloon angioplasty and stent placement have
become the predominant modes of coronary revascular-
ization, restenosis remains the major limitation for
catheter-based therapies. Restenosis rates in short type
A and B lesions are reported to be 30–40% for conven-
tional balloon angioplasty and 15–30% for stents[1,2].
Coronary radiation is a promising therapy potentially
reducing restenosis. Current concepts for coronary
irradiation include external radiation[3], radioactive
balloons[4], radioactive stents[5–7] and afterloading.
Currently, only limited data on this treatment are
available[8–10]. The safety and feasibility in daily routine
application, however, are unknown. We report on the
acute procedural and long-term clinical success using
routine 90Strontium/Yttrium radiation in a patient
population at high risk for recurrence of stenosis.
Methods
Patients
The patient population consisted of consecutive patients
within the multicentre RENO registry[11] with angina
Revision submitted 9 October 2001, accepted 10 October 2001, and
published online 21 December 2001.
Correspondence: Prof. P. W. Serruys, MD, PhD, Head of Interven-
tional Department, Thoraxcentre, Bd. 408, University Hospital
Dijkzigt, Dr. Molewaterplein 40, 3015 GD Rotterdam, The
Netherlands.
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and/or objective evidence of ischaemia, who had
angiographically documented coronary artery disease
and were scheduled to undergo beta-brachytherapy.
Patients were included after successful treatment with
conventional angioplasty and/or debulking procedures.
Patients with impaired left ventricular function (<30%),
undergoing or having prior chest radiotherapy, acute
myocardial infarction or angiographic evidence of fresh
thrombus (ﬁlling defect proximal to or involving the
stenosis) prior to radiation therapy were excluded. All
included patients had given written informed consent.
Angioplasty and radiation procedure
Angioplasty was performed via the femoral approach
using routine procedures with commercially available
systems and 8F guiding catheters. The position of all
balloons, stents or debulking devices was documented
angiographically. After the initial catheter-based pro-
cedure, the absence of dissection, thrombus or spasm
prior to placement of the Beta-Rail delivery catheter
was assured by contrast injection after a waiting period
of 5–10 min.
Pre-interventional medication included non-enteric
aspirin (325 mg) and intravenous heparin (10 000 to
15 000 IU), in order to keep the activated clotting time
to >300 s during the procedure. Post-interventional
medication consisted of long-term aspirin and anti-
platelet therapy (clopidogrel 75 mg daily after a loading
dose of 300 mg on the day of the procedure) for
3–7 months.
Intracoronary beta-irradiation was performed using a
90Strontium/Yttrium source with a non-centring catheter
(Novoste Beta-Cath). Following successful angio-
plasty, the Beta-Rail delivery catheter was advanced
over the guide wire into the vessel so that the radiopaque
markers on the delivery catheter were equidistant from
the centre of the injured segment, with a margin to the
edge of the injured segment of 7 mm. After withdrawal
of the guide wire, the source train was transported
hydraulically to the distal end of the delivery catheter.
The position of the source was documented angio-
graphically. At the end of the calculated radiation time,
the source was withdrawn and the Beta-Rail delivery
catheter was removed over the guide wire. The dose was
delivered at 2 mm from the source axis and adapted to
the vessel diameter. Dosage calculation and delivery of
the radioactive seeds was carried out by a radiation
oncologist. The length of the source train was 30 mm,
40 mm or 60 mm. If the injured segment could not be
covered completely with one source, a pullback pro-
cedure was performed. The source train was ﬁrst posi-
tioned to cover the distal portion of the injured segment,
then withdrawn to cover the proximal portion of the
injured segment. Proximal positioning of the delivery
catheter was performed using a dummy source train
and overlay imaging technique. An ECG-gated video-
loop, showing the distal source position projected on
the ﬂuoroscopic image, was performed in the same
projection, table position and expiration position of the
patient. The delivery catheter was placed in such a way
that the radiopaque marker, indicating the proximal end
of the distal source, overlapped with the distal marker of
the proximal dummy source. After exact positioning, the
dummy source was removed hydraulically and the active
source train inserted.
Success
Procedural success was deﬁned as 30% residual
stenosis post procedure before removal of the guiding
catheter and a successful radiation therapy procedure.
Brachytherapy success was deﬁned as complete (>90%)
delivery of the prescribed radiation dose, including dose
interruption and resumption. Clinical success was
deﬁned as procedural success without the occurrence of
major adverse cardiac events (death, myocardial infarc-
tion, target vessel re-PTCA or coronary artery bypass
grafting (CABG)) during the hospital stay.
Angiography
On-line quantitative coronary analysis was performed
using the CAAS II system (Pie Medical, Maastricht,
NL)[12]. All angiograms were evaluated after intra-
coronary administration of nitrates. The minimal lumen
diameter was determined by edge detection; the refer-
ence diameter was automatically calculated by the inter-
polated method. The percent diameter stenosis was
calculated from the minimal lumen diameter and the
reference diameter. Lesions were classiﬁed as discrete
(<10 mm length) or diﬀuse (>10 mm length)[13].
Follow-up
Clinical follow-up for the occurrence of major adverse
cardiac events, was performed within 12 months of the
radiation procedure.
Statistical analysis
All statistical analysis was performed with commercially
available software (SPSS 9.0, SPSS Inc. Chicago,
Illinois, U.S.A.). Data are presented as meanstandard
deviation, median and [interquartile range] or propor-
tions. Survival analysis was conducted using the
Kaplan–Meier method.
Results
In the 100 patients who were included prospectively, 108
arteries were treated.
Patient characteristics
Patient baseline characteristics are given in Table 1.
Coronary risk factor distribution was typical of the
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population in terms of age and gender. Twenty-seven
patients presented with unstable angina (of whom one
had acute myocardial infarction), 29 had prior myo-
cardial infarction and 45 showed severe coronary artery
disease with signiﬁcant lesions in several epicardial
arteries.
Lesion characteristics and angiographic data
Lesions were located in 102 native arteries (36 LAD, 28
LCx, 38 RCA) and in six venous bypass grafts. Forty
were de-novo lesions and 68 were restenoses, of which 47
were in-stent restenotic lesions. Lesion type was A in
four lesions, B1 in 17, B2 in 46 and C in 33 lesions, of
which 12 showed total occlusion. Lesion length was
24·315·3 mm, with 90% of lesions being longer than
10 mm. Reference diameter was 3·020·58 mm and
minimal lumen diameter 1·090·18 mm, resulting in a
mean diameter stenosis of 77·213·4%. The ﬁnal refer-
ence diameter was 3·130·56 mm, the ﬁnal minimal
lumen diameter 2·470·21 mm and the ﬁnal diameter
stenosis 21·27·8%.
Angioplasty procedure
Angioplasty was performed in all lesions (n=108). In
four lesions, debulking was used prior to balloon angio-
plasty and irradiation (three laser, one directional
atherectomy). Angioplasty consisted of balloon inﬂation
in 25 lesions and stent implantation in 79 lesions.
Stenting was performed electively in 80%, due to an
insuﬃcient angioplasty result in 9% and to dissection
after balloon dilatation in 11%. In 39 lesions direct
stenting was performed. The procedural success rate
was 92%.
Brachytherapy success
Intracoronary beta-irradiation was possible in all 108
lesions, resulting in a brachytherapy success rate of
100%. The mean prescribed dose was 19·82·5 Gy at
2 mm from the centre of the source axis. To cover the
injured vessel segment, a long source of 60 mm was used
in three lesions and in 21 lesions a pullback procedure
was performed (Table 2). Complete coverage with a
safety margin of at least 7 mm proximal and distal to the
injured segment could be achieved in 99/108 lesions; thus
geographic miss occurred in only 8·3% of the lesions.
Irradiation had to be fractionated in four patients due
to severe angina and ECG changes indicative of myo-
cardial ischaemia. Non ﬂow-limiting thrombus forma-
tion, successfully treated with GPIIb/IIIa inhibitors,
occurred in four lesions. Dissections were observed after
manipulation of the delivery catheter in nine lesions. Of
these, three were type B and C dissections, necessitating
stent implantation, six were non ﬂow-limiting type A
dissections not requiring further treatment.
Clinical success
After the procedure and during hospital stay, no death,
acute myocardial infarction, or repeat revascularization
was observed. One patient, who underwent the pro-
cedure for acute myocardial infarction showed a rise in
creatinine kinase up to 723 IU . l1. Thus, the clinical
success rate was 91%. Median time to hospital discharge
after the procedure was 2 (1;2) days. One patient, treated
for a type C lesion in the medial right coronary artery
with direct stent implantation (slotted tube stent 3·0/
20 mm) followed by irradiation with a 30 mm source,
developed pericardial tamponade after the procedure
caused by the exit of the PTCA guide wire prior to
irradiation. It was successfully treated with pericardial
drainage. The patient was discharged 4 days after the
procedure. Two patients with insulin-dependent diabetes
mellitus and pre-existing impairment of renal func-
tion (creatinine 137 mmol . l1 and 154 mmol . l1)
Table 1 Patient baseline characteristics. Data are pre-
sented as meanstandard deviation or proportions of
patients (n=100)
Mean age (years) 5910
Gender (male) 72
Angina status
Stable angina (CCS 1–4) 73
Unstable angina 27
Cardiovascular risk factors
History of smoking 46
Diabetes mellitus 14
History of hypertension 39
History of hypercholesterolaemia 58
Prior myocardial infarction, related to target vessel 29
Extent of vessel disease
One-vessel disease 55
Two-vessel disease 32
Three-vessel disease 13
CCS=Canadian Cardiovascular Society.
Table 2 Radiation procedure. Data are presented as
meanstandard deviation or proportions of lesions
(n=108)
Source length (mm)
30 36·1
40 61·1
60 2·8
Pullback procedure 19·0
Radiation dose (Gy)
16·1 6·7
18·4 61·0
20·7 2·9
23·0 24·8
25·3 4·8
Dwell time (min) 3·340·44
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developed acute transient renal insuﬃciency after the
procedure. This resolved after forced hydration in com-
bination with furosemide. The subsequent hospital stay
of these patients was uneventful, one left the hospital
4 days, the other 10 days after the procedure. Four
patients developed isolated mild creatinine kinase elev-
ation (mean 374123 IU . l1) within 24 h of the
procedure without chest pain or ECG changes (Table 3).
One year follow-up
During 12 months clinical follow-up, 34 patients
experienced major adverse cardiac events, which are
given in Table 4. Mean follow-up time was 35934
days. Event-free survival is given in Fig. 1. Target vessel
repeat PTCA was clinically driven by the recurrence of
angina in all patients. In the patient group undergoing
CABG, one patient showed severe progression of cor-
onary artery disease, including the left main stem, but no
restenosis at the target vessel. Three patients experienced
myocardial infarction prior to CABG.
In the 29 patients with target vessel restenosis, rest-
enosis was discrete (<10 mm length) in 17 patients and
located at the proximal (n=6), the distal (n=5) or both
extremities (n=6) of the index lesion. Seven patients
showed diﬀuse restenosis (>10 mm length) and ﬁve
patients total vessel occlusion. During the follow-up
period, nine patients experienced acute myocardial
infarction (while one patient underwent the index pro-
cedure for acute myocardial infarction as described
above). Out of these nine patients, three received a new
Table 3 In-hospital major adverse cardiac and clinical
events. Data are given as numbers (no.) of events, no
patient experienced multiple events
Event No. of events
Major adverse cardiac event (MACE)
Death 0
Q-wave myocardial infarction 1*
CABG 0
Repeat PTCA 0
Clinical event
Pericardial tamponade 1
Renal insuﬃciency 2
Isolated CK elevation 4
CABG=coronary artery bypass graft; PTCA=percutaneous
transluminal coronary angioplasty; CK=creatinine kinase.
*One patient underwent the angioplasty procedure for acute
myocardial infarction.
Table 4 Major adverse cardiac events at 12 months
follow-up. Data are given as numbers (no.) of events and
ranked (ranking) as follows: death, Q-wave myocardial
infarction, CABG, repeat PTCA
Event No. of events Ranking
Death 1 1
Q-wave myocardial infarction 10* 10
CABG 6 3
Repeat PTCA 24 20
CABG=coronary artery bypass graft; PTCA=percutaneous
transluminal coronary angioplasty.
*One patient underwent the angioplasty procedure for acute
myocardial infarction.
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Figure 1 Event-free survival at 12 months follow-up (Kaplan–Meier).
TVR=target vessel revascularization, includes repeat PTCA and CABG.
MACE=major adverse cardiac events. Events are given ranked as
follows: death, Q-wave myocardial infarction, CABG, repeat PTCA.
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stent at the index procedure, ﬁve underwent stent
in-stent implantation and one balloon dilatation of a
restenotic stent. Myocardial infarction occurred in two
patients under clopidogrel medication at days 13 and 54
after the index procedure. The other seven patients
experienced myocardial infarction after stopping clopi-
dogrel medication between days 191 and 363 after the
index procedure. The maximum creatinine kinase rise
was 1361 (762; 2409) IU . l1.
The patient population who developed major adverse
cardiac events was predominantly female (37%), diabetic
(27%), or had three-vessel disease (23%) and unstable
angina (41%). Indications for angioplasty were de-novo
lesions in 46%. A total of 88% patients received a new
stent at the index procedure.
Discussion
Study population
This study describes the clinical outcome of routine
intracoronary beta-irradiation in a large number of
patients at high risk for recurrence of stenosis. This is
indicated by the relatively high proportion of patients
with multivessel disease, restenosis, type B2 and C
lesions and the lesion length. Thus, our series is likely to
reﬂect ‘real world’ lesions in a tertiary care centre. The
generalizability of study results is important as the
number of centres licensed for intracoronary radiation
therapy has grown rapidly since randomization of the
ﬁrst patients in Europe in 1997 at our centre.
Feasibility in the ‘real world’
Brachytherapy was applied routinely and with consider-
able success. The prescribed radiation dose could be
delivered to all lesions. Special care was taken to com-
pletely cover the injured vessel segment in order to avoid
‘geographic miss’, the deleterious eﬀect of balloon-
induced injury and low dose radiation at the extremities
of the source train[14]. To overcome this potential limi-
tation of intracoronary irradiation, sequential pullback
or a combination of source trains of diﬀerent lengths
was performed in a relatively high proportion of
patients. The 60 mm long source became available only
at the end of the study. The use of a long source,
however, might in future spare the relatively complex
pullback procedures. Every step of the procedure needed
to be documented by contrast injection to avoid geo-
graphic miss. This increased the consumption of con-
trast agents, which was not without risk, as seen in our
patients who developed transient renal insuﬃciency.
Procedural complications
No acute or subacute major adverse cardiac events
or irradiation-induced major complications were seen.
The procedural costs (assessed by the costs of the used
material), however, were raised substantially from
a mean of 3200 Euro for conventional coronary
angioplasty procedures (1/2000–5/2000) to 4100 Euro.
Thus, the cost-eﬀectiveness of intracoronary brachy-
therapy still needs to be proven. Our ﬁndings are in
accordance with previous published data[9] on various
afterloading techniques. In some of these series, how-
ever, irradiation-induced adverse events were reported.
Using a 192 Iridium source, Condado et al. describe
successful gamma-radiation delivery in all 21 patients
following balloon angioplasty; however, one patient
developed prolonged coronary spasm, and another suf-
fered subacute thrombosis[15]. In contrast in another
series of 26 patients with restenotic or in-stent restenotic
lesions, no in-hospital adverse events were seen[8]. In a
larger patient cohort (n=130) undergoing randomized
gamma irradiation for in-stent restenosis, two patients in
the placebo and two in the radiation group required
fractionation of radiation due to angina and ischaemia,
two patients required vascular access site repair and
8% of patients had creatine kinase MB elevation[16].
Similarily, dose fractionation due to ischaemia was
required in 11/50 patients receiving beta-afterloading
with a centred device for in-stent restenosis[17], indicat-
ing insuﬃcient distal perfusion with the centring balloon
during irradiation. This was similar to that seen in 4/15
patients in the Geneva series[18]. In our study with a
non-centred device, dose fractionation was necessary in
only 4/108 lesions. The need for dose fractionation
might be further reduced by the introduction of smaller
3·5 F brachytherapy catheters.
Thrombus
The most frequently seen events with a possible
irradiation association were thrombus formation and
dissections. In our series, in four lesions intracoronary
thrombus formation during the procedure could be
visualized by angiography as a contrast ﬁlling defect. In
all four lesions, thrombus formation was not ﬂow-
limiting. All patients received GP IIb/IIIa inhibitors
intravenously for 12 h, their in-hospital course was
uneventful, without evidence for (sub-)acute thrombosis.
Weight-adjusted heparin dosage and more frequent use
of GP IIb/IIIa inhibitors could have possibly prevented
thrombus formation.
Dissection
In 9/108 lesions, dissections were documented angio-
graphically at the end of the irradiation procedure. In
3/9 lesions, further preventive stent implantation was
performed[19]. However, the prognostic impact of non
ﬂow-limiting dissections in patients undergoing brachy-
therapy is poorly understood. Previous case series (16
patients each) with acute dissection following balloon
angioplasty and intracoronary beta-irradiation have
shown that these dissections persist in approximately
50% of the patients[20,21] at the 6 month follow-up.
Persisting dissections were not associated with a change
in angina status or any acute or subacute clinical
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sequelae[21]. In contrast, 2/6 patients presenting with
sudden thrombotic events after balloon angioplasty and
beta irradiation showed a type B dissection after the
procedure[22]. No correlation between persistence of
dissection and the prescribed dose was seen[20].
One year outcome
Major adverse event-free survival in our patients was
66% at 1 year. This seems worse than after conventional
stent implantation in the Benestent trial, were a major
adverse cardiac event-free survival of 77% at 1 year is
reported[23]. However, our patient population, present-
ing with less than 5% ‘Benestent’ type A lesions, was at
high risk for recurrence of stenosis. When looking at
patient populations which are more comparable to ours,
such as patients treated with gamma-radiation for
in-stent restenosis, our data are very similar to the
reported event-free survival of 65%[16].
Major adverse cardiac events comprized target vessel
revascularization and delayed myocardial infarction.
This was possibly caused by increased thrombogenicity
and prolonged wound healing reported in
experimental[24–26] and clinical series[22]. The evolving
clinically important question is the duration of platelet
inhibition and whether or when to stop clopidogrel
prescription. Data from the SCRIPPS Clinic suggest
that late thrombosis and myocardial infarction are in-
frequent after 12 months[10]. Furthermore, the complex
interaction between freshly implanted stents, radiation
therapy and late thrombosis needs to be clariﬁed. In our
patients, late thrombosis with consecutive myocardial
infarction was not exclusive to freshly implanted stents
and after discontinuing clopidogrel medication. Other
data suggest an association between these parameters[27].
Further investigations are clearly needed.
Limitations
This is a non-randomized, non-placebo controlled
monocentre experience. We evaluated only one type of
beta-radiation delivery catheter; thus, these results
cannot be extrapolated to other radiation (e.g.
centering) delivery systems or other (e.g. gamma)
sources. These data are restricted to the 12 month
outcome. Radiation-induced delayed restenosis needs to
be further investigated. The small number of events in
this study does not allow the identiﬁcation of patient-
or lesion-related factors predicting adverse procedural
outcome.
Conclusion
Routine catheter-based intracoronary beta-radiation
therapy after angioplasty is safe and feasible with a high
acute procedural success. However, the clinical 1-year
follow-up showed delayed major adverse cardiac events
occurring between 6 and 12 months after the index
procedure.
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OBJECTIVES We sought to determine the incidence and causes of geographical miss (GM) and to evaluate
its impact on edge restenosis after intracoronary beta-radiation therapy.
BACKGROUND Edge restenosis is a limitation of intracoronary beta-radiation therapy. Geographical miss is
the situation in which the radiation source does not fully cover the injured segment and may
lead to edge restenosis.
METHODS We analyzed 175 vessels treated according to the Beta-Radiation In Europe (BRIE) study
protocol. The effective irradiated segment (EIRS) and both edges were studied with
quantitative coronary angiography. The edges of the EIRS that were injured constituted the
GM edges. Restenosis was deﬁned as diameter stenosis 50% at follow-up. Geographical
miss was determined by simultaneous electrocardiographic-matched, side-by-side projection
of the source and balloons deﬂated at the injury site, in identical angiographic projections
surrounded by contrast.
RESULTS Geographical miss affected 41.2% of the edges and increased edge restenosis signiﬁcantly
compared with non-GM edges (16.3% vs. 4.3%, respectively, p  0.004). Restenosis was
increased both in the proximal (p  0.05) and distal (p  0.02) GM edges compared with
noninjured edges. Geographical miss associated with stent injury signiﬁcantly increased edge
restenosis (p  0.006), whereas GM related to balloon injury did not signiﬁcantly increase
edge restenosis (p  0.35). The restenosis in the EIRS was similar between vessels with and
without GM (24.3% and 21.6%, respectively, p  0.8).
CONCLUSIONS Geographical miss is strongly associated with restenosis at the edges of the EIRS. This effect
is more prominent when caused by stenting. Geographical miss does not increase restenosis
in the EIRS. (J Am Coll Cardiol 2001;38:415–20) © 2001 by the American College of
Cardiology
Intracoronary radiation therapy is a new technique for the
prevention of restenosis after percutaneous coronary inter-
ventions (1–3). Catheter-based systems and radioactive
stents are currently used to deliver radiation (4). The
development of stenotic lesions at the edges of the segment
receiving the full-prescribed dose is a potential limitation of
this treatment. This phenomenon described both after
radioactive stent implantation and catheter-based intracoro-
nary radiation was termed the “edge effect” (5–7). The
pathophysiology of the “edge effect” may be the result of
vessel wall injury (8–10) concomitant with low-dose radia-
tion at the edges of the irradiated segment (11,12). The
term geographical miss (GM) was invented in radio-
oncology to deﬁne a cause of treatment failure due to low
dose radiation. In such cases, a small part of the treatment
zone either escaped radiation or was inadequately irradiated
because the total volume of the tumor was not appreciated
and hence an insufﬁcient margin was taken (13). This
concept was translated in interventional cardiology to deﬁne
those coronary segments that were injured but received
low-dose radiation (14). Aims of the study were to deter-
mine the incidence and causes of GM and to evaluate the
impact of this inadequate treatment on the angiographic
outcome in vessels treated according to the protocol of a
multicenter intracoronary beta-radiation study using a
catheter-based system.
METHODS
Patient selection. We retrospectively analyzed 149 pa-
tients treated with catheter-based beta-radiation using the
Beta-Cath system (Novoste Corp., Norcross, Georgia) en-
rolled in the Beta-Radiation In Europe (BRIE) trial.
Patients included in the radiation protocol were those with
objective signs of ischemia and presence of signiﬁcant de
novo lesions. Out of the total population, 123 patients
underwent single-vessel percutaneous transluminal coronary
angioplasty and the remaining 26 patients underwent two-
vessel angioplasty, giving 175 vessels in total. In 36 patients
(44 vessels) GM was not interpretable, leaving 113 patients
with 131 vessels for further analysis. Characteristics of
patients with interpretable angiographic documentation are
summarized in Table 1.
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Device description. The device consists of three compo-
nents: 1) the transfer device, which stores the radiation
source train and allows its positioning within the catheter;
2) the delivery catheter, which is a 5 Fr multilumen
noncentered catheter that uses saline to send and return the
radiation source train; and 3) the radiation source train,
consisting of 12 independent cylindrical seeds that contain
the radioisotope 90Sr/90Y source, encompassed by two
radiopaque gold markers (30 mm in length) (4). The
longitudinal distance of the “full” prescribed dose (100%
isodose) coverage measured by radiochromic ﬁlm is about
26 mm (15), constituting the effective irradiation length.
Dosimetry. Prescribed dose at 2 mm from the centerline of
the source axis was 14 to 18 Gray (Gy), based on the
reference diameter, by on-line quantitative coronary angiog-
raphy (QCA), measured 3.35 mm or 3.35 mm, respec-
tively. The radiation source remained at the treatment site
for approximately 2 to 4 min to deliver the prescribed dose.
Post-hoc QCA conﬁrmed appropriate dosimetry in all
treated vessels.
Deﬁnitions. Vessel segment (VS) deﬁned the coronary
segment bordered by two side branches that encompassed
the original lesion, angioplasty balloon and radiation source.
The injured segment (INS) was encompassed by the most
proximal and distal position of the radiopaque markers of
the balloons used for dilation or stent implantation. The
irradiated segment, 30-mm in length, was deﬁned as the
segment encompassed by the two gold markers of the
radiation source train. The effective irradiated segment
(EIRS) was the segment that received the full-prescribed
dose and corresponded to the 26-mm central part of the
radioactive source train. These segments are illustrated in
Figure 1. The edges of the EIRS are the adjacent (proximal
and distal) 5 mm coronary segments, consisting of the 2 mm
inside and 3 mm outside the gold markers. These edges
received low-dose radiation because of fall-off of dose in the
beta-emitting 90Sr/90Y source (16,17). The highest pre-
scribed dose was 18 Gy at 2 mm from the centerline of the
source axis and the calculated dose at each millimeter away
from the 100% isodose in the axial direction was expected to
be 15.5 Gy at 1 mm, 11 Gy at 2 mm, 5.5 Gy at 3 mm, 2.4
Gy at 4 mm and 1 Gy at 5 mm (Fig. 1). Those edges,
which were traumatized by balloon inﬂation (minimum
inﬂation pressure was 6 atmospheres) or received new stent
implantation during the procedure, were deﬁned as GM
edges. Noninjured edges were those that were not trauma-
tized during the intervention.
Determination of the GM edges. To determine whether
the edges of the EIRS were injured, we retrospectively
analyzed, blind to the presence or absence of restenosis and
its location at follow-up, all the baseline (intervention plus
radiation) angiograms. The following steps were followed:
during the procedure all the interventions (balloons or
stents) deﬂated at the site of injury and the radioactive
source in place were ﬁlmed with contrast in identical
angiographic projections. This approach allowed us to
deﬁne the location of the various subsegments (EIRS, INS
and edges) in relation to side branches and the correct
matching of the angiograms in the ofﬂine analysis. A
continuous electrocardiogram recording was also dis-
played, allowing the selection of still frames in the same part
of the cardiac cycle. Multiple angiographic loops and
electrocardiographic-matched still frames could be dis-
played simultaneously, side by side, on the screen with the
Rubo DICOM Viewer (Rubo Medical Imaging, Uithoorn,
Netherlands). By identifying the relationship between the
EIRS and its edges relative to the INS, we determined the
GM edges. Two independent cardiologists (G.S., M.C.)
performed the above-mentioned analysis. There was only
10% disagreement on the presence or absence of GM and its
location proximal or distal. These were borderline cases that
were reanalyzed by a third reviewer (P.W.S.) with the use of
transparencies before a ﬁnal conclusion was determined.
In cases where one or more of the following criteria were
present, the procedure was reported as noninterpretable: 1)
incorrect ﬁlming of the radiation source or the balloons
deﬂated with contrast injection; 2) more than 10° difference
in the angiographic projections not allowing correct match-
ing; and 3) interventions reported in the technician’s work
sheet but not ﬁlmed.
QCA analysis. The EIRS and both edges were analyzed by
QCA before and after intervention, and at six-month
follow-up. All angiograms were evaluated after intracoro-
nary administration of nitrates. The ofﬂine analysis of two
Abbreviations and Acronyms
BE  balloon edges
BRIE  Beta-Radiation In Europe study
CI  conﬁdence interval
EIRS  effective irradiated segment
GM  geographical miss
Gy  Gray
INS  injured segment
IVUS  intravascular ultrasound
OR  odds ratio
QCA  quantitative coronary angiography
SE  stent edges
VS  vessel segment
Table 1. Patients and Procedural Characteristics
Age (range) 59 (35 to 85 yrs)
Males 83/113 (73.4%)
Diabetes 17/113 (15%)
Hypertension 39/113 (34.5%)
Prior MI 39/113 (34.5%)
Prior CABG 5/113 (4.4%)
LAD 51/131 (38.9%)
LCX 28/131 (21.4%)
RCA 52/131 (39.7%)
Balloon angioplasty 48/131 (36.6%)
Rescue stenting 12/131 (9.2%)
Provisional stenting 71/131 (54.2%)
CABG  coronary artery bypass graft operation; LAD  left anterior descending;
LCX  left circumﬂex; MI  myocardial infarction; RCA  right coronary artery.
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orthogonal projections was performed with the CAAS II
analysis system (Pie Medical BV, Maastricht, Netherlands).
Calibration of the system was based on dimensions of the
catheters not ﬁlled with contrast. This method of analysis
has been previously validated (18–20). The following QCA
parameters were computed in the VS: computer-deﬁned
minimal luminal diameter, reference diameter obtained by
an interpolated method and percentage diameter stenosis.
Binary restenosis was deﬁned in every segment as diameter
stenosis 50% at follow-up. This allowed the determina-
tion of restenosis in the VS (overall restenosis). Computer-
deﬁned subsegmental analysis (mean subsegment length
was 5  0.3 mm, depending on the length of the analyzed
VS) was also performed. In each subsegment, percentage
diameter stenosis was also automatically calculated. This
allowed the determination of restenosis in relation to the
dose-based subsegments, which was termed regional resten-
osis.
Determination of the restenosis location. Three observ-
ers analyzed all the ﬁlms that appeared to have restenosis at
the follow-up angiogram. The printouts of the pre-, post-
and follow-up angiograms, in two orthogonal projections,
with the subsegmental analysis and the dose-based subseg-
ments superimposed, were compared. The observers desig-
nated the location of the computer-deﬁned QCA subseg-
ments with restenosis in relation to the dose-based
segments. Restenosis was classiﬁed as restenosis in the
EIRS, edge restenosis (proximal or distal) and restenosis
outside the irradiated segment. It is important to realize that
the criterion for binary restenosis might be fulﬁlled in more
than one subsegment in the same VS.
Statistical analysis. Continuous data are presented as
mean values; discontinuous data are presented as percent-
ages. Differences in restenosis rates between edges with and
without GM were evaluated with chi-square or Fisher exact
tests as appropriate. Because the behavior of different
Figure 1. (Left) Isodose contour rate map and radiation source train. Isodose rate contour map at a depth of 1.89 mm (10 mGy/s contour intervals) as
described by National Institute of Standards and Technology. This depth (1.89 mm) illustrates an isodose model resembling the radius of the coronary artery
wall. The longitudinal dose falloff may be extrapolated from this graphic. The central part of the source train (26 mm) radiates approximately full dose
constituting the effective irradiation length (EIRL). (Right) A diagram of an irradiated coronary artery and the anatomical and dose-based segment
deﬁnition. EIRS  effective irradiated segment; INS  injured segment; IRS  irradiated segment; IRL  irradiation length; SB  side branch; VS 
vessel segment.
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segments in the same vessel and the behavior of different
vessels in the same patient may not be independent, the
relation between GM and edge restenosis was further analyzed
by logistic regression analysis, using generalized estimation
equation modeling techniques to correct for possible within-
patient effects. The presented odds ratios (OR) and 95%
conﬁdence intervals (CI) are based on these analyses. Statistical
signiﬁcance of all tests was deﬁned at the p  0.05 level.
RESULTS
Incidence and causes of GM. VESSELS. A total of 131
vessels were interpretable. The incidence of GM was 67.9%
(Table 2).
EDGES. In each vessel, both proximal and distal edges of the
EIRS were analyzed, giving in total 262 edges. Out of the 89
vessels with GM, 70 had one GM edge, proximal or distal, and
in 19 vessels both edges were injured, giving in total 108 GM
edges. The incidence of GM at the edges was 41.2%. The
location proximal and distal was comparable (Table 3).
Procedural causes of GM. The following reasons were
responsible for the GM: 1) development of procedural
complications (additional stent implantation postradiation)
that extended the treatment beyond the margins of the
EIRS (52.8%, 57/108) (unexpected GM); 2) the INS from
prior inﬂations was not appropriately covered by the source
(34.2%, 37/108), termed as lack of accurate matching; and
3) treatment of long lesions requiring balloons or stents
longer than 26 mm (EIRS) and lack of availability of longer
(30 mm) radiation source (13%, 14/108).
Restenosis rate. Follow-up angiograms were available in
115 out of 131 vessels. The restenosis rate in the EIRS was
23.5%. The presence or absence of GM did not affect the
incidence of restenosis in the EIRS (24.3% and 21.6%
respectively, p  0.8). The restenosis in the proximal edge
was 9.5% and in the distal edge 8.7%. Because binary
restenosis can be encountered more than once per VS
(either in the EIRS or at the edges) the summation of the
regional restenosis rate is higher than the restenosis rate in
the VS. There were three vessels with restenosis in both the
EIRS and the proximal edge and four vessels with restenosis
in both EIRS and the distal edge. There were no cases with
restenosis in both edges.
Generalized estimation equation analysis, which was used to
account for within-patient effects, showed that the probability
for restenosis at the edges of the EIRS depended on the GM
(p  0.0039), but not on distal/proximal lesion location (p 
0.6) or the device (balloon/stent) used (p  0.1).
Regional restenosis rate in relation to GM. In each of the
115 vessels (101 patients), the impact of GM on restenosis
was analyzed in both proximal and distal edge (230 edges).
Geographical miss signiﬁcantly increased the incidence of
restenosis at the edges of the EIRS compared with lesions
without GM (4.35% vs. 16.3%, p  0.004). This effect was
observed both in the proximal (5.56% vs. 16.28%, p 0.05)
and distal (3.03% vs. 16.33%, p  0.02) edges and seems to
be more pronounced at the distal edge (OR  5.3)
compared with the proximal (OR  3.2). The OR and the
CI are presented in Figure 2.
Impact of GM on the restenosis rate in relation to the
type of injury. Out of the 230 interpretable edges, 84
(36.5%) were related with balloon angioplasty termed as
balloon edges (BE) and 146 (63.5%) with stent implanta-
tion termed as stent edges (SE). The incidence of GM at
the BE and the SE was comparable (33.4% and 43.8%,
respectively). At the SE, GM increased the incidence of
restenosis signiﬁcantly compared with edges without GM
(3.66% vs. 18.75%, p  0.006). At the BE, GM did not
signiﬁcantly increase the incidence of restenosis (5.36% vs.
10.71%, p  0.35). The OR and the CI are presented in
Figure 3.
DISCUSSION
This study reports on the incidence and causes of GM and
its implications on edge restenosis in vessels treated with
intracoronary beta-radiation according to the BRIE proto-
Table 2. Vessel Characteristics in Relation to GM
Noninterpretable vessels 25.1% (44/175)
Interpretable vessels 74.9% (131/175)
Noninjured vessels 32.1% (42/131)
GM vessels 67.9% (89/131)
Vessels with GM proximal only 37% (33/89)
Vessels with GM distal only 41.5% (37/89)
Vessels with GM both proximal and distal 21.5% (19/89)
GM  geographical miss.
Table 3. Edge Characteristics in Relation to GM
Noninterpretable edges 25.1% (88/350)
Interpretable edges 74.9% (262/350)
Noninjured edges 58.8% (154/262)
GM edges 41.2% (108/262)
Proximal GM edges 48.2% (52/108)
Distal GM edges 51.8% (56/108)
GM  geographical miss.
Figure 2. Difference in the restenosis rate in the proximal distal and both
edges of the effective irradiated segment between geographical miss (GM)
and noninjured edges. White bars  no GM; black bars  GM. CI 
conﬁdence interval; OR  odds ratio.
Geographical Miss in  BRIE study
95
col. By careful retrospective angiographic analysis of all
vessels treated with the same radiation system, we deﬁned
the effect of the injury on those areas located at the margins
of the source where the delivered dose was potentially rather
low.
Dosimetric zones. In any given vessel undergoing an
intervention followed by radiotherapy there are six possible
combinations of injury and irradiation: 1) segments injured
and fully irradiated (received the prescribed dose), repre-
senting the ideal treatment; 2) segments injured and receiv-
ing less than the prescribed dose deﬁned as GM segments;
3) segments injured and receiving no dose (falling into the
category of conventional interventions); 4) segments non-
injured and receiving a full dose; 5) segments noninjured
and receiving a low dose, which represents a well-applied
treatment because there is no indication of any adverse
impact from low-dose radiation without injury after either
beta (15) or gamma radiation (21); and 6) segments non-
injured and receiving no radiation, falling into the category
of natural progression of atherosclerosis.
Geographical miss occurred in 67.9% of the vessels and
41.2% of edges analyzed. This concept requires the concur-
rence of two conditions: low-dose radiation and injury. It is
a dose-related term rather than an anatomical one. Injury
outside the ﬁeld of radiation or low-dose irradiation of
noninjured tissue cannot be termed GM.
Stimulatory effect of low-dose radiation. The stimulatory
effect of low-dose radiation on smooth muscle cell prolifer-
ation has been previously reported in a swine coronary
balloon overstretch injury model (11). In the low-dose
radiation group (10 Gy), neointima was composed of
smooth muscle cells with a marked increase in inﬂammatory
cells and less medial and intimal ﬁbrosis as compared with
higher dose groups (15 and 20 Gy) and the control group.
Similarly, after low-activity radioactive stent implantation
(1.0 Ci) in a porcine model, neointimal hyperplasia was
signiﬁcantly greater than that after nonradioactive stenting
(12). Our group reported a late loss in injured edges treated
with the same system that was higher than that demon-
strated in the noninjured edges (14) and in previous studies
after balloon angioplasty or stent implantation (22,23). In a
three-dimensional volumetric intravascular ultrasound
(IVUS) investigation, our group again observed a decrease
in lumen volume at the edges because of an increase in
plaque volume not accommodated by vessel enlargement
(7). In patients receiving 6 to 12 Ci 32P radioactive stents,
where GM systematically occurs because of the current
balloon technology (6), 50% edge restenosis was reported
compared with 0% in-stent (5).
Proximal versus distal. Geographical miss increased re-
stenosis in both edges of the EIRS. This effect seems to be
more prominent at the distal edge compared with the
proximal. The smaller lumen distally attributable to normal
tapering of the vessels and the even less effectively irradiated
proximal edge because of its larger diameter may also be the
cause. Comparing the values of restenosis proximal and
distal at the GM edges, we can see that they are identical in
the range of 16.3%. What makes the OR higher for the
distal edge is the increased incidence of restenosis in the
noninjured proximal edges. Our group has reported this
through analysis of the noninjured edges of irradiated
segments by three-dimensional IVUS. Greater increase in
the plaque volume in the proximal edges compared with the
distal (27% vs. 9.2%, respectively) was reported (15). Non-
measurable vessel injuries (guiding catheter guidewires)
were hypothesized as the cause. Rheological factors may
play an important role and careful shear stress analysis could
elucidate the cause of restenosis at the proximal edge (24).
Balloon versus stent injury in relation to GM. Geo-
graphical miss related to stent injury is more prominently
associated with edge restenosis than is GM related to
balloon injury. The mechanisms involved in restenosis after
balloon angioplasty are different compared with these of
stenting. Negative remodeling and elastic recoil are the
causes of restenosis after balloon angioplasty, as opposed to
neointimal formation after stent implantation (25). Absence
of negative remodeling has been reported at the edges of the
irradiated segments after balloon angioplasty (14). This
might partly compensate for the stimulatory effect of radi-
ation on plaque growth at the balloon-injured GM edges,
making the combination less harmful.
The acute injury after stenting differs from that of the
coronary balloon angioplasty (8). The stent is a foreign body
and produces a permanent strain on the vessel wall, resulting
in a chronic injury and a prolonged stimulus for neointimal
formation (26). It is logical to conclude that the greater and
more prolonged the injury, the greater the impact on plaque
growth, and subsequently on restenosis, in conjunction with
low-dose radiation. In our study, signiﬁcantly higher late
loss was observed in the irradiated segment in patients
treated with balloons compared with the stent-treated
patients (0.14 mm vs. 0.44 mm respectively, p  0.001).
This observation is in keeping with the other serious
adverse effects of the combination of stenting and radiation,
such as delayed stent thrombosis (27) and late stent mal-
apposition (28).
Figure 3. Difference in edge restenosis between geographical miss (GM)
edges associated with stent and balloon injury and noninjured edges. White
bars  no GM; black bars  GM. CI  conﬁdence interval; OR  odds
ratio.
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Study limitations. This study is not placebo-controlled
and the effect of a sham source on injured coronary
segments has not been evaluated.
Only one type of radiation delivery catheter using the
beta-source 90Sr/90Y has been evaluated. Thus, the effect of
other systems using centering balloons and different sources
or gamma-radiotherapy on the GM edges cannot be extrap-
olated from our results.
Balloon inﬂation or stent implantation was considered
the only source of injury. Minor injuries from guiding
catheters, guidewires or radiation delivery catheters cannot
be completely ruled out.
Only binary restenosis data are quoted and the determi-
nation of GM is qualitative because there was no QCA
methodology available at the time to measure the length of
the GM.
Conclusions. Geographical miss is strongly correlated with
the development of restenosis at the edges of the EIRS. This
is a local phenomenon with a speciﬁc pathophysiology (com-
bination of injury and low-dose radiation) and is different from
the restenosis observed in the EIRS. This effect was observed
in both edges of the EIRS and seems to be more pronounced
at the distal edge compared with the proximal. Geographical
miss related to stent injury is associated with higher edge
restenosis compared with GM related to balloon injury. Geo-
graphical miss did not increase the incidence of restenosis in
the EIRS. If GM can be eliminated, the results of intracoro-
nary beta-radiation will be improved.
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Geographical miss and restenosis during catheter-based intracoronary
h-radiation for de novo lesions$
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Abstract Objectives: We sought to determine the impact of geographical miss (GM) on restenosis rates after
intracoronary h-radiation therapy for de novo lesions.
Background: GM is the situation in which injured vessel segments (VSs) are receiving low-dose
radiation and is accounted for edge restenosis. Its impact on the overall restenosis rates remains to
be determined.
Methods: We analyzed 330 patients (356 vessels) treated according to the Beta Radiation in Europe
(BRIE) and the Dose Finding study protocols. Using quantitative coronary angiography (QCA), the
effective irradiated segment (EIRS), its edges and the total VS were analysed. The edges of the EIRS
that were injured constituted the GM edges. Restenosis was defined as diameter stenosis > 50% at
follow-up. GM was determined by the simultaneous electrocardiographic-matched, side-by-side
projection of the source and balloons deflated and surrounded by contrast, at the site of injury, in
identical angiographic projections.
Results: In 20.5% of the vessels, GMwas non-interpretable due to inadequate filming. GM occurred at
30.4% of the interpretable edges and 53% of the interpretable vessels that were analysed. Edge
restenosis was significantly increased in the GM compared to non-GM edges (13.16% vs. 4.17%,
respectively, P= .001), both in the proximal (P= .03) and the distal (P= .001) edges. GM associated
with stent injury significantly increased edge restenosis (P= .006). GM related to balloon injury tended
to be associated with increment in edge restenosis (P= .07). The restenosis in the EIRS was similar
between vessels with and without GM (17.78% and 14.85%, respectively, P= .6). GM was associated
with significant increment in the restenosis at the analyzed VS (31.85% vs. 21.48%, P= .05).
Conclusions: GM is strongly associated with edges and restenosis in the analysed VS. GM does not
increase restenosis in the EIRS.
D 2003 Elsevier Inc. All rights reserved.
Keywords: Geographical miss; Intracoronary radiation; Restenosis; Edge restenosis
1. Introduction
Following coronary balloon angioplasty, restenosis of the
dilated segment occurs in 30–50% of patients and results
from elastic recoil, neointima formation and negative remod-
elling [1–4]. The advent of coronary stenting has reduced
restenosis to 15% in certain types of lesions [5,6], but it
also introduced the even more difficult to treat in-stent
restenosis [7]. After extensive evaluation in animal balloon
and stent restenosis models [8–11], clinical feasibility
studies with beta and gamma emitters proved that brachy-
therapy is safe, feasible and promising for the prevention of
restenosis [12–15]. Following these encouraging results,
large randomised studies confirmed the effectiveness of
intracoronary radiation therapy for the treatment of in-stent
restenosis both with beta [16–19] and gamma emitters
[20–23]. Its efficacy for the treatment of de novo lesions
$ No financial support was received for this study.
* Corresponding author. Tel.: +31-10-4635260; fax: +31-10-4369154.
E-mail address: serruys@card.azr.nl (P.W. Serruys).
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especially in combination with the use of stents is ques-
tionable and remains to be determined [15,24,25].
Soon after its application, the limitations of this treatment
such as the development of renarrowing at the edges of the
irradiated segment, described as the ‘‘edge effect’’ [26,27], the
late total and thrombotic occlusions [28,29], the delayed healing
[30], the increased thrombogenicity [31] and the persistent
dissections [32,33] were recognised, limiting its effectiveness.
The geographical miss (GM), a term invented in radio-
oncology to define a cause of treatment failure due to low
dose [34] and translated in interventional cardiology to define
those coronary segments, which were injured but received
low-dose radiation [26], has been related with the edge
restenosis after beta and gamma radiation therapy for de
novo and restenotic lesions [35–37]. Its implication on the
overall angiographic outcome of patients is still unclear,
mainly due to the limited number of observations.
The aim of the present study was to determine the
incidence and causes of GM and to evaluate its impact in
the angiographic outcome of a large cohort of patients
treated according to the protocols of the Beta Radiation In
Europe (BRIE) [15] and the Dose Finding [24] studies using
catheter-based systems for de novo lesions.
2. Methods
2.1. Patient selection
We retrospectively analysed 330 patients treated with
catheter-basedh-radiation enrolled in theBRIE (149 patients)
[15] and Dose Finding studies (181 patients) [24]. Patients
included in the radiation protocol were those with object-
ive signs of ischaemia and presence of significant de novo
lesions. Out of the total population, 304 patients underwent
single vessel PTCA, and in the remaining 26 patients (all
in the BRIE study), two vessels were treated, giving in
total 356 vessels. In 55 patients (73 vessels), GM was not
interpretable leaving 265 patients (283 vessels) for further
analysis (Table 1). The baseline and angiographic character-
istics of the patients have been previously reported [15,24].
2.2. Device description
Patients enrolled in the BRIE study were treated with the
noncentered, 30-mm-long, 90Sr/90Y beta source (Beta-Cath
System). The device has been previously described [38].
The longitudinal distance of ‘‘full’’ prescribed dose (100%
isodose) coverage measured by radiochromic film is about
26 mm [39], constituting the effective irradiation length.
Patients enrolled in the Dose Finding study were treated
with the centered, 29-mm-long, Yttrium-90 beta-emitting
source. The device has been described previously [40–43].
It consists of the radioactive source (half-life, 64 h; maximal
energy, 2.284 MeV), a centering balloon and an automated
delivery device. The effective length of the vessel segment
(VS) being irradiated (100% isodose) is 24 mm.
2.3. Dosimetry
According to the BRIE study protocol, the dose pre-
scribed at 2 mm from the centerline of the source axis was
14–18 Gy, based on the reference diameter, by on-line
quantitative coronary angiography (QCA), measured <3.35
or >3.35 mm, respectively. The dwelling time was on
average 3.12F 0.43 min.
In the Dose Finding study, the patients were randomly
assigned by computer, over the telephone, to receive 9, 12, 15
or 18 Gy of radiation at a tissue depth of 1 mm. The mean
duration of radiation treatment was 1.81F 0.10, 2.55F 0.20,
3.01F 0.16 and 3.17F 0.19min in the 9-, 12-, 15- and 18-Gy
groups, respectively.
2.4. Definitions
VS defined as the coronary segment bordered by two
side branches that encompassed the original lesion, angio-
plasty balloon and radiation source. The injured segment
(INS) was the segment encompassed by the most proximal
and distal position of the radiopaque markers of the bal-
loons used for dilation or stent implantation. The irradiated
segment was defined as the segment encompassed by the
markers of the radiation source train, 30 mm in length for
the 90Sr/90Y source and 29 mm for the Yttrium-90. The
effective irradiated segment (EIRS) was the segment that
received the full-prescribed dose (100% isodose) and cor-
responded to the central part of the radioactive source train,
26 mm in length for the 90Sr/90Y source and 24 mm for the
Yttrium-90. These segments are illustrated in Fig. 1. The
edges of the EIRS are the adjacent (proximal and distal) 5-
mm coronary segments. These edges received low-dose
radiation due to falloff of the dose in both sources. If these
edges were traumatized by balloon inflation (minimum
Table 1
Vessel characteristics in relation to GM
Total 356
Noninterpretable vessels 20.5% (73/356)
Nonanalysable 28% (100/356)
Interpretable vessels Analysable vessels
All 79.5% (283/356) 72% (256/356)
Non GM vessels 47% (133/283) 47.3% (121/256)
GM vessels 53% (150/283) 52.7% (135/256)
GM proximal only 36% (54/150) 34.8% (47/135)
GM distal only 49.3% 74/150 52.6% (71/135)
GM both proximal
and distal
14.7% (22/150) 12.6% (17/135)
Balloon vessels 55.1% (156/283) 55.9% (143/256)
GM 40.4% (63/156) 40.5% (58/143)
Non-GM 59.6% (93/156) 59.5% (85/143)
Stent vessels 44.9% (127/283) 44.1% (113/256)
GM 68.5% (87/127) 68.1% (77/113)
Non-GM 31.5% (40/127) 31.9% (36/113)
Geographical Miss for De-novo Lesions
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inflation pressure was 6 atm) or received new stent
implantation during the procedure, they were defined as
GM edges. Noninjured or non-GM edges were those that
were not traumatized during the intervention.
2.5. Determination of the GM edges
To determine whether the edges of the EIRS were in-
jured, we retrospectively analyzed, blinded to the presence or
absence of restenosis and its location at follow-up, all the
baseline (intervention plus radiation) angiograms. The fol-
lowing steps were followed: During the procedure, all the
interventions (balloons or stents, deflated at the site of injury)
and the radioactive source in place were filmed surrounded
by contrast medium in identical angiographic projections.
This approach allowed us to define the location of the various
subsegments (EIRS, INS, edges) in relation to side branches
and the correct matching of the angiograms in the off-line
analysis. A continuous ECG recording was also displayed,
allowing the selection of still frames in the same part of the
cardiac cycle. Multiple angiographic loops and ECGmatched
still frames could be displayed simultaneously, side-by-side,
on the screen using the Rubo DICOMViewer (RuboMedical
Imaging, Uithoom, The Netherlands). By identifying the
relationship between the EIRS and its edges relative to the
INS, we determined the GM edges. Two independent car-
diologists performed the above-mentioned analysis. There
was only 10% disagreement on the presence or absence of
GM and its location proximal or distal. These were borderline
cases that were reanalyzed by a third reviewer with the use of
transparencies, and a final conclusion was made.
In cases where one or more of the following criteria were
present, the procedure was reported as noninterpretable: (1)
absence of documentation of all interventions reported in
the technicians work sheet or the radiation procedure, and
(2) more than 10j difference in the angiographic projections
not allowing correct matching.
2.6. QCA analysis
The EIRS and both edges were analyzed by QCA prior to,
after intervention, and at 6-month follow-up. All angiograms
were evaluated after intracoronary administration of nitrates.
The off-line analysis of two orthogonal projections was
performed by means of the CAAS II analysis system (Pie
Medical, Maastricht, The Netherlands). Calibration of the
system was based on dimensions of the catheters not filled
with contrast [44–46]. The following QCA parameters were
computed in the VS: computer-defined minimal luminal
diameter (MLD), reference diameter, obtained by an interpo-
lated method, and percentage diameter stenosis. Binary
restenosis was defined in every segment as diameter stenosis
> 50% at follow-up. This allowed the determination of
restenosis in the VS (overall restenosis). Computer-defined
subsegmental analysis (mean subsegment length was
5.0F 0.3 mm, depending on the length of the analyzed VS)
was also performed. In each subsegment percentage diameter
stenosis was also automatically calculated. This allowed the
determination of restenosis location in relation to the defined
subsegments, which was termed as regional restenosis.
2.7. Determination of the restenosis location
Three observers analyzed all the films that appeared to
have restenosis at the follow-up angiogram. The printouts of
the pre, post and the follow-up angiograms, in two orthog-
onal projections, with the subsegmental analysis and the
Fig. 1. A diagram of the radiation sources and an irradiated coronary artery
with the anatomical and dose-based subsegment definition. SB denotes side
branch, RGM denotes radiopaque gold marker, RS denotes radioactive
seeds, BRM denotes balloon radiopaque marker, RTM denotes radiopaque
tungsten markers, CB denotes compartment balloons, EIRS denotes ef-
fective irradiated segment (24 mm for the 90Y source and 26 mm for the
90Sr/90Y source), INS denotes injured segment, IRS denotes irradiated
segment (29 mm for the 90Y source and 30 mm for the 90Sr/90Y source), VS
denotes vessel segment, IRL denotes irradiation length, EIRL denotes ef-
fective irradiation length.
Table 2
Edge characteristics in relation to GM
Total 712
Noninterpretable edges 20.5% (146/712)
Nonanalysable 28% (200/712)
Interpretable edges Analysable edges
All 79.5% (566/712) 72% (512/712)
Noninjured edges 69.6% (394/566) 70.3% (360/512)
GM edges 30.4% (172/566) 29.7% (152/512)
Proximal GM edges 44.2% (76/172) 42.1% (64/152)
Distal GM edges 55.8% (96/172) 57.9% (88/152)
Balloon edges 55.1% (312/566) 55.9% (286/512)
GM 21.8% (68/312) 21.3% (61/286)
Non-GM 78.2% (244/312) 78.7% (225/286)
Stent edges 44.9% (254/566) 44.1% (226/512)
GM 40.9% (104/254) 40.3% (91/226)
Non-GM 59.1% (150/254) 59.7% (135/226)
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dose-based subsegments superimposed, were compared. The
observers designated the location of the computer-defined
QCA subsegments with restenosis in relation to the dose-
defined segments. Restenosis was classified as restenosis in
the EIRS, edge restenosis (proximal or distal) and restenosis
outside the irradiated segment. It is important to realize that
the criterion for binary restenosis might be fulfilled in more
than one subsegment in the same VS.
2.8. Statistical analysis
Continuous data are presented as mean values; discon-
tinuous data are presented as percentages. Differences in
restenosis rates between edges with and without GM were
evaluated with chi-square or Fisher’s exact tests as appro-
priate. Because the behaviour of different segments in the
same vessel and the behaviour of different vessels in the
same patient may not be independent, the relation between
GM and edge restenosis was further analyzed by logistic
regression analysis, using generalized estimation equation
modelling techniques to correct for possible within-patients
effects. Statistical significance of all tests was defined at the
P < .05 level.
3. Results
3.1. Incidence of GM
3.1.1. Vessels
Overall, 283 vessels (265 patients) were interpretable.
The incidence of GM was 53%. There was a balance
between GM 53% (CI: 47–59) and non-GM vessels 47%
(CI: 41–53). The vessel characteristics in relation to GM are
presented in Table 1.
3.1.2. Edges
In each vessel, both proximal and distal edges of the
EIRS were analyzed giving in total 566 edges. Out of the
150 vessels with GM, 128 had one GM edge, proximal or
distal and in 22 vessels both edges were injured giving in
total 172 GM edges. The incidence of GM at the edges was
30.4% and comparable between the proximal and distal edges
(44.2% [CI: 37–52] vs. 55.8% [CI: 48–63], respectively).
The edge characteristics in relation to GM are presented
in Table 2.
3.2. Procedural causes of GM
The following reasons were responsible for this phenom-
enon: (1) development of procedural complications (addi-
tional stent implantation post radiation), which extended the
treatment beyond the margins of the EIRS, 54.1% (93/172);
(2) noncomplete coverage of the INS by the radiation
source, 33.7% (58/172); and (3) treatment of long lesions
requiring balloons or stents longer than EIRL of the sources
12.2% (21/172).
3.3. Overall restenosis in relation to GM
Follow-up angiogram was available in 256 vessels (242
patients). The restenosis rate in the EIRS was 16.4% and in
the VS 26.95%. Because binary restenosis can be encoun-
tered more than once per VS (either in the EIRS or at the
edges), the summation of the regional restenosis rate is
higher than the restenosis rate in the VS. The presence or
absence of GM did not affect the incidence of restenosis in
the EIRS (17.78% and 14.85%, respectively, P= .6). GM
significantly increased restenosis at the analyzed VS
(31.85% vs. 21.48%, P= .05), related to the significant
increment in edge restenosis. The restenosis rate at the GM
vessels was significantly increased from the EIRS to the VS
(P= .007) as opposed to the non-GM vessels (P= .2),
resulting in significant increment in the restenosis from the
EIRS to the VS (P= .004). The relation of GM with the
overall restenosis is presented in Table 3.
3.4. Edge (regional) restenosis in relation to the GM
In each of the 256 vessels, the impact of GM on reste-
nosis was analyzed in both proximal and distal edge (512
edges). Overall, edge restenosis was 6.83%, and there was
no difference between the proximal and the distal edge. GM
significantly increased the incidence of restenosis at the
edges of the EIRS compared with the lesions without GM
(4.17% vs. 13.16%, P= .001). This effect was observed
Table 3
GM and incidence of restenosis
EIRS VS EIRS vs. VS
Total 42/256 (16.4%) 69/256 (26.95%) P= .004
GM 24/135 (17.78%) 43/135 (31.85%) P= .007
Non-GM 18/121 (14.85%) 26/121 (21.48%) P= .18
GM vs. non-GM P= .6 P= .05
Table 4
GM and incidence of edge restenosis
All edges Proximal Distal Proximal vs. distal
All edges 35/512 (6.83%) 20/256 (7.81%) 15/256 (5.86%) P= .38
GM edges 20/152 (13.16%) 9/64 (14.06%) 11/88 (12.50%) P= .77
Non-GM edges 15/360 (4.17%) 11/192 (5.73%) 4/168 (2.38%) P= .09
GM vs. non-GM P= .001, OR= 3.5 (1.7–7) P= .031, OR= 2.7 (1.1–6.8) P= .001, OR= 5.9 (1.8–18.9)
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both in the proximal (5.73% vs. 14.06%, P= .03) and distal
(2.38% vs. 12.5%, P= .001) edges. It seems to be more
pronounced at the distal edge (OR = 5.9) compared to the
proximal (OR=2.7) mainly due to a tendency for increased
restenosis at the proximal non-GM edges compared with
the distal (P= .09). The relation of GM with edge reste-
nosis is presented in Table 4.
Generalized estimation equation analysis, which was used
to account for within-patients effects, showed that the
probability for restenosis at the edges of the EIRS depends
on the GM (P= .001), but not on distal/proximal lesion
location (P= .4) or the device (balloon/stent) used (P= .1).
3.5. Edge restenosis and GM in relation to the type of injury
Out of the 512 interpretable edges, 286 (55.85%, CI: 41–
49) were related with balloon angiosplasty termed as balloon
edges (BEs) and 226 (44.15%, CI: 41–49) with stent
implantation termed as stent edges (SEs). Significantly higher
incidence of GM was observed at the SE (40.2%, 91/226),
compared to the BE (21.3%, 61/286) (P<.0001). At the SE,
GM significantly increased the incidence of restenosis com-
pared to edges without GM (4.44% vs. 15.38%, P=.005).
There was a tendency for restenosis increment at the balloon
GM edges compared with the non-GM BEs (4% vs. 9.84%,
P=.07). There was no difference in the restenosis between the
balloon and SEs and in overall restenosis in vessels with and
without GM. The vessel and edge characteristics in the
balloon and stent vessels in relation to GM are presented in
Tables 1 and 2. The effect of GM on restenosis rate in relation
to the type of injury is presented in Table 5.
4. Discussion
The incidence of GMwas significantly higher in the BRIE
study resulting in significantly lower noninjured vessels
compared with the Dose Finding study. Differences in the
protocols led to imbalance of balloon and stent vessels in the
two studies. These differences, in combination with the low
number of observations, are limiting the conclusions made
when analyzed separately. By combining the data, a balanced
population between the GM and non-GM vessels (53% vs.
47%) and the balloon and stent vessels (55.1% vs. 44.9%)
with overlapping confidence intervals is obtained. The differ-
ences between the two studies are summarised in Table 6.
4.1. Stimulatory effect of low-dose radiation
The stimulatory effect of low-dose radiation on smooth
muscle cell proliferation has been previously reported in a
swine coronary balloon overstretch injury model [47]. There
was a dose-dependent effect in the reduction of neointima
formation with evidence of significant stimulatory effect at
low dose (10 Gy), while the therapeutic dose begins at
approximately 15 Gy. In patients treated with balloon angio-
plasty, a higher late loss in injured edges compared with the
noninjured edges has been reported [26]. By IVUS, this was
due to a significant increase on plaque volume not accom-
modated by vessel enlargement [48]. Similarly, after low-
activity radioactive stent implantation (1.0 ACi) in a porcine
model, neointimal hyperplasia was significantly greater than
that after nonradioactive stenting [49]. When half-radioactive
stents were implanted in porcine coronary arteries, the highest
late loss and neointimal thickening was observed at the
midstent dose falloff zone of the half-radioactive stents and
not at the edges [50]. In patients receiving 6.0–12.0 ACi 32P
radioactive stents, where GM systematically occurs due to the
current balloon technology, 50% edge restenosis was
reported compared to 0% in-stent [27]. This effect, called
‘‘candy-wrapper,’’ is primarily a focal exaggeration of neo-
intimal hyperplasia accumulation at the edge of the stent [51].
4.2. Restenosis location and its relation the type of injury
The incidence of GMwas comparable in the proximal and
distal edges (44.2% [CI: 37—52] vs. 55.8% [CI: 48–63],
respectively). GM significantly increased restenosis in
both edges of the EIRS. This effect seems to be more
prominent at the distal edge compared to the proximal
Table 5
GM and edge restenosis in relation to the type of injury
All edges Balloon edges Stent edges Balloons vs. stents
All edges 35/512 (6.83%) 15/286 (5.24%) 20/226 (8.84%) P= .1
GM 20/152 (13.16%) 6/61 (9.84%) 14/91 (15.38%) P= .32
Non-GM 15/360 (4.17%) 9/225 (4.00%) 6/135 (4.44%) P= .8
GM vs. non-GM P= .001, OR= 3.5 (1.7–7) P= .07, OR= 2.6 (0.9–7.6) P= .005, OR= 3.9 (1.5–10.6)
Table 6
Differences between the studies
BRIE DF BRIE vs. DF Both
GM vessels 67.9% (89/131) 40.1% (61/152) P< .0001 53% (150/283), CI: 47–59
Non-GM edges 32.1% (42/131) 59.9% (91/152) P< .0001 47% (133/283), CI: 41–53
Balloon vessels 35.9% (47/131) 71.7% (109/152) P< .0001 55.1% (156/283), CI: 49–61
Stent vessels 64.1% (84/131) 28.3% (43/152) P< .0001 44.9% (127/283), CI: 39–51
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(OR: 5.9 [CI: 1.8–18.9] and OR:2.7 [CI: 1.1–6.8], respect-
ively). There was no difference in the restenosis rate between
the proximal and distal GM edges (7.8% vs. 5.8%, P= .38)
(Table 4). What makes the OR higher for the distal edge is a
tendency for increased restenosis in the noninjured edges
proximal compared to the distal (5.7% vs. 2.3%, P= .09).
This has been reported through analysis of the noninjured
edges of irradiated segments by means of three-dimensional
IVUS. Greater increase in the plaque volume in the proximal
edges compared with the distal (27% vs. 9.2%, respectively)
was reported [39]. The same was also observed after radio-
active stent implantation [52].
There was a tendency for increased restenosis at the SEs
compared to the BEs (8.84% vs. 5.24%, respectively,
P= .1). GM related with stent injury is more prominently
associated with edge restenosis compared with GM related
with balloon injury (OR: 3.9 [CI: 1.5–10.6] vs. OR: 2.7 [CI:
1.1–6.8], respectively). The mechanisms involved in reste-
nosis after balloon angioplasty are different compared with
these of stenting. Negative remodelling and elastic recoil are
the causes of restenosis after balloon angioplasty as opposed
to neointimal formation after stent implantation [54].
Absence of negative remodelling has been reported at the
edges of the irradiated segments after balloon angioplasty
[26]. This might partly compensate for the stimulatory effect
of radiation on plaque growth at the balloon injured GM
edges making the combination less harmful. The signific-
antly higher incidence of GM at the SEs compared to the
BEs (68.5% vs. 40.4%, respectively, P<.001), as a result of
the studies design, might also account for this phenomenon.
4.3. GM and restenosis in de novo lesions
The incidence of edge restenosis after initial stent
implantation without radiation has been reported to be
between 5% and 10% [53–55]. A clue for its incidence in
the current area of new generation stents can be obtained by
the control group of the SIRIUS study [56]. Edge restenosis
was around 8% equal between the proximal and distal
margins. It increased restenosis in the whole analysed seg-
ment only by 1% as compared with the in-stent segment (35.4
vs. 36.3%) due to its concomitance with in-stent restenosis in
the majority of cases. This was the reason that edge stent
restenosis remained unattended during a decade of trials
using bare stents.
In the first report by Sabate et al. [26], the incidence of
GM was 32%, and it increased the edge restenosis from 2%
in the noninjured edges to 41%, while the restenosis rate in
the irradiated segment was 10%. The Beta-Cath trial, the
largest randomised trial of h-radiation for de novo lesions,
failed to show any difference in the primary end point, the
target vessel failure, in the combined radiation arms com-
pared to the placebo arms [25]. In the balloon group, the
reduction in binary restenosis observed with radiation in the
lesion segment was not maintained in the VS analysis. Even
worse in the stent group, the significant reduction in the
stented segment inverted to a significant increment in the
analysis segment with worse outcome in the radiation group.
Clearly, in this study, the dose falloff zone appears to be in
the culprit for the higher restenosis, especially the proximally
dose falloff, likely due to a greater reduction in dose
proximal relative to distal. Because GM was very frequent
( >85%), the authors were unable to ascertain the contri-
bution of GM to the higher restenosis in these zones.
With increased experience, GM was reduced to 6.5% in
the RENO registry, and this was not associated with
increased edge restenosis but with increased target vessel
thrombosis and target vessel related death [57].
4.4. GM restenosis in in-stent restenotic lesions
The incidence of edge restenosis after treatment of in-
stent restenotic lesions without radiation is less clear. It was
3–4% in the control groups of WRIST [21] and GAMMA 1
[22]. In a meta-analysis of patients enrolled in the placebo
arms of randomised brachytherapy trials for in-stent reste-
nosis with beta and gamma sources, SE restenosis was
4.4%, significantly lower compared to radiated patients.
Interestingly, edge restenosis in the radiation group was
reported to be higher with beta sources (17.1%) as compared
with gamma sources (9.3%) [58].
In the WRIST–GAMMA randomised trial, the incidence
of GM was 34% and was strongly associated with devel-
opment of edge binary restenosis [36]. A failure to dem-
onstrate a relation of GM with the overall restenosis was
probably related with the small number of observations.
In the START 30 randomised trial, there was no asso-
ciation of GM with edge restenosis, but the authors specu-
late that this was related to the fact that the short source used
in this study was insufficient to cover the injured zone in the
majority of the cases [17]. In the START 40 trial, the
incidence of GM was 46% and was associated with sig-
nificantly increased edge restenosis and restenosis in the
analysis segment. This was the first study to relate GM with
restenosis in the total analysed segment [18] and is in
keeping with our observations.
In a recently published study, the incidence of GM was
37.5% and significantly increased edge and total vessel
restenosis [37]. Interestingly, the highest restenosis rate
was reported in INSs that received negligible irradiation
(<10% of the prescribed dose).
In the more recently conducted trials, INHIBIT [19] and
WRIST-SVG [23], in which the issue of GM and its
implications were known, its avoidance, as mandated by
the protocol, resulted in the elimination of edge restenosis.
4.5. Restenosis in the era of drug-eluting stents
In the RAVEL study [59], binary restenosis at the edges
was 0% in both arms, but the late loss, a more sensitive
index of restenosis, was significantly lower in the sirolimus-
eluting stent group compared with the control group in both
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stent edges. IVUS analysis of patients enrolled in the FIM
study revealed no significant changes in the lumen plaque
or vessel volumes at the edges of sirolimus-eluting stents
up to 2 years follow-up [60]. Edge restenosis was observed
after sirolimus-eluting stent implantation in the randomised
SIRIUS study, in which more complex patients were
enrolled, with an incidence of 5% predominantly in the
proximal edge, and they increase restenosis in the analysis
segment from 3.2% to 8.9% [56]. It is very clear that this
effect is an unmasking of the edge restenosis due to very
effective inhibition of restenosis within the stented segment
because its incidence is lower than the edge restenosis
observed in the control group (8%).
The difference with brachytherapy for de novo lesions
with stent implantation is that this effect, when added on the
top of a successful inhibition in the stented segment, signific-
antly attenuates [15] or inverses the favourable outcome [25]
observed, indicating that it is not an unmasking due to
absence of neointima formation within the length of the stent,
but an active phenomenon.
4.6. Safety margins
The safety margins after brachytherapy for avoidance of
GM and subsequently edge restenosis have not yet been
defined. Many factors such as the extent of the perivascular
injury, which can extend up to 10 mm away from the micro-
scopic injury [61], the barotrauma caused by the balloons,
which can be up to 2.5mm away from the actual stent margins
[62], the source displacement during the cardiac cycle (up to
5.4 mm) [63] and the falloff the dose at the margins of each
source must be taken into account.
Taking into account these parameters, Tripuraneni et al.
[64] proposed that for an 18-mm lesion treated with a 20-mm
balloon, a 39-mm Iridium source should be used. In an animal
model, a safety margin of 14.5 mmwas sufficient to eliminate
edge restenosis [65]. Recently, a 10-mm safety margin per
vessel was found to have 95% specificity for avoidance of
GM [37]. As a general simple rule, a ratio of 1–2 for the
lesion to source length is advised. The availability of longer
sources and stepping application of radiation will help for the
elimination of GM.
4.7. Study limitations
The studies were not placebo-controlled, and the effect
of a sham source on injured coronary segments cannot
be evaluated.
Balloon inflation or stent implantation was considered
as the only source of injury. Minor injuries from guiding
catheters, guidewires or radiation delivery catheters cannot
be completely ruled out.
Only binary restenosis data are quoted, and the deter-
mination of GM is qualitative because there was no QCA
methodology available at that time for the measurement of
the length of the GM.
5. Conclusions
GM is strongly related with the development of edge
restenosis. This effect was observed in both edges of the
EIRS and seems to be more pronounced at the distal edge
compared to the proximal. GM related with stent injury
seems to be associated with higher incidence of edge
restenosis compared with GM related with balloon injury.
GM significantly increase restenosis in the total analysed
segment but was associated with increased restenosis in the
EIRS. It is a local phenomenon with a specific pathophysi-
ology (combination of injury and low-dose radiation). The
elimination of GM will improve the outcome of patients
treated with intracoronary h-radiation therapy.
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Abstract 
   Objectives: We sought to determine the long term outcome after intracoronary beta-radiation 
therapy. 
   Background: intracoronary beta-radiation therapy (IRT) is effective for the treatment of in-
stent restenosis, though its efficacy for the treatment of de novo lesions especially in 
combination with the use of stents is questionable. The long-term outcome after IRT is not yet 
established. 
   Methods: The rate of major adverse cardiac events (MACE) was retrospectively determined 
in 301 consecutive patients who were treated with IRT. MACE was defined as death, 
myocardial infarction, or any re-intervention. Long-term clinical outcome was obtained from 
an electronic database of hospital records, and questionnaires to the patients and referring 
physicians. Long-term survival status was assessed by written inquires to the Municipal Civil 
Registries. 
   Results: The mean follow up was 3.55±1.17 years. The cumulative incidence of MACE at 
six months was 19.1%, at one year 36.4%.and at 4 years 58.3%. The target lesion 
revascularization (TLR) rate at six months was 12.9%, at one year 28.3%, and at 4 years 
50.4%. From multivariate analysis, dose <18 Gy was the most significant predictor of TLR. At 
4 years the cumulative incidence of death was 3.8%, of myocardial infarction 13.4% and of 
coronary artery bypass surgery 11.3%. A total vessel occlusion was documented in 12.3% of 
the patients. 
   Conclusions: In the long-term follow-up of patients following IRT, there are increased 
adverse cardiac events beyond the first 6 months.  
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Introduction
   Intracoronary radiation therapy has been evaluated as a therapeutic modality for restenosis 
prevention. Randomized studies have confirmed its effectiveness for the treatment of in-stent 
restenosis both with gamma (1-3), and beta emitters (4-6), but its efficacy for de novo lesions 
especially in combination with the use of stents is questionable (7-9). 
   The safety and efficacy of IRT in the long-term has yet to be determined. In a porcine model 
of restenosis of balloon and stent arterial injury followed by IRT, the inhibition of neointimal 
formation observed at 1 month was not sustained at six months. Furthermore this lack of effect 
on neointimal formation was also accompanied by subacute and late thrombosis that lead to 
cardiac death (10). Reports on the long-term outcome of small randomized studies and 
registries have raised issues regarding the long-term efficacy of IRT. The angiographic analysis 
from the SCRIPPS trial at 3 years showed a reduction of the MLD in irradiated patients but not 
the placebo group, (11) with a further increase in TLR between 3 to 5 years in the irradiated 
patients only (12). In addition, an increase in the revascularization rate between 6 months and 3 
years was only observed in the irradiated group of the gamma-WRIST randomized trial (13). 
   In this study, we report the long-term outcome of patients treated with beta-radiation therapy 
for de-novo and in-stent restenotic lesions in our centre. 
Methods 
Patient population 
Between April 1997 and December 2002, 331 patients received IRT in our institution. In 4 
patients irradiation was not successful (total success rate 99%). Fifteen patients treated during 
2002 with limited follow up were excluded from this analysis. Another 11 patients that were 
treated with gamma radiation (GRANITE study) were also excluded. In total 301 patients were 
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analysed for determination of the long-term follow-up after beta-radiation therapy. The 
baseline characteristics of the patients are presented in Table 1. Procedural characteristics and 
radiation details are presented in Table 2. The number of patients treated with IRT per year is 
presented in Figure 1. 
Follow up 
Baseline clinical and procedural data were entered prospectively into a dedicated database. 
Long-term clinical outcome was obtained from an electronic database of hospital records. The 
Thoraxcentre is a tertiary cardiology centre serving a group of 14 local hospitals, and is the 
only one with facilities for percutaneous interventions in the region of Rotterdam. As required 
by the local medical system organisation all baseline procedures were performed in this tertiary 
facility, as well as the vast majority of re-interventions. 
Long-term survival status was assessed by written inquires to the Municipal Civil Registries. 
Questionnaires were sent to all living patients focusing on the occurrence of MACE such as, 
myocardial infarction, and repeat intervention (surgical and percutaneous). The referring 
physician and institutions as well as the general practitioners were directly approached 
whenever necessary. Complete follow-up was obtained in all patients. 
Definitions 
MACE was defined as: 1) death, 2) non-fatal myocardial infarction, 3) repeat revascularization. 
TLR was defined as any surgical or percutaneous re-intervention due to restenosis within the 
irradiated segment or the 5mm proximal or distal segments (edge restenosis). TVR was defined 
as any re-intervention driven by lesions located in the treated vessel beyond the target lesion 
limits. Non TLR-TVR was defined as any re-intervention in vessels other than the target 
vessel. CABG was considered not as a separate event but as a type of re-intervention (TLR, 
Long Term Outcome After Intracoronary Beta Radiation Therapy
135
TVR or non TLR-TVR). The diagnosis of acute myocardial infarction, indiscriminately Q or 
non-Q, required an elevation of creatine kinase to twice above the upper limit of normal 
together with a rise in creatine kinase-MB fraction, or if made following patient admission to 
another hospital, was confirmed through direct contact with the referring physician, using the 
same criteria. 
Total occlusion was defined as occlusion of the irradiated segment documented by coronary 
angiography. Subacute thrombosis was defined as angiographically documented total occlusion 
≤ 30 days. Late total occlusion was defined as angiographically documented total occlusion > 
30 days post intervention. Thrombotic occlusion was defined as any occlusion that resulted in 
an acute coronary syndrome (myocardial infarction or unstable angina). (14). 
For the determination of the length of follow up, the start day was that of the index procedure 
with IRT between April 1997 and December 2001. The last day for the follow up was the 31
st
March 2003. 
Statistical Analysis 
Event-free survival was estimated with Kaplan-Meier curves. Among patient subgroups the log 
rank test was used to compare survival curves. Data are expressed as mean value ± SD. 
Continuous variables were compared by Student’s t-test, categorical variables by chi-square-
tests. Statistical significance of all tests was defined at the p<0.05 level. The independent 
association of clinical characteristics with long-term mortality, infarction, TLR and vessel 
occlusion (the first occurrence of death, myocardial infarction, TLR) was tested by using the 
Cox proportional hazard model. Pre-selected pre and peri-procedural variables were age, 
gender, diabetes, hypertension, hypercholesterolemia, smoking, unstable angina, prior 
myocardial infarction, prior CABG, extent of coronary artery disease, left ventricular ejection 
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fraction, indication for PTCA (de-novo or in-stent restenosis), device used (stent or balloon), 
dose (<18 Gy or Gy), and duration of dual antiplatelet medication (<6 months versus 6
months). 
Results 
MACE
The cumulative incidence of MACE at six months was 19.1%, at one year 36.4%.and at 4 years 
58.3 %. The MACE free survival curve is presented in Figure 2. The total count of MACE is 
presented in Table 3. At four years, the cumulative incidence of MACE was neither dependant 
on the indication (de-novo versus in-stent restenosis, p=0.8), nor the device used (balloon 
versus stent, p=0.5). The independent predictors of MACE are presented in Table 6. 
At 4 years the cumulative incidence of death was 3.8%, and of myocardial infarction 13.4%. 
Half of the deaths were cardiac in origin and in the other half the aetiology is unknown. A 
higher incidence of myocardial infarction was observed in patients treated for de novo lesions 
compared to those treated for in-stent restenosis (13.7% vs 6.3%, p=0.04 respectively).  
Re-intervention
The majority (85%) of re-interventions were TLRs, with low rates of TVR and non TLR-TVR 
observed at 4 years (2.3% and 4.7% respectively). The cumulative incidence of TLR at 6 
months was 12.9%, at one year 28.3%, and at 4 years 50.4%. The TLR free survival curve is 
presented in Figure 2. The mean time to the first TLR was 1.15±1.0 years. The re-intervention 
free survival rate at six months was 83.4% and at 4 years 46.2%. The total count of TLR and 
re-intervention is presented in Table 3. At four years, the cumulative incidence of TLR was 
neither dependant on the indication (de-novo versus in-stent restenosis p=0.8), nor the device 
used (balloon versus stent, p=0.8), Figure 3. The cumulative incidence of TLR was higher in 
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patients who received <18 Gy compared with 18 Gy, p=0.01, Figure 4. The independent 
predictors of TLR are presented in Table 4.  
Total occlusions 
A total occlusion was documented in 37 patients (12.3%), Table 3. The incidence of sub-acute 
thrombosis was 0.3% (1/301) and of late total occlusion 12% (36/301). Almost half (6.0%) 
were related to an acute coronary syndrome (late thrombotic occlusion). Six patients underwent 
TLR before the vessel finally occluded. Patients treated for de-novo lesions had a higher 
incidence of total occlusions compared to those treated for in-stent restenosis (15.4% versus 
7.9%, p=0.03). The treatment of a de-novo lesion was an independent predictor for total vessel 
occlusion in the long-term HR=2, 95% CI: (1.1-5). 
CABG 
In total 30 patients underwent CABG, Table 3. In 15 patients surgery was the first TLR. In 11 
patients it was the second TLR and in 1 the third TLR (recurrence after an initial percutaneous 
TLR). In two patients CABG was regarded as TVR and in one further patient as non-TLR-
TVR.
Discussion 
Evidence of reduced efficiency over time 
Long-term outcome for de-novo lesions 
   Very limited data are available for the long-term outcome of patients treated with 
intracoronary radiation for de-novo lesions. In the Canadian arm of the BERT trial the TLR 
rate at six months was 10% and increased to 23% at two years indicative of a late catch up 
phenomenon. The positive remodelling observed at six months was lost due to a decrease in 
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MLD between six months and two years. No death, myocardial infarction or late vessel 
occlusion were reported in this small cohort of thirty patients (15). 
Long-term outcome for in-stent restenosis for beta and gamma 
   In the WRIST series of patients TLR increased by 14% between 6 months and 2 years both 
after beta and gamma radiotherapy, significantly higher than the 2% increment of the control 
group (16). Between 2 years and 3 years TLR further increased by 7% in patients treated with 
gamma radiotherapy compared with 2% in the control group (13) indicative that radiation 
therapy may merely delay the restenotic biological process. 
   The angiographic analysis from the SCRIPPS randomized study at 3 years showed a 
reduction of MLD by 0.37mm in the irradiation group while remaining unchanged in the 
placebo group (11). Between 6 months and 5 years TLR increased by 11.6% (from 11.5 to 
23.1%) in the irradiated group compared with only 3.5% (44.8% vs 48.3%) in the placebo 
group; and at five years the composite end-point of death, myocardial infarction and TVR, no 
longer reached statistical significance between the two groups (12). In both studies, despite the 
apparent mitigation of efficacy of radiation over time there remained a significant overall 
benefit in the clinical outcome of irradiated patients compared to the non-irradiated in the long-
term. 
   In our population between year 1 and 4, TLR increased from 28% to 50% and MACE from 
36% to 58%. These results compare poorly with results after conventional stent implantation. 
In the Benestent I study TLR at five years was 17.2% (2% increment between years 1 and 5) 
and total MACE 34.4% (11% increment between years 1 and 5) (17). Even in more complex 
subsets of patients TLR was not higher than 20% up to 10 years follow up (18,19). 
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Indication, dosage administered, and antiplatelet treatment. 
   There was no difference in the long-term outcome based on the indication (de-novo versus 
in-stent restenosis) or the device used (balloon versus stent). Increased dose (18 Gy) was the 
strongest radiation-related independent predictor of TLR. In patients treated for de-novo 
lesions in a dose finding study the group who received 18 Gy had a better angiographic 
outcome compared with groups receiving lower doses (7). In the Long WRIST study of 
patients treated for diffuse in-stent restenosis, improved clinical and angiographic outcomes 
were observed in the group who received 18 Gy compared with placebo and those who 
received 15 Gy (20). Patients treated with gamma radiation in the Venezuela study had a better 
long-term outcome compared with patients from SCRIPPS and WRIST, and the authors 
speculate that this was related to the higher dose administered during this study (21). 
   In the current study the duration of double antiplatelet medication was not a predictor of 
MACE or TLR. In the WRIST 12 study at 15 months follow up, patients that received double 
antiplatelet medication for 12 months had improved clinical outcome compared to those 
received 6 months only (22,23). Since the majority of our patients received double antiplatelet 
medication for 6 months or less, the duration was probably not long enough. 
Total occlusions  
   The incidence of late total occlusion and late thrombosis after brachytherapy varies between 
6-14%. (14,24). In our study a 12.3% incidence of occlusion was documented with the majority 
of events occurring beyond 6 months. It probably underestimates the real incidence as it does 
not include silent occlusion in asymptomatic patients without angiographic follow up. 
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   Patients treated for de-novo lesions had a significantly higher incidence of total occlusions 
and myocardial infarction suggesting that brachytherapy should not be used as treatment for 
primary prevention of restenosis. 
Brachytherapy in the era of DES 
   Drug eluting stents have been proven to be very effective in preventing restenosis for 
relatively simple de-novo lesions (25). Preliminary reports are indicative that this beneficial 
effect is maintained in the long-term (up to two years) (26). These results, in combination with 
the disappointing outcome of brachytherapy for de-novo lesions (especially with the use of 
stents) have had a dramatic impact in the use of brachytherapy in our centre (Figure 1). 
The broad application of eluting stents, may limit brachytherapy as a therapeutic technique, for 
the limited number of patients with failure of eluting stents. 
Limitations 
   This is a single centre retrospective analysis with all the limitations originating from such an 
approach. The enrolment of the patients was done over a period of four and a half years. The 
dose administered and the duration of dual antiplatelet medication were variable, based on the 
protocol and the current evidence available at that time. 
Conclusions 
   In the long-term follow-up of patients following IRT, there are increased adverse cardiac 
events beyond the first 6 months. Intracoronary beta-radiation therapy delays rather than 
abolishes cardiac events in the long-term. Patients treated with IRT require longer follow-up 
evaluation than those treated with standard techniques. 
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Table 1 
Baseline and procedural characteristics 
 N % 
Age,(years)  59±10.2 
Male sex 215 71.4 
Medical history 
Previous myocardial infarction 105 34.9 
Previous CABG 52 17.3 
Previous PTCA 158 52.5 
Risk factors 
Hypercholesterolemia 168 55.8 
Hypertension 93 30.9 
Diabetes 45 15.0 
Smoking 57 18.9 
Family history 51 16.9 
Ejection fraction 
Normal >50% 280 93.0 
Moderate 35-50% 16 5.3 
Poor <35% 5 1.7 
CABG denotes coronary-artery bypass grafting, PTCA percutaneous transluminal coronary angioplasty. 
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Table 2 
Procedural characteristics and radiotherapy details 
 n %
Patients 301 
Follow-up (range) in years 3.55 (1.2-5.92) 
One vessel treated 273 90.7 
two vessels treated 28 9.3 
Total vessels 329  
Failed radiation 4 1.3 
Second radiation 4 1.3 
Vessel treated 
LM 2 0.6 
LAD 120 36.5 
RCA 115 35.0 
LCx 73 22.2 
SVG 19 5.8 
Dual antiplatelet treatment 
No 51 16.9 
1-3 months 71 23.6 
6 months 142 47.2 
> 6 months 37 12.3 
IIb-IIIa inhibitors 109 36.2 
Study 
BERT 30 10.0 
BETA-CATH 13 4.3 
BRIDGE 11 3.7 
BRIE 14 4.7 
COMPASSIONATE 23 7.6 
EURO-START 40 12 4.0 
PREVENT 29 9.6 
Routine use* 169 56.1% 
Source  
P32 40 13.3 
Sr/Y 261 86.7 
Source length (vessels) 
P32 27mm 40 12.2 
90Sr/90Y 30mm 142 43.2 
90Sr/90Y 40mm 109 33.1 
90Sr/90Y 60mm 38 11.6 
Tandem radiation 48 14.6 
Delayed radiation 7 2.1 
LM denotes left main coronary artery, LAD left anterior descending coronary artery, RCA right coronary artery, 
and LCX left circumflex coronary artery. Tandem radiation refers to administration in a stepwise fashion, and 
delayed radiation refers to patients who had delay between intervention and the administration of brachytherapy. 
* 138 of these patients were enrolled in the RENO registry. 
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Table 3 
All events 
 <6m <1y <2y <3y <4y 
Death 4 4 9 10 12 
MI 8 17 27 32 32 
TLR 30 86 119 141 153 
TVR 5 17 22 23 27 
non TLR-TVR 15 36 50 58 65 
any re-intervention 50 139 191 222 245 
CABG 4 12 22 29 30 
total occlusions 6 17 29 34 37 
All events reflects the total count of events i.e. if a patient required repeat intervention and later suffered a MI the 
total count would reflect both events and not just the worst occurred. For the CABG and the total occlusions the 
total count of events is the same as the hierarchical ranking since there were no patients with repeated such events. 
CABG was not considered as separate event but was regarded as a type of re-intervention. 
MI denotes myocardial infarction, TLR denotes target lesion revascularization, TVR denotes target vessel 
revascularization, MACE denotes major adverse cardiac events and CABG denotes coronary artery bypass graft 
operation. 
Table 4 
Independent predictors of MACE and TLR during follow up 
 Hazard ratio 95% confidence interval 
MACE
Unstable angina 1.6 1.1-2.1 
Hypercholesterolemia 1.4 1-2 
Previous intervention  1.7 1.2-2.4 
TLR
Dose <18 Gy 1.6 1.1-2.3 
Source length <30mm 1.4 1-2,1 
MACE denotes major adverse cardiac events, TLR denotes target lesion revascularization. 
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Figure 1 
Number of patients treated with intracoronary radiation (IRT) per year. The recognition of the limitations of IRT 
and the advent of drug eluting stents in our institution had a dramatic impact in its use after 2000. 
Figure 2 
Death, myocardial infarction, re-intervention and MACE free survival curves up to four years (Kaplan-Meier). 
The TLR and MACE curves have three distinct segments. Up to six months a relapse is clearly visible followed by 
a sharp decrease related to the angiographic control undertaken in almost 65% of the patients. From one year and 
up to four years a constant and gradual decrease is clearly visible. 
MACE denotes major adverse cardiac events, TLR denotes target lesion revascularization, MI denotes myocardial 
infarction. 
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Figure 3 
TLR-free survival curves (Kaplan-Meier) based on the indication (de-novo/in-stent restenosis) and the device used 
(balloon/stent). 
TLR denotes target lesion revascularization, ISR denotes in-stent restenosis. 
Figure 4 
TLR-free survival curves (Kaplan-Meier) between patients that received <18 Gy and 18 Gy 
TLR denotes target lesion revascularization. 
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A 57 year old male with a history of anterior myocardial infarction in April 1997, initially 
treated with successful trombolysis, underwent cardiac catheterisation due to persistent post 
infarction angina. A single vessel disease, with a significant lesion in the left anterior 
descending coronary artery (LAD), was found. The patient was treated with balloon 
angioplasty followed by intracoronary beta radiation therapy according to the Beta Energy 
Restenosis Trial (BERT). He received 16 Gray at two millimetres from the centreline of the 
90Sr/90Y source. He remained asymptomatic for four and a half years. During this period he 
underwent control angiography with the use of Intravascular Ultrasound (IVUS) at six months 
and three years, as mandated by protocol. After this period he developed again angina and an 
exercise test was positive for ischemia. Diagnostic coronary angiogram at almost five years 
revealed single vessel disease, with totally occluded LAD with collateral filling from the right 
coronary artery. The angiographic sequence is presented in figure 1. The IVUS images are 
presented in figure 2. Before the re-intervention a 16-row, electrocardiographic-gated, 
cardiac, multi-slice spiral computed tomography scan was also performed (figure 3). Attempt 
for percutaneous recanalisation was not successful and the patient underwent coronary artery 
bypass surgery with implantation of the left internal mammary artery in the LAD. 
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Figure 1 
   The left anterior descending coronary artery, filmed at the left anterior oblique and cranial projection. At 
baseline a severe focal lesion (arrow) just before the bifurcation of the second diagonal branch (D2) with a septal 
perforator branch (S) was observed. A big first diagonal branch (D1) can also been noticed. The patient was 
treated with balloon angioplasty (single dilatation with a 3 x 12 mm balloon at 12 atmospheres) followed by 
catheter based irradiation with the use of the 30mm long, 90Sr/90Y Beta-Cath source, with good final result. The 
balloon and the radiation source were filmed in the right anterior oblique and cranial projection. The irradiated 
segment (IRS) is indicated by the two black horizontal lines at the final result frame. Control angiogram at six 
months and 3 years revealed well preserved result without restenosis. At five years there is severe lumen 
compromise through out the length of the irradiated segment, with minimal contrast penetration up to the D2 and 
complete occlusion after its take off. 
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Figure 2 
   Left side: longitudinal Intravascular Ultrasound (IVUS) reconstruction of the left anterior descending coronary 
artery (LAD) at six months follow-up, corresponding to the angiographic projection in figure 1. The Left main 
coronary artery (LM) is on top of the image and the distal LAD at the bottom. (a) Slice depicting the bifurcations 
with the left circumflex coronary artery (LCx) and the first diagonal branch (D1). (b) Slice depicting the 
bifurcations with the second diagonal (D2) and the septal (S) branches. There is 60 degrees difference between 
the planes of slices (a) and (b). Right side: longitudinal IVUS reconstruction of the LAD at three years follow-
up. (e) Corresponds to slice (a). (f) Corresponds to slice (b). Middle: cross-sectional images corresponding to the 
site of the initial stenosis at baseline, just before the bifurcations of the LAD with the D2 and the septal branches, 
as indicated by the yellow-red horizontal lines at the longitudinal reconstructions. (c) At six months. (d) At 3 
years. The red line delineates the external elastic membrane and the green line the lumen surface. Between six 
months and three years a reduction in the total vessel area (TVA) can be observed (negative remodelling) with 
accompanying reduction in the plaque area (PA), (plaque regression). This results in unchanged lumen area (LA) 
between 6 months and three years. 
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Figure 3 
   (a) Electrocardiographic-gated multi-slice computed tomography three-dimensional volume rendered image of 
the heart and the great vessels. The aortic root (Ao) the pulmonary artery (PA) and the left ventricle (LV) are 
clearly visible. (b) Detailed picture of the left coronary artery corresponding to the angiographic frames in figure 
1. The left main coronary artery (LM) is divided in the left anterior descending (LAD) and the left circumflex 
(LCx) coronary arteries. A severe stenosis at the ostium of the LAD (double arrowhead) can be seen. This lesion 
was not obvious at the angiographic images presented, due to overlap of the ostium of the LAD with LCx. More 
distally the LAD is occluded (arrowhead) after the take off of the first diagonal branch (D1), at the site of 
previous treatment with balloon dilatation and beta irradiation. 
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Abstract
Aims: Intracoronary brachytherapy (IRT) has been associated with the development 
of late occlusion. We reviewed the presentation, incidence, and prognosis of coronary 
occlusion following beta-radiation therapy at our institution. 
Methods and results: Between April 1997 and December 2001, 301 consecutive 
patients were treated with IRT, and 37(12.3%) developed target vessel occlusion. 
Mean follow-up was 40.3 months, mean time between IRT and occlusion was 16.0 
months (range 21 days-66.8 months). Presentation of occlusion was acute myocardial 
infarction in 27.0%, unstable angina in 21.6%, stable angina in 45.9%, asymptomatic 
in 5.4%. The timing of occlusion could be determined in 35 patients. Of these, 94.3% 
occurred once dual antiplatelet therapy had been stopped. 
The only factor predictive for development of occlusion was treatment of a de novo 
lesion rather than in-stent restenosis (15.4% versus 7.9%, p=0.03), with a trend 
towards worse results when IRT was combined with new stent implantation compared 
with balloon-only therapy (14.6% versus 8.9%, p=0.07). Occlusion was not related to 
the dose, the source length, or the “learning curve” of brachytherapy use.
Those with occlusion had a significantly higher combined rate of death and 
myocardial infarction compared to both the population without target lesion 
revascularization (TLR), and the population who underwent TLR for non-occlusive 
restenosis (35.1% versus 8.8%, p<0.00001 and versus 15.7%, p<0.01 respectively).
Conclusion: A high incidence of late vessel occlusion is observed after IRT 
especially when used for de novo lesions, and is associated with significant morbidity. 
The majority occur after stopping dual antiplatelet medication. Further studies are 
warranted to evaluate whether longer/life-long dual anti-platelet therapy is 
advantageous in reducing vessel occlusion following IRT. 
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Introduction 
In the mid-1990’s, intracoronary brachytherapy (IRT) was shown in the 
porcine animal model to inhibit smooth muscle cell proliferation and reduce the 
subsequent development of neointima hyperplasia (1-3). Following on from this, 
studies in clinical practice have subsequently proven its efficacy in the treatment of 
in-stent restenosis and it is currently the gold-standard therapy for these patients. It is 
the only therapy in this group proven in several randomised trials to be superior to 
placebo, with efficacy maintained up to 5 years (4-9). 
The utilisation of stents in standard percutaneous coronary intervention (PCI) 
provides a scaffold, thus reducing the risk of abrupt vessel closure compared to 
balloon-only angioplasty. However, there still remains a risk of occlusion related to 
acute thrombosis. Acute and subacute thrombosis within the first month after stent 
implantation occurs in <1-2% cases (10). Although not common, studies have shown 
that it is associated with significant morbidity and mortality, with a combined rate of 
death and myocardial infarction of 64% (10). By definition, late thrombosis develops 
more than 30days after treatment. Though it may occur following standard PCI in 
<1%, (11, 12) it has been a feature of brachytherapy occurring in up to 15% patients. 
(6, 13-15) It is thought to be related to delayed re-endothelialisation, and the strategy 
of prolonging dual antiplatelet therapy, with clopidogrel given in addition to aspirin in 
patients treated for in-stent restenosis, has proven to reduce the rate of late thrombosis 
to 3-4% (16). 
A chronic total coronary occlusion may be associated with an adverse 
mortality in the long-term. A recent study of a 20 year period of treating chronic 
occlusions showed an increased rate of death at 10 years in those in whom angioplasty 
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was unsuccessful compared to those with successful percutaneous revascularization. 
(17).
The aim of this study therefore, was to evaluate the predictors of total 
occlusions of the target vessel following percutaneous coronary intervention (PCI) 
with intracoronary brachytherapy, together with the incidence, time course of 
presentation, and prognosis. In addition, we evaluated the impact of increased 
experience in the application of brachytherapy administration in conjunction with 
prolongation of antiplatelet therapy.
Methods
Between April 1997 and December 2001, 301 consecutive patients were 
successfully treated with intracoronary beta-radiation therapy at the Thoraxcenter, 
Rotterdam. Over a mean follow-up period of 40.3 months, 37 patients have 
subsequently been found to have an occlusion of the treated vessel and form the 
present study population. Patient and procedural data was retrospectively analysed 
from a dedicated database. Long-term survival status was assessed by written inquires 
to the Municipal Civil Registries. Follow-up clinical data were determined from 
electronic hospital archives and by questionnaires sent to all living patients focusing 
on the occurrence of adverse cardiac events such as myocardial infarction and repeat 
intervention (surgical and percutaneous). The referring physician and institutions as 
well as the general practitioners were directly approached whenever necessary. 
Complete clinical follow-up was obtained in all patients up until 31
st
 March 2003. 
Definitions
Target vessel occlusion was defined as 100% occlusion with TIMI 0 flow 
demonstrated on angiography at the site of previous brachytherapy. Timing of 
occlusion was defined as acute (<24 hours), subacute (30days), or late (>30 days) 
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after therapy. Follow-up period was defined as that between the index procedure 
involving brachytherapy and 31
st
 March 2003. 
Brachytherapy treatment was classed as early if it was administered in the 
period April 1997 – 30
th
 June 1999 inclusive, or late if given after 1
st
 July 1999 up 
until 31
st
 December 2001. This corresponds to a change in policy of dual antiplatelet 
therapy duration from 0-3 months to a minimum of 6 months, Table 1. The diagnosis 
of acute myocardial infarction, indiscriminately Q or non-Q wave, required an 
elevation of creatine kinase to twice above the upper limit of normal together with a 
rise in creatine kinase-MB fraction; if made following patient admission to another 
hospital, was confirmed through direct contact with the referring physician, using the 
same criteria. Dual antiplatelet therapy was defined as the use of either ticlopidine or 
clopidogrel given in addition to aspirin. 
Statistical Analysis 
Data are expressed as mean value ± SD. Continuous variables were compared 
by Student’s t-test with statistical significance defined at the p<0.05 level. The 
independent association of clinical characteristics with coronary occlusion was tested 
by using the Cox proportional hazard model. Pre-selected pre and peri-procedural 
variables were age, gender, diabetes, hypertension, hypercholesterolemia, smoking, 
unstable angina, prior myocardial infarction, prior CABG, extent of coronary artery 
disease, left ventricular ejection fraction, indication for PTCA (de-novo or in-stent 
restenosis), device used (stent or balloon), dose (<18 Gy or Gy), and duration of dual 
antiplatelet medication (<6 months versus 6 months). 
Results
Mean follow-up period for the total population treated with IRT was 40.3 
months (range 15.1-70.1 months, median 40.1 months). The rate of coronary 
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occlusion in the overall population was 12.3% and presented a mean period of 16.0 
months after brachytherapy (range 21 days-66.8 months, median 12.7 months). 
Baseline patient characteristics and site of vessel treated were not significantly 
different between those who did, or did not develop coronary occlusion, Table 2. 
Brachytherapy was used in the treatment of de novo lesions in 175 patients 
(58.1%) and for in-stent restenosis in the remaining 126 (41.9%). Patients treated for a 
de novo lesion had a significantly higher incidence of occlusion compared to those 
treated for in-stent restenosis (15.4% versus 7.9% respectively, p=0.03). By 
multivariate analysis the treatment of a de-novo lesion was the only independent 
predictor for total vessel occlusion in the long-term (hazard ratio=2, 95%CI: 1.1-5). In 
addition, there was a trend towards worse results when brachytherapy was combined 
with new stent implantation (incidence 14.6%) compared with balloon-only therapy 
(incidence 8.9%), p=0.07. Target vessel occlusion rate was not related to the length of 
source used (13.0% for source length >30mm versus 11.6% for source length 30mm, 
p=NS); or the dosage administered (12.0% for >18 Gray versus 12.5% for 18 Gray, 
p=NS).
Over the course of brachytherapy administration, the duration of dual anti-
platelet therapy increased (Table 1). During the early period of brachytherapy 
treatment, 108 patients were treated with a subsequent overall occlusion rate of 8.3%. 
During the later period, 193 patients were treated with a rate of subsequent occlusion 
of 14.5% (p=NS). 
The presentation of target coronary occlusion was an acute myocardial 
infarction in 27.0%, with a further 21.6% presenting with unstable angina. The timing 
of occlusion was determined in 35 patients (2 asymptomatic patients were excluded) 
either due to the onset of an acute coronary syndrome or recurrence of anginal 
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symptoms. Of these, 94.3% occlusions occurred once dual antiplatelet therapy had 
been stopped. 
Treatment was percutaneous intervention in 25 patients (67.6%) with a 
successful revascularization rate of 72% (18/25). In total 11 (29.7%) were treated 
medically (7 after failed intervention), and 8 (21.6%) underwent CABG, Table 3. 
There was just one subacute occlusion, with the majority of all occlusions (83.8%) 
presenting more than 6 months after brachytherapy treatment, including 8 myocardial 
infarctions (21.6%), Table 4. 
There was no significant difference in the overall follow-up period duration 
between those patients with or without coronary occlusion. Compared to those who 
did not develop target vessel coronary occlusion, the cohort of 37 patients with 
coronary occlusion showed a trend towards an increased risk of death (8.1% versus 
3.4%, p=0.09), with 2 patients (5.4%) dying as a direct result of AMI related to the 
occlusion event. Table 5 shows the clinical adverse events occurring in the population 
with target vessel occlusion compared with those with non-occlusive restenosis, and 
the population without any evidence of restenosis. Those who developed occlusion 
had a significantly higher combined rate of death and MI compared to both the 
population with non-occlusive restenosis and those without TLR (35.1% versus 
15.7%, p<0.01 and versus 8.8%, p<0.00001 respectively). 
Discussion
In current practice, acute and subacute thrombosis following standard PCI 
with stent implantation occurs in 1-2% patients, with nearly two-thirds suffering 
either a myocardial infarction or death (10). In the present population where 
successful PCI therapy was combined with the administration of beta-radiation 
therapy, there were no episodes of acute thrombosis and a single patient presented 
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with acute myocardial infarction related to subacute thrombosis occurring 21 days 
after treatment (0.3%). However, a further 36 patients (12.0%) developed target 
vessel occlusion >30days after treatment, the majority (83.8%) occurring more than 6 
months after brachytherapy treatment, and more than half (54.1%) presenting more 
than 1 year after treatment. Approximately half of the patients (48.6%) presented 
acutely, suggestive of an underlying thrombotic occlusion.  
The phenomenon of late thrombosis is a characteristic of brachytherapy and 
thought to relate to delayed healing and re-endothelialisation (18-22). In the porcine 
model, brachytherapy has previously been shown to induce apoptosis in the adventitia 
and media, and reduce re-endothelialisation at 14 days from 82% in a control group, 
to 36-38% in an irradiated group (18). More recently, in rabbit iliac arteries, stent 
endothelialisation was shown to be <50% complete at 6 months after IRT, compared 
to 98% complete in the control group (19). In humans, angioscopy carried out 3 
months after stent implantation and brachytherapy has shown that the struts remain 
highly visible with only a very thin layer of intima; furthermore the presence of 
ulceration beneath the stent was also seen (20). In conjunction with this delayed re-
endothelialisation there is evidence for impairment of endothelial function following 
IRT. Vasodilation to nitroglycerin has been shown to be impaired (21) and Thorin et 
al demonstrated in a porcine model that endothelium-derived nitric oxide and 
endothelium-derived hyperpolarizing factor release was reduced at 6 weeks following 
IRT, and actually prevented when IRT was combined with angioplasty (22). In 
addition to delayed re-endothelialisation, beta-radiation therapy used in patients with 
in-stent restenosis, has been found to be associated with sustained platelet activation 
more than 6 months after treatment, despite the use of clopidogrel in addition to 
aspirin throughout the period (23). Data from the WRIST-12 study have suggested 
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that in addition to aspirin, the use of 12 months of clopidogrel, as opposed to 6 
months, leads to a reduction in the need for target lesion revascularization and rate of 
adverse cardiac events (16). In the current study, the majority (83.3%) of the 18 
patients who presented acutely did so more than 6months after brachytherapy; and all 
but one of these 18 (94.4%) presented following the termination of dual anti-platelet 
therapy. This is in concordance with results from both WRIST-PLUS and WRIST-12. 
In both studies the rate of total occlusion dramatically increased once the clopidogrel 
had been stopped. Between 6months and 15months follow-up, in WRIST-PLUS (6 
months of dual antiplatelet therapy) the rate of occlusion increased from 5.8% to 
11.7%, and in WRIST-12 (12months dual antiplatelet therapy) it increased from 2.5% 
to 9.2% (16). This suggests that clopidogrel exerts a protective effect against 
occlusion, and there may therefore be a benefit in continuing dual antiplatelet therapy 
for much longer periods perhaps even life-long. 
Brachytherapy was introduced into clinical practice in the Thoraxcenter in 
1997 and like all new modalities has been associated with a learning curve. To try to 
overcome the problem of late thrombosis, the duration of dual anti-platelet therapy 
given to most patients was increased to a minimum of 6months duration in the second 
half of 1999. In addition, early results of brachytherapy were hindered by the 
phenomenon of edge restenosis. This is thought to relate to geographical miss with 
mismatch between the segment of artery injured and the length of radiation source 
utilised (24). We hypothesised that with the evolution in IRT with increasing 
knowledge and understanding of the problems of late thrombosis and edge restenosis 
would come a reduction in the rate of events such as target vessel occlusion. However 
contrary to this, in our study, despite adopting a policy of increased duration of dual 
antiplatelet therapy, there was no such reduction between the early and late treatment 
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periods (8.3 versus 14.5% respectively, p=NS). In addition, neither the length of 
source used nor the dosage administered, were predictive for the development of 
target vessel occlusion. 
Brachytherapy is the only treatment modality proven to be effective in the 
treatment of in-stent restenosis. However, its efficacy preventing restenosis in de novo 
lesions is more contentious. In the beta-cath study, restenosis following stent 
implantation for a de novo lesion in conjunction with the use of brachytherapy was 
actually higher than the controls (44.9% versus 35.3%) (25). Consistent with this, in 
our study, the factor most predictive for the development of coronary occlusion was 
the treatment of a de novo lesion, with a trend towards this being particularly 
associated with stent implantation. 
The overall incidence of 12.3% target vessel occlusion in our study is likely to 
be an underestimate as patients did not undergo elective follow-up angiography 
beyond 6months, and we cannot therefore assess the rate of silent occlusion. We have 
clearly demonstrated that the development of target vessel occlusion following 
brachytherapy is associated with a significant increase in morbidity, and a trend 
towards an increased rate of mortality. Almost a third of patients suffered an acute 
myocardial infarction, and 21.6% required CABG surgery.
It is perhaps not surprising that the rate of AMI and CABG was significantly 
higher in the population with target vessel occlusion compared to those without 
restenosis and TLR. However, survival free of death, AMI or CABG was also 
significantly worse in the population with occlusion compared to the population who 
underwent TLR for non-occlusive restenosis (51.4% versus 67.5%, p<0.05).  
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Study limitations 
This is a single centre retrospective analysis and therefore carries all the 
inherent problems associated with this type of analysis. The cohort is somewhat 
heterogeneous, with the duration of dual antiplatelet therapy increasing over the 
treatment period based on the protocol and the current evidence at the time of therapy. 
However, this variability in treatment did not appear to influence the rate of target 
vessel occlusion. 
Conclusions
The occurrence of target vessel occlusion following brachytherapy is high and 
is associated with significant morbidity. In order to reduce the risk of developing 
occlusion, the use of beta-radiation therapy should be limited to the treatment of in-
stent restenosis where its efficacy is proven. Furthermore, studies are needed to 
evaluate whether there is a benefit in administering dual anti-platelet therapy for much 
longer periods - perhaps even life-long. 
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Table 1 
Study N Source 
Date of 
inclusion
Duration of dual 
antiplatelet
therapy (months) 
Lesion type 
BERT 30 90Sr/90Y 4/97-12/97 0-1* De novo 
Compassionate use 23 90Sr/90Y 5/97-6/99 0-1* ISR 
PREVENT 29 32P 4/98-5/99 0-1* De novo 
BETA-CATH 13 90Sr/90Y 4/98-5/99 1 De novo/ISR 
BRIE 14 90Sr/90Y 10/98-6/99 1-3 De novo 
Routine use** 169 90Sr/90Y 7/99-12/01 6-9 De novo/ISR 
EURO-START 40 12 90Sr/90Y 5/01-12/01 6 ISR 
BRIDGE 11 32P 2/01-12/01 12 De novo 
The studies into which patients were enrolled, together with the time period of inclusion and the policy 
of dual anti-platelet therapy duration. 
ISR denotes in-stent restenosis. 
* In the absence of new stent implantation, some patients were not given additional anti-platelet 
therapy. 
** 138 included as part of the RENO registry. 
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Table 2 
 Target vessel 
occlusion population
(n=37)
Total population 
without occlusion 
(n=264)
p
value
Mean age (years) 59.3 59.1 NS 
Male sex (%) 24 (64.9) 190 (72.0) NS 
Diabetes mellitus (%) 7 (18.9) 39 (14.8) NS 
Smoking (%) 7 (18.9) 49 (18.6) NS 
Hypertension (%) 10 (27.0) 81 (30.7) NS 
Hypercholesterolaemia (%) 19 (51.4) 149 (56.4) NS 
Previous AMI (%) 12 (32.4) 93 (35.2) NS 
Previous PCI (%) 15 (40.5) 143 (54.2) NS 
Previous CABG (%) 8 (21.6) 44 (16.7) NS 
LMS (%) 0 1 (0.4%) NS 
RCA (%) 15 (40.5) 94 (35.6) NS 
LCX (%) 8 (21.6) 52 (19.7) NS 
LAD (%) 11 (29.7) 101 (38.3) NS 
Initial therapy  
SVG (%) 3 (8.1) 16 (6.1) NS 
Glycoprotein IIb/IIIa inhibitor use (%) 14 (37.8) 95 (36.0) NS 
Dual antiplatelet therapy  6 months (%) 24 (64.9) 155 (58.7) NS 
Comparison of baseline patient characteristics, vessel treated, and usage of anti-platelet therapy 
between those treated with brachytherapy who did, or did not develop target vessel occlusion. 
AMI denotes myocardial infarction, PCI denotes percutaneous coronary intervention, CABG denotes 
coronary artery bypass surgery, LMS denotes left main stem, RCA denotes right coronary artery, LCX 
denotes circumflex artery, LAD denotes left anterior descending artery, SVG denotes saphenous vein 
graft. 
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Table 3 
Target vessel occlusion 
population
(n=37)
AMI (%) 10 (27.0) 
Unstable (%) 8 (21.6) 
Stable (%) 17 (45.9) 
Clinical
presentation of 
occlusion
Asymptomatic (%) 2 (5.4) 
<24hours 0 
24hours to 30 days (%) 1 (2.7) 
>30 days to 6months (%) 6 (16.2) 
>6months to 12months (%) 10 (27.0) 
Time of 
presentation of 
occlusion
>12months (%) 20 (54.1) 
Medical (%) 4 (10.8) 
Failed PCI – medical therapy (%) 7 (18.9) 
Balloon (%) 4 (10.8) 
Total (%) 14 (37.8) 
Bare (%) 8 (21.6) Stent
Sirolimus (%) 6 (16.2) 
Treatment
CABG (%) 8 (21.6) 
Clinical presentation of target vessel occlusion and its’ treatment. 
AMI denotes myocardial infarction, PCI denotes percutaneous coronary intervention, CABG denotes 
coronary artery bypass surgery. 
178
Chapter 13
Table 4 
30
days
>30days -
6months 
>6months - 
1year
>1year - 
2years
>2 years 
AMI (n=10) 1 1 5 3 0 
UA( n=8) 0 1 2 2 3 
Presentation 
of occlusion 
SA (n=17) 0 1* 4 7 5 
Timing of target vessel occlusion and its’ relationship to clinical presentation. 
AMI denotes acute myocardial infarction, UA denotes unstable angina, SA denotes stable angina. 
* An additional 2 patients were found to have asymptomatic target vessel occlusion at 6month control 
angiography. 
Table 5 
 Target vessel 
occlusion population
(n=37)
Population with 
TLR for restenosis  
(n=83)
Population without 
TLR
(n=181)
Mean follow-up period (months) 43.0 ± 12.7 46.9 ± 12.6 39.6 ± 14.1 
Death 3 (8.1%) 3 (3.6%) 6 (3.3%) 
AMI 12 (32.4%) 10 (12.0)
†
 10 (5.5%)
‡
Death or AMI 13 (35.1%) 13 (15.7)
†
 16 (8.8%)
‡
CABG 8 (21.6%) 19 (22.9) 3 (1.7%)
‡
Death or AMI or CABG 18 (48.6%) 27 (32.5)* 19 (10.5%)
‡
*p<0.05 †p<0.01 ‡p<0.00001 compared with the target vessel occlusion population. 
Comparison of the rate of adverse events (death, myocardial infarction or coronary artery bypass 
surgery) between those treated with brachytherapy who developed target vessel occlusion, compared 
with the population who underwent target lesion revascularization for non-occlusive restenosis, and the 
remaining population without restenosis and target lesion revascularization. 
AMI denotes acute myocardial infarction, CABG denotes coronary artery bypass surgery, TLR denotes 
target lesion revascularization. 
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Abstract
Background: Recurrent restenosis following vascular brachytherapy has been reported in up to 
one third of the patients enrolled in clinical trials. The long-term outcome of repeat percutaneous 
intervention (PCI) after failed beta-brachytherapy is currently unknown. 
Methods: We retrospectively analyzed 97 consecutive patients undergoing percutaneous 
coronary re-intervention after failed beta-brachytherapy at our institution (80.8% of all 
brachytherapy failures). Long-term incidence of major adverse cardiac events (MACE: death, 
myocardial infarction, target lesion revascularization) was assessed. 
Results: The procedure was successful in 90 (92.8%) patients. A new stent was implanted in 72% 
of the procedures (sirolimus-eluting stent in 16.5%). After 3 years, survival was 94.3%, survival-
free from myocardial infarction 86.7%, and MACE-free survival 66.1%. Overall, a second target 
lesion revascularization was performed in 27 (27.8%) patients after an average of 11.2±11.2 
months; 21 (21.6%) patients had restenosis, and 6 (6.2%) developed late total vessel occlusion 
(related to acute myocardial infarction in 2 cases). 
Conclusions: Repeat PCI is the most common choice after failed brachytherapy. This strategy 
appears as a reasonable therapeutic option for this complex iterative pathology. 
Key words: restenosis, brachytherapy, coronary angioplasty 
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Introduction 
Ionizing radiation has been shown to reduce neointimal formation after balloon angioplasty 
through the reduction of vascular smooth muscle cells proliferation and positive vessel 
remodeling (1). Whilst coronary vascular brachytherapy for prevention of restenosis in de novo 
lesions is controversial (2-4), it represents the gold standard treatment for diffuse in-stent 
restenosis (5-9). However, in clinical trials brachytherapy failure (angiographic restenosis and 
target lesion revascularization) has been reported in a consistent number of patients, with a slow 
but progressive increase over long-term follow-up (10). Although in this clinical setting bypass 
surgery may represent a more definitive choice of treatment, repeat percutaneous coronary 
intervention (PCI) remains an appealing strategy. 
Recently, two studies reported the outcome of repeat PCI in patients after failure of 
gamma-brachytherapy in the GAMMA (11) and the WRIST trials (12). They showed that the 
pattern of recurrent restenosis was predominantly focal. In these studies, percutaneous re-
intervention was accomplished safely, but in up to one third of the patients a repeat reintervention 
was necessary during follow up. 
Beta radiation, in contrast with gamma, has limited penetration and does not require 
modifications to the standard shielding used in the catheterization laboratory. As a result, beta-
sources became the most widely used type of vascular brachytherapy. Nevertheless, there is no 
specific information in the literature regarding the outcome of patients who failed beta-
brachytherapy. The process of restenosis after coronary irradiation is still not entirely understood, 
and a possible different vascular response to percutaneous treatment following beta and gamma 
radiation cannot be ruled out a priori.
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The aim of this study was therefore to assess the long-term clinical outcome of patients 
who underwent percutaneous revascularization for restenosis following intracoronary beta-
brachytherapy with catheter-based techniques. 
Methods
Patient population 
We retrospectively analyzed the data from all patients treated with catheter-based beta-
brachytherapy at our institution between the 29th of April 1997 and the 31st of December 2001 
(n=301). The majority of the patients were enrolled in clinical studies whose design and principal 
results are published elsewhere (table 1) (4,6,13-17). A total of 120 patients with a diagnosis of 
brachytherapy failure were identified (39.9% of the entire brachytherapy-treated population in the 
pre-defined period): in 44 patients brachytherapy was originally administered for in-stent 
restenosis, and in 76 for de novo lesions. The subsequent management of these patients, including 
revascularization strategy (surgical or percutaneous), was decided conjointly by a team of 
interventional cardiologists and cardiac surgeons. Overall, 8 (5.8%) asymptomatic patients with 
angiographic restenosis were treated conservatively, 15 (12.5%) patients underwent bypass 
surgery, and the remaining 97 (80.8%) patients were treated with repeat percutaneous 
intervention and comprise the present analysis. 
Percutaneous re-intervention procedure 
All patients were pre-treated with aspirin (>75 mg/d). Clopidogrel (75 mg/d or 300 mg as 
a loading bolus dose) was given to those in which stent implantation was planned in advance. 
During the procedure weight-adjusted heparin was administrated to achieve an activated clotting 
time of >300 sec. Final treatment strategy and medications were left to the operator’s discretion. 
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Definitions 
Restenosis was defined as >50% diameter stenosis by quantitative coronary analysis. At 
baseline, lesions were classified as: 1) restenosis in the irradiated segment; 2) edge-restenosis,
defined as restenosis occurring in the 5 mm proximal or distal to the irradiated segment; 3) late 
total occlusion, defined as total vessel occlusion angiographically documented at the irradiated 
site more than 30 days after the brachytherapy procedure. The percutaneous re-intervention was 
considered successful when a good angiographic result was obtained in combination with TIMI 
flow 3. Major adverse cardiovascular events (MACE) were defined as death, nonfatal myocardial 
infarction, and target lesion revascularization, either percutaneous or surgical. The diagnosis of 
myocardial infarction was based on an increased level of creatine kinase to more than twice the 
upper limit of normal with an increased level of creatine kinase-MB isoform. For patients 
admitted to peripheral hospitals in the acute phase, the diagnosis of myocardial infarction was 
confirmed by the referring physician based on the same criteria. Target lesion revascularization 
was defined as any surgical or percutaneous re-intervention due to restenosis within the irradiated 
segment or the 5mm proximal or distal segments (edge restenosis). Target vessel 
revascularization was defined as any re-intervention driven by lesions located in the treated vessel 
beyond the target lesion limits. Non-target vessel revascularization was defined as any re-
intervention in vessels other than the target vessel. Subacute thrombosis was defined as 
angiographically documented total occlusion ≤ 30 days after the percutaneous re-intervention. 
Late total occlusion was defined as an angiographically documented total occlusion at the treated 
site at >30 days after the percutaneous re-intervention. 
Follow-up 
Baseline clinical and procedural data were entered prospectively into a dedicated 
database. Information about re-interventions was obtained from an electronic database of hospital 
186
Chapter 14
records. The Thoraxcentre is a tertiary cardiology centre serving a group of 14 local hospitals, 
and is the only one with facilities for percutaneous interventions in the region of Rotterdam. As 
required by the local medical system organisation all baseline procedures were performed in this 
tertiary facility, as well as the vast majority of re-interventions. Long-term survival status was 
assessed by written inquires to the Municipal Civil Registries. Questionnaires were sent to all 
living patients focusing on the occurrence of adverse cardiac events such as myocardial infarction 
and repeat intervention (surgical and percutaneous). The referring physician and institutions as 
well as the general practitioners were directly approached whenever necessary. Follow-up period 
was defined as that between the first re-intervention following failed brachytherapy and the 31
st
March 2003. Complete follow-up was obtained for all patients. 
Statistical methods 
Continuous variables are expressed as mean ± standard deviation, and categorical 
variables are reported as count and relative percentage. Event-free survival rates were estimated 
according to the Kaplan-Meier method. 
Results
Baseline clinical and angiographic characteristics 
Baseline characteristics of the 97 patients who failed brachytherapy and underwent a new 
PCI are described in table 2. The average time from the brachytherapy procedure to this first TLR 
was 13.4±13.4 months. In 11 patients (11.3%) irradiation had been performed with a 
32
Phosphorus (
32
P) source, and in 86 (88.7%) with a 
90
Strontium/
90
Yttrium (
90
Sr/
90
Y). The 
average dose administered was 18.7±5.5 Gy, and the average source length was 35±8 mm. Acute 
coronary syndrome was the presenting diagnosis in 36 (37.1%) patients; of these, 5 (4.2%) had 
acute myocardial infarction due to late thrombosis (all had been treated and had received 
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brachytherapy for de novo lesions, and 4 of them had received a new stent). Restenotic post-
brachytherapy lesions were classified as restenosis within the irradiated segment in 55 (56.7%) 
patients, edge-restenosis in 21 (21.6%) patients, and late total occlusion in 21 (21.6%) patients. 
During repeat PCI, procedural success was achieved in 90 (92.8%) patients. There were 7 
procedural failures, all in patients with totally occluded vessel. A new stent was implanted in 65 
(72.2%) cases. Sixteen patients (16.5%) received a sirolimus-eluting stent during the re-
intervention.  
Follow-up 
Figure 1 shows a flowchart with the design and the principal results of the study. Total 
revascularization rate was 30.9% (30 patients). Repeat TLR was performed in 27 (27.8%) 
patients: 10 (10.3%) of these were treated with bypass surgery and in the remaining 17 (17.7%) a 
second percutaneous TLR was performed. The average time from the first to the second TLR 
procedure was 11.2±11.2 months. The clinical presentation at the time of the second TLR was 
stable angina in 17 patients (63.0%), unstable angina in 7 (25.9%), and acute myocardial 
infarction in 3 (11.1%). All the patients with acute myocardial infarction received a new stent 
during the first re-intervention following brachytherapy (in individual basis, the time elapsed 
from the brachytherapy procedure was 8.4, 11.5 and 28.1 months, whereas the time elapsed from 
the first re-intervention post-brachytherapy was 4.4, 5.9 and 12.0 months). Angiographically late 
total occlusion was documented in 6 patients. In two of these, the late total occlusion was 
associated with an acute myocardial infarction, (one of them was still on combined antiplatelet 
regimen). At three years the cumulative survival rate was 94.3%, the survival free of myocardial 
infarction 86.7%, and MACE free survival was 66.1%, Figure 2. 
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Sirolimus-eluting stent subgroup 
Among the sixteen patients treated with sirolimus-eluting stents 3 patients (18.7%) 
underwent a second clinically-driven TLR, 1 (6.2%) patient died of progressive congestive heart 
failure (pre-existing) and in 2 more patients (12.5%) angiographic restenosis was found at 
elective angiographic control. No further re-intervention was done because they were 
asymptomatic. Overall, a failure of sirolimus eluting stents was clearly documented in 5 (31.2%) 
patients. 
Discussion 
In this study we report the outcome of a consecutive series of patients treated with PCI 
after recurrent restenosis following catheter-delivered coronary beta-irradiation. In this setting, a 
percutaneous strategy appeared feasible, with high rate of procedural success and low peri-
procedural risk. Moreover, considering the complexity of these patients, the long-term outcome 
could be considered acceptable. Indeed, our results are similar to what previously described for 
re-interventions after failed gamma-brachytherapy, where a long-term incidence of MACE of 
42.2%, and a revascularization rate of 33.3% were reported (11). 
Defining the outcome after re-interventions following vascular brachytherapy failure is of 
great importance. In fact, although brachytherapy is considered the best therapeutic option for 
patients with complex in-stent restenosis (5-9), up to one third of these patients will subsequently 
develop restenosis and need for re-intervention (11,12). Geographical miss (18), late stent 
thrombosis (19), late total occlusion (20), delayed restenosis (21), persistent dissections (22), are 
well documented phenomena. Most of them are intrinsically related to the radiation’s effects and 
cannot be completely avoided, despite technical improvements and the increased experience of 
the operators using this therapeutic modality. Moreover, the risk of late thrombosis following 
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brachytherapy has been reduced, but not abolished, by prolonged antiplatelet therapy (23,24). In 
this scenario, a definitive intervention would be desirable, especially considering that these 
patients had already suffered a number of recurrent failures. Notably, repeat PCI was the most 
common choice at our institution, with 80.8% of the patients who failed brachytherapy treated 
with this modality. This is consistent with a previous report from the WRIST trial (12). As 
possible explanations for this choice we could indicate the high-risk baseline profile of many 
patients, therefore deemed unsuitable for coronary artery bypass graft surgery, coronary anatomy 
unfavorable for bypass surgery (for example, small vessel diameter), absence of disease in the left 
anterior descending coronary artery, patient’s preference. In our study, 24% of the patients had a 
previous coronary bypass operation. Coronary bypass re-interventions are associated with an 
operative mortality distinctly higher than the mortality of first-time operations, and carry a higher 
risk of peri-operative complications, including re-operation for bleeding, peri-operative 
myocardial infarction, and neurological and pulmonary problems (25). 
Our study confirms that the risk of late vessel occlusion after re-intervention for failed 
brachytherapy remains in a sizable proportion (6.2%). In one third of these cases this led to an 
acute myocardial infarction. This was especially true for patients in which a new stent was 
implanted. Even if this phenomenon is well known when a new stent is implanted at the time of 
irradiation, it has not been described after a subsequent re-intervention. The most likely 
explanations are the long-term endothelial dysfunction and the delayed vascular healing, two 
established drawbacks of vessel irradiation (26). 
Drug-eluting stents may have a role in the management of patients who have failed 
brachytherapy. However, preliminary results suggest that sirolimus-eluting stents, which have 
been proven to be very effective in other clinical settings (27-29), seem to have a reduced 
efficacy for recurrent restenosis after failed brachytherapy (30). Thus, although more extensive 
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evaluation is necessary, it seems unlikely that drug-eluting stents could further improve the 
results in this “biologically modified” environment. 
Conclusions 
The results of the present study, suggest that patients treated with coronary brachytherapy 
have a consistent risk for repeat interventions at the irradiated segment in the long-term. 
Percutaneous re-intervention is the most common choice. With this strategy, rates of MACE and 
further re-interventions are contained, although not negligible, with a residual risk of vessel 
occlusion, especially when a new stent is implanted. Percutaneous re-intervention appears as a 
reasonable therapeutic option for this complex iatrogenic pathology. 
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Table 1
Patient population and studies 
 Lesion Type Radiation source n=97 
BERT
15
 De novo 
90
Sr/Y 12 
BETA-CATH
13 * 
De novo 
90
Sr/Y 4 
PREVENT
6
 De novo / restenosis 
32
P 9 
BRIE
4
 De novo / restenosis 
90
Sr/Y 7 
EURO-START 40* In-stent restenosis 
90
Sr/Y 2 
Compassionate use
17 
In-stent restenosis 
90
Sr/Y 17 
RENO Registry
14
 De novo / In-stent restenosis 
90
Sr/Y 44 
BRIDGE* De novo 
32
P 2 
*studies not published 
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Table 2 
Baseline clinical and angiographic characteristics 
 n=97 
Age, y* 59±10 
Men, % 70.1 
Diabetes, % 13.4 
Hypercholesterolemia, % 57.7 
Hypertension, % 33.0 
Current smoker, % 17.5 
Family history, % 16.5 
Previous myocardial infarction, % 33.0 
Previous coronary bypass surgery, % 23.7 
Multivessel disease, % 45.4 
Clinical presentation  
 Silent ischemia, % 3.1 
 Stable angina, % 59.8 
 Unstable angina, % 32.0 
 Acute myocardial infarction, % 5.1 
Lesion type  
 Restenosis in the irradiated segment, % 56.7 
 Edge-restenosis, % 21.6 
 Total occlusion, % 21.6 
Coronary vessel treated  
 Left anterior descending, % 28.9 
 Left circumflex, % 26.8 
 Right, % 37.1 
 Saphenous vein graft, % 7.2 
Time from brachytherapy procedure*, months 13.4±13.4 
Glycoprotein IIb/IIIa inhibitors, % 20 
*values are expressed as mean ± standard deviation 
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Figure 1 
Flowchart illustrating the design and the principal results of the study. Asterisk (*) denotes that all the percentages 
given between brackets refer to that number (97 patients). CABG denotes coronary artery bypass graft; PCI denotes 
percutaneous coronary intervention; non-TVR denotes other vessel revascularization; TLR denotes target lesion 
revascularization; TVR denotes target vessel revascularization; VBT denotes vascular brachytherapy. 
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Figure 2 
Kaplan-Meier curves showing survival, survival free of myocardial infarction, and survival free of major adverse 
cardiac events (MACE) in patients treated with repeat percutaneous coronary interventions following failed beta-
brachytherapy. Time “0” represents the first repeat target lesion revascularisation after failed vascular brachytherapy. 
MI denotes myocardial infarction, TLR denotes target lesion revascularization. 
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Effectiveness of Sirolimus-Eluting Stent Implantation
for Recurrent In-Stent Restenosis After Brachytherapy
Francesco Saia, MD, Pedro A. Lemos, MD, Georgios Sianos, MD,
Muzaffer Degertekin, MD, Chi-Hang Lee, MD, Chourmouzios A. Arampatzis, MD,
Angela Hoye, MD, Kengo Tanabe, MD, Evelyn Regar, MD, PhD,
Willem J. van der Giessen, MD, PhD, Pieter C. Smits, MD, PhD, Pim de Feyter, MD, PhD,
Jurghen Ligthart, MSc, Ron T. van Domburg, MSc, PhD, and Patrick W. Serruys, MD, PhD
Coronary vascular brachytherapy is, to date, theonly effective treatment available for complex in-
stent restenosis (ISR).1 However, its efﬁcacy is ham-
pered by late restenosis,2 late thrombosis,3,4 edge ef-
fect,5 geographic miss,6 and delayed healing.3 More-
over, the fate of the patients after “failed” brachytherapy
is uncertain, as well as the result of the various percuta-
neous treatments employed thereafter. Sirolimus is a
macrolide antibiotic produced by Streptomyces hygro-
scopicus with immunosuppressive effects; it is approved
for the prevention of renal transplant rejection.7 The
main effect of sirolimus is the interruption of G1 to S cell
cycle progression mediated by its binding to a cytosolic
receptor (FK506 protein binding protein 12) and a cas-
cade of subsequent actions. Importantly, sirolimus inhib-
its proliferation andmigration of vascular smooth muscle
cells, a key element in the development of restenosis
after percutaneous coronary interventions (PCIs). Re-
cently, stent-based local sirolimus delivery has been
shown to strongly suppress neointimal hyperplasia and
prevent restenosis in de novo lesions followed up for 2
years.8,9 The revolutionary results obtained with drug-
eluting stents have encouraged the assessment of their
efﬁcacy in more complex clinical and morphologic sub-
sets. The ﬁrst human experience evaluating the siroli-
mus-eluting stent (SES) for the treatment of ISR has
been recently reported; it showed this strategy to be
highly effective.10 We describe here the ﬁrst series of
patients treated with SESs for recurrent ISR after brachy-
therapy.
• • •
The patients described in this report consist of 2
cohorts treated during separate time periods. The ﬁrst
cohort was treated between March 2001 and June
2001, as part of a pilot study on SESs for treatment of
ISR. Since April 2002, shortly after European Com-
munity market approval, SES implantation has been
adopted as the default strategy in all patients treated
with PCI at our institution, irrespective of clinical
presentation and coronary morphology. These latter
patients have been included in the RESEARCH Reg-
istry (Rapamycin-Eluting Stent Evaluated At Rotter-
dam Cardiology Hospitals) and will be followed up
for 1 year.11 The only exclusion criteria were unavail-
ability of an adequately sized SES at the time of the
procedure and enrollment in another revascularization
protocol (SESs were available in diameters from 2.25
to 3.0 mm and lengths of 8, 18, and 33 mm). All
patients treated with SES after “failed” brachytherapy
were scheduled for 6-month angiography.
ISR was deﬁned as 50% diameter stenosis by
quantitative coronary angiography within a previously
stented vessel segment and classiﬁed as proposed by
Mehran et al.12 Treatment strategy and device utiliza-
tion other than stenting was left to the physician’s
discretion. The procedure was considered successful
when residual stenosis 30% by quantitative coro-
nary angiography was achieved together with Throm-
bolysis In Myocardial Infarction (TIMI) ﬂow grade 2
to 3. The study stent utilized was the sirolimus-eluting
Cypher (Cordis Europa NV, Johnson & Johnson, Ro-
den, The Netherlands), which contains a 140 g siroli-
mus/cm2 metal surface area in a slow release formu-
lation (28 days). Pretreatment with clopidogrel for
48 hours or a 300-mg loading dose was required.
During the procedure, intravenous heparin was given
to maintain an activated clotting time 300 seconds.
After the procedure, all patients received aspirin in-
deﬁnitely (75 mg/day) and clopidogrel (75 mg/day)
for at least 2 months. Clinical status information was
collected at follow-up visits or by telephone contact
with the patient or referring physician. Data are pre-
sented as number and relative percentage or mean 
SD. Median and range have been reported when
deemed necessary for a better description.
From the beginning of the study until August 15,
2002, 12 consecutive patients (both cohorts) under-
went PCI with SES implantation for recurrent ISR
after local radiation therapy. All of them presented
with angina pectoris and/or myocardial ischemia as
documented by stress test or thallium scan. Coronary
brachytherapy had been previously performed in 11
patients with catheter-based local irradiation (10 beta,
1 gamma) and in 1 patient with phosphorus-32 radio-
active stent implantation.
Baseline clinical and angiographic characteristics
are listed in Tables 1 and 2, respectively.
Nine patients (75%) had had more than 1 previous
episode of restenosis. Average time from the preced-
ing percutaneous reintervention was 24 months (range
111 to 1,678 days, median 719).
Remarkably, 9 patients (75%) presented with a
From Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands. Dr.
Serruys’ address is: Erasmus MC, Thoraxcenter, Bd404, Dr. Molewa-
terplein 40, 3015 GD Rotterdam, The Netherlands. E-mail: p.w.j.
c.serruys@erasmusmc.nl. Manuscript received January 16, 2003; re-
vised manuscript received and accepted April 14, 2003.
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proliferative pattern of restenosis, 5 of whom (42%)
had a totally occluded target vessel. The occlusion
dated more than 3 months in 4 patients.
Overall, we implanted 18 SESs (average 1.5/pa-
tient). Mean stent length was 33.9  30.1 mm (range
8 to 92; median 18), and mean stent diameter was 2.88
 0.33 mm. Multivessel PCI was performed in 3
patients (25%).
Angiographic success was obtained in 11 of 12
patients (92%). The remaining patient showed a 34%
residual stenosis during quantitative coronary angiog-
raphy and stent underexpansion despite very high-
pressure inﬂation (24 atm). Individual clinical out-
comes are listed in Table 3. With the obvious excep-
tion of the single patient presenting with acute
TABLE 1 Patients’ Baseline Characteristics and Demographics
Patients 12
Age (yrs) 62  11
Men 9 (75%)
Current smoker 4 (33%)
Hypercholesterolemia* 11 (92%)
Systemic hypertension 6 (50%)
Diabetes mellitus 3 (25%)
Family history of coronary
heart disease
4 (33%)
Stable angina pectoris 7 (58%)
Unstable angina pectoris 4 (33%)
Acute myocardial infarction 1 (8%)
Multivessel coronary disease 10 (83%)
Previous myocardial infarction 9 (75%)
Previous coronary bypass 4 (33%)
Time from last target lesion
revascularization (d)
111–1,678 (719)
Time from brachytherapy (d) 111–1,968 (792)
Episodes of ISR
1 9 (75%)
2 5 (42%)
*Total cholesterol 200mg/dl and/or receiving lipid lowering treatment.
Values expressed as mean  SD, range (median), or as number of patients
(%).
TABLE 2 Angiographic and Procedural Characteristics
Variable
Target coronary artery
Left anterior descending 2 (17%)
Left circumﬂex artery 5 (42%)
Right 4 (33%)
Left main 1 (8%)
Quantitative coronary analysis, before procedure
Reference diameter (mm) 2.83  0.48
Minimum lumen diameter (mm) 0.67  0.76
Diameter stenosis (%) 77  25
Quantitative coronary analysis, after procedure
Reference diameter (mm) 2.76  0.38
Minimum lumen diameter (mm) 2.38  0.45
Diameter stenosis (%) 13  11
Acute gain (mm) 1.71  0.58
Late loss (mm) 0.68  1.20
Multivessel coronary procedure 3 (25%)
Other devices utilized
Cutting balloon 3 (33%)
Cross Safe* 1 (8%)
Values expressed as mean  SD or number (%).
*Intraluminal Therapeutics Inc., Carlsbad, California.
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myocardial infarction, no postprocedural cardiac en-
zyme elevation was observed, and all the patients
were discharged home free from events.
Average follow-up was 8.5  4.5 months. Ten
patients (83%) underwent angiography between 4 and
7 months after the procedure. Two patients who re-
fused angiographic follow-up were asymptomatic af-
ter 4 and 6 months. One patient died after 9.5 months
because of congestive heart failure, shortly after hos-
pital admission for acute pulmonary edema. He was
79 years old, with a history of 2 coronary artery
bypass graft operations and 2 PCIs. Left ventricular
dysfunction and end-stage congestive heart failure
were diagnosed before the last coronary angioplasty.
During the 4-month follow-up, no intravascular ultra-
sound evidence of neointimal hyperplasia was found.
Recurrent ISR after SES implantation was found in
4 out of 10 patients who underwent angiography dur-
ing follow-up (40%). One of them, in whom complete
stent expansion could not be achieved at index proce-
dure, was found to have silent reocclusion after 4
months. No further treatment was performed, and at
19 months the patient remained asymptomatic. Two
other patients, both diabetics, presented with stable
angina (Canadian Cardiovascular Society class 3) and
ISR that required target lesion revascularization. In 1
of them, intravascular ultrasound showed a clearly
underexpanded stent with a very small minimal in-
stent diameter (1.3 mm). In the fourth case, a very
focal restenosis (5 mm) was diagnosed by elective
angiography 5 months after the procedure. Originally,
the patient had been treated with 4 SESs (overall
length 92 mm) for chronic total occlusion of the left
anterior descending artery (ISR). Intravascular ultra-
sound examination conﬁrmed the absence of neointi-
mal hyperplasia in the remaining portion of the stents.
The patient was asymptomatic, but percutaneous re-
vascularization was performed based on intravascular
ultrasound ﬁndings.
Another patient had recurrent angina 4 months
after the procedure. Angiography showed minimal
in-stent hyperplasia in the region of interest, whereas
a severe lesion due to ISR requiring percutaneous
treatment was found in a different vessel.
One of the lesions treated with an SES during the
index procedure was composed of echolucent tissue
(“black hole”).13 Interestingly enough, the intravascu-
lar ultrasound examination at follow-up showed a
reappearance of this tissue, although it did not signif-
icantly affect the lumen area.
• • •
SESs have been recently shown to strongly prevent
the development of neointimal hyperplasia after stent-
ing. The ﬁrst randomized clinical trial reported an
exceptional 0% binary restenosis rate.8 Whether a
similar result is obtainable in different clinical situa-
tions and for more complex coronary lesion subsets is
the subject of extensive investigation. Preliminary re-
sults for their use in the treatment of ISR are positive,
although less impressive than in de novo lesions.10
In the present investigation, we sought to assess the
safety and outcome of SES implantation in patients
with recurrent ISR after brachytherapy. The strategy
evaluated is safe and is believed to be clinically ef-
fective, considering the complex population under in-
vestigation. The 0% incidence of in-hospital events as
well as the absence of subacute stent thrombosis is
noteworthy because the average stent length was re-
markably high, and these patients are likely to have
endothelial dysfunction. The only death that occurred
is highly unlikely to be related to either the procedure
or to the stent, but rather to the severely compromised
left ventricular function. Nevertheless, our report
raises a series of unresolved issues. The antiprolifera-
tive effect of sirolimus after brachytherapy seems to
be strongly reduced compared with other situations.
The 40% incidence of restenosis in our population is
noteworthy. Diabetes mellitus, a well-known risk fac-
tor for restenosis, may also represent a predisposing
factor for failure in this setting. However, in 2 cases,
technical causes of failure (stent underexpansion)
could be implicated, and in a third patient, a very focal
neointimal growth was observed compared with the
very long baseline lesion and total stent length. The
optimal duration of combined antiplatelet therapy is
unclear. In this series there was a striking variety in
the duration of clopidogrel prescribed after the proce-
dure due to decisions made on an individual patient
basis. Currently, we prescribe combined antiplatelet
therapy for 12 months or lifelong after very long stent
implantation, but this approach deserves further eval-
uation.
Our investigation presents a few limitations. First,
we do not have a control population. Whether a con-
ventional approach would have provided comparable
results cannot be inferred from our data. Second, the
present series of patients is quite heterogenous; this is
not surprising given the “real world” setting. The time
elapsed from the last target vessel revascularization
was considerably different among patients. The un-
derlying physiopathologic process of late (around 2
years) recurrent restenosis after brachytherapy and
subsequent response to treatment is not known
(whether it is neointimal tissue or late atherosclerotic
progression is unclear). Moreover, the incidence of
black hole may be higher than suspected, and the
biologic properties of this tissue may be responsible
for a blunted response to antiproliferative drugs.
Last, but not least, the number of patients in our
investigation was low, and larger studies with ex-
tended follow-up are warranted to draw deﬁnitive
conclusions.
In this investigation, 12 patients were treated
with sirolimus-stent implantation for recurrent
ISR after failed brachytherapy. The strategy eval-
uated was safe and is believed to be clinically ef-
fective, although our data suggest a different atten-
uated efﬁcacy of sirolimus in preventing neointimal
growth in this setting compared with the treatment
of de novo lesions.
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The pattern of restenosis and vascular remodelling
after cold-end radioactive stent implantation
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Background Edge restenosis is a major problem after
radioactive stenting. The cold-end stent has a radioactive
mid-segment (15·9 mm) and non-radioactive proximal and
distal 5·7 mm segments. Conceptually this may negate the
impact of negative vascular remodelling at the edge of the
radiation.
Method and Results ECG-gated intravascular ultrasound
with three-dimensional reconstruction was performed post-
stent implantation and at the 6-month follow-up to assess
restenosis within the margins of the stent and at the stent
edges in 16 patients. Angiographic restenosis was witnessed
in four patients, all in the proximal in-stent position. By
intravascular ultrasound in-stent neointimal hyperplasia,
with a >50% stented cross-sectional area, was seen in eight
patients. This was witnessed proximally (n=2), distally
(n=2) and in both segments (n=4). Echolucent tissue,
dubbed the ‘black hole’ was seen as a signiﬁcant component
of neointimal hyperplasia in six out of the eight cases of
restenosis. Neointimal hyperplasia was inhibited in the area
of radiation:  neointimal hyperplasia=3·72 mm3 (8·6%);
in-stent at the edges of radiation proximally and distally 
neointimal hyperplasia was 7·9 mm3 (19·0%) and 11·4 mm3
(25·6%), respectively (P=0·017). At the stent edges there
was no signiﬁcant change in lumen volume.
Conclusions Cold-end stenting results in increased
neointimal hyperplasia in in-stent non-radioactive
segments.
(Eur Heart J 2001; 22: 1311–1317, doi:10.1053/
euhj.2000.2542)
 2001 The European Society of Cardiology
Key Words: Stents, remodelling, radioisotopes, angio-
plasty, ultrasonics.
See page 1245 for the Editorial comment on this article
Introduction
Conventional stenting has eliminated recoil and negative
remodelling as components of the restenotic process.
However, this has been at the cost of exacerbating
neointimal proliferation secondary to chronic vessel wall
irritation, leading to in-stent restenosis[1,2].
Intracoronary radiation has been developed in an
attempt to decrease restenosis after balloon angioplasty
and stent implantation. Studies recently performed
in humans demonstrated a dose-dependent inhibition
of neointimal hyperplasia at the 6-month follow-up
in stents with activity levels >3 Ci[3,4]. However, a
signiﬁcant increase in neointimal hyperplasia was noted
at the extremes of the stent and at the edges. Edge
restenosis was mainly due to an increase in plaque and
to a lesser extent, remodelling of the native vessel
wall[4,5]. A fall-oﬀ in radiation in areas receiving vascular
injury was proposed as a possible stimulatory mech-
anism. In order to minimize the eﬀect of vascular
remodelling on stent-edge restenosis, the stent design
was modiﬁed. The ‘cold-end’ stent (Isostent Inc., San
Carlos, CA, U.S.A.) was rendered radioactive in its
mid-portion (15·9 mm in length); the edges (5·7 mm
each) were non-radioactive (Fig. 1).
We aimed to analyse tissue growth within the stent
and at its edges and to deﬁne the segments that had the
greatest propensity to restenosis after the implantation
of a cold-end stent.
Revision submitted 7 November 2000, and accepted 22 November
2000.
Correspondence: P. W. Serruys, MD, PhD, FACC, FESC,
Professor of Interventional Cardiology, Thoraxcenter, Academisch
Ziekenhuis Rotterdam, PO Box 1738, Dr. Molewaterplein 40,
3000 DR Rotterdam, The Netherlands.
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Methods
Patient selection
We analysed neointimal hyperplasia and vascular
remodelling in 16 patients who had completed a
6-month angiographic follow-up with intravascular
ultrasound analysis. All patients had single native vessel
coronary artery disease, normal left ventricular function
and objective evidence of ischaemia.
Implantation technique
Pre-dilation of the lesion was performed where necessary
followed by stent implantation High-pressure balloon
inﬂation to ensure good strut apposition to the vessel
wall was then performed at the operator’s discretion. At
this time we used a shorter balloon to ensure that the
edges of the balloon did not extend beyond the limits of
the stent3. Intravascular ultrasound was used to ensure
optimal stent deployment.
Medication
Patients received 250 mg aspirin and 10 000 inter-
national units of heparin at the initiation of the pro-
cedure and the activated clotting time was maintained
at >300 s. All patients received aspirin 80 mg daily
indeﬁnitely and clopidogrel 75 mg daily for 6 months.
Radioactive stent
The stent was 27·3 mm in length and available in diam-
eters of 3·0 and 3·5 mm. It was made radioactive in its
central portion by phosphorus-32 (32P)[3]. The 5·7 mm
edges were shielded from radiation. The initial activity
of the stents was measured and thereafter it was
calculated at what date the activity had decreased to
3·0–12·0 Ci, suitable for implantation.
Intravascular ultrasound image acquisition
analysis
After the ﬁnal balloon inﬂation and administration
of intracoronary nitrates, ECG-gated intravascular
ultrasound pullback was performed. This was repeated
at the 6 month follow-up. The segment was subjected to
three-dimensional reconstruction and examined with a
mechanical intravascular ultrasound system (Clearview,
CardioVascular Imaging System, Sunnyvale, CA,
U.S.A.) with a sheath-based intravascular ultrasound
catheter incorporating a 30 MHz single-element trans-
ducer rotating at 1800 rpm. The intravascular ultra-
sound transducer was withdrawn through the stationary
imaging sheath by an ECG-triggered pullback device
with a stepping motor[6]. Intravascular ultrasound
images were acquired, coinciding with the peak of the R
wave, which eliminates the artefacts caused by the
movement of the heart during the cardiac cycle. After
each image acquisition, the transducer was withdrawn
0·2 mm to acquire the next image coincident with the
R-wave. By deﬁnition, this permits acquisition of ﬁve
slices per mm, enabling the operator to easily deﬁne the
stent margins. By increasing the frequency of sampling
this approach may also decrease error due to regression
to the mean created by the use of greater step sizes and
non-ECG-gating[7,8].
ECG-gated image acquisition and digitation was
performed using a workstation designed for three-
dimensional reconstruction of echocardiographic
images[6] (EchoScan, Tomtec, Munich, Germany). A
Microsoft Windows-based contour detection program,
developed at the Thoraxcenter, was used for automated
three-dimensional analysis of up to 200 intravascular
ultrasound images[9]. This program constructs two
longitudinal sections and identiﬁes the contours corre-
sponding to the lumen–intima and media–adventitia
boundaries, using a minimum-cost based software
algorithm. The feasibility, reproducibility and the inter-
and intra-observer variability of this system have been
previously described in clinical protocols[5,9].
Quantitative intravascular ultrasound
analysis
At the stent edges, the area encompassed by the lumen–
intima and media–adventitia boundaries deﬁned the
luminal and the total vessel volumes, respectively. The
diﬀerence between luminal and total vessel volumes
deﬁned the plaque volume. Within the boundaries of
the stent total vessel volume, stent volume, neointimal
hyperplasia, and lumen volumes were obtained. The
   
Figure 1 A cold-end stent with a central radioactive segment and proximal and distal non-radioactive
segments. Analysis of each segment was performed individually to assess neointimal hyperplasia. This
included neointimal hyperplasia over the length of the stent and edges.
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neointimal hyperplasia presented was a value measured
at follow-up (stent volume–lumen volume).
The assessment of total vessel volume in stented
patients has previously been reported[5,10]. In our study
the delineation of the total vessel volume boundary was
possible in all stented patients. When the total vessel
volume boundary was not visible in a single cross-
sectional view, the computer extrapolated it from the
contours of the immediately previous and following
cross-sections. In addition, the use of three-dimensional
reconstruction with multiple longitudinal views, facili-
tates the visualization of vessel structures outside the
stent.
Deﬁnitions and segments of analysis
Stent edges were deﬁned as those volumes axially 5 mm
proximal and distal to the ﬁnal stent strut. In addition,
segments in-stent proximally and distally were analysed
separately to assess neointimal hyperplasia in areas
which were subject to injury and received stent implan-
tation. Eﬀectively, these were segments which received a
fall-oﬀ in radiation. Finally the in-stent radioactive
segment was analysed (see Fig. 1). To facilitate com-
parison between the non-radioactive in-stent segments
(5·7 mm) and the central radioactive segment (15·9 mm),
lengths were normalized to a standard length (5 mm)
and appropriate comparisons made. Restenosis was
deﬁned as an angiographic restenosis >50% at
6-month follow-up, by oﬀ-line quantitative coronary
angiography.
Statistical analysis
Quantitative data are presented as meanstandard
deviation. Volumetric data derived from the three-
dimensional reconstruction of the intravascular ultra-
sound image were compared immediately after
treatment and at follow-up using the two-tailed paired
Student’s t-test. ANOVA was used to compare multiple
variables. A value of P<0·05 was considered statistically
signiﬁcant.
The Medical Ethical Committee of the University
Hospital Rotterdam approved the study and all patients
provided written informed consent before the procedure.
Results
Baseline clinical and procedural characteristics are
described in Tables 1 and 2. Table 3 describes
quantitative coronary angiography data pre- and
post-intervention and at the 6-month follow-up.
In-stent radioactive segment
Neointimal hyperplasia measured within the margins of
the stent is presented in Fig. 2. Intra-stent neointimal
hyperplasia was signiﬁcantly decreased in the radio-
active mid-segment of the stent: 3·723·3 mm3 (8·6%),
compared with the proximal: 7·907·2 mm3 (19·0%)
and distal: 11·4210·5 mm3 (25·6%) in-stent segments.
Over the entire stent length there was a 30·48 mm3 (14%)
increase in neointimal hyperplasia. No evidence of
remodelling was seen behind the stent with the total
vessel volume remaining unchanged.
In-stent non-radioactive segment
Signiﬁcant neointimal in-growth was noted distally and
proximally from 2–3 mm within the radioactive segment
and extended on average to the extremities (non-
radioactive) of the stent (see Fig. 3). Four individuals
experienced angiographic restenosis in the proximal
Table 1 Clinical characteristics
Age (mean) 52 (41–78)
Male (%) 69
Prior MI (%) 75
Unstable angina (%) 40
Smoking (%) 56
Hypercholesterolaemia (%) 69
Family history (%) 56
Hypertension (%) 40
Diabetes (%) 0
Table 2 Procedural characteristics
Vessel
LAD 6
LCx 7
RCA 3
Lesion length (mm) 11·24·5
Balloon length-post (mm) 15·65·7
Final balloon size (mm) 3·90·5
Max inﬂation pressure1 (atms) 104·0
Max inﬂation pressure2 (atms) 162·2
Balloon-to-artery ratio 1·12
Max inﬂation pressure1=balloon at time of stent implantation.
Max inﬂation pressure2=balloon inﬂation within stent.
LAD=left anterior descending coronary artery; LCx=left
circumﬂex artery; RCA=right coronary artery.
Table 3 Angiographic data
Pre Post FU
MLD 0·980·40 2·260·40 1·670·48
DS 6714 268 4213
RD 2·970·46 3·060·41 2·820·43
Acute gain 1·280·46
Late loss 0·590·49
Late loss index 0·570·56
FU=6-month follow-up.
MLD=minimum lumen diameter; DS=diameter stenosis;
RD=reference diameter.
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portion of the stent. However, the greatest mean volume
of tissue growth as quantiﬁed by intravascular ultra-
sound was seen in the distal stent. Neointimal hyper-
plasia, with a >50% stented cross-sectional area, was
seen in eight patients. This was witnessed proximally
(n=2), distally (n=2) and in both segments (n=4).
Tissue growth in-stent was due to a combination of
conventional neointimal hyperplasia and echolucent,
hypodense material, described by this group as the
‘black hole’ (P. W. Serruys, personal communication,
Rotterdam, 1999). This was witnessed (Fig. 4) in the
non-radioactive proximal and distal in-stent segments in
six out of the eight patients.
Total vessel volumes
No signiﬁcant change in total vessel volumes or plaque
behind the stent was seen between post-procedure and
follow-up. No echolucent tissue was seen behind the
stent.
Stent edge
Late lumen loss was seen at the stent edge without
evidence of restenosis. On average, there was evidence of
a decrease in total vessel volume, with little change in
plaque as a cause of late lumen loss.
Stent activity
Mean stent activity at implantation was 6·91·9 Ci.
Discussion
Dose-ﬁnding studies in humans have shown that in-stent
neointimal hyperplasia is decreased in a dose-dependent
manner after the implantation of stents with activity
levels >3·0 Ci[3,4]. Unfortunately, stent edge restenosis
was a side eﬀect of this treatment modality at these
activity levels. Because the stent edge is systematically
0
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Figure 2 Neointimal hyperplasia (mm3) in the three
in-stent segments. Each segment is standardized to a 5 mm
length for comparison.
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Figure 3 Graph showing neointimal hyperplasia (% increase) over the length of the stent and edges.
Note signiﬁcant hyperplasia proximally and distally in-stent and the relative sparing of the radioactive
mid-segment of the stent. Note also that signiﬁcant in-growth begins within the radioactive segment of
the stent and extends to the non-radioactive proximal and distal extremities of the stent.
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damaged by barotrauma at the time of balloon expan-
sion, a situation of geographical miss[11], in which the
damaged edges receive low dose radiation, is germane to
radioactive stenting in the absence of appropriately
shaped balloons. Previously we have argued: ‘If the
candy wrapper (bilateral edge restenosis) were purely the
result of negative remodeling induced by low-dose radia-
tion in an injured area, then the lengthening of the stent
by a non-radioactive, cold-end would be a logical solu-
tion to prevent remodeling at the extremities. If plaque
constitutes a large percentage of the healing process
manifested by the candy wrapper then cold-end stent
implantation is unlikely to work. Similarly neointimal
proliferation may occur at the edges of the radiation
within stent using this treatment modality’[12]. This
prediction appears to have materialized in the current
study, with migration of the restenotic edge from outside
the stent to within the stent at the edges of radiation.
Neointimal hyperplasia
Neointimal hyperplasia in the true radioactive segment
was suppressed at the 6-month follow-up to a degree
similar to that noted in the 32P radioactive stent dose-
ﬁnding trial previously reported by this group (mean
neointimal hyperplasia=17·67 mm3 (13·94%)), using a
15 mm stent[5]. Regrowth of tissue starting 1–2 mm
within the radioactive extremes and extending out of the
stent was noted in the 32P radioactive stent dose ﬁnding
trial, translating to signiﬁcant stent-edge hyperplasia
proximally. In the cold-end stent, neointimal hyper-
plasia was noted in the ﬁnal millimetres of radiation and
extended bilaterally. In the latter study, this left the true
stent edges relatively, although not completely, spared
as there remained evidence of tissue growth in three
individuals, which started within the radioactive portion
and continued to the true vessel lumen. No angiographic
restenosis occurred in these three however. Again, we
must assume that the position of such restenosis is
caused by geographical miss. Why some individuals are
aﬀected and others not is unclear, but may be explained
by an idiosyncratic individual response to healing,
dose heterogeneity along the length of the stent, tissue
type behind the stent, plaque burden and even strut
apposition to the vessel wall.
Echolucent tissue
In nearly 50% of subjects, echolucent tissue was present
within the stent at the distal or proximal (in-stent) edge
of radiation and consituted on average 50% of neo-
intimal ingrowth in areas of restenosis. These echolucent
lesions had the following characteristics: a homogeneous
black appearance without backscatter. Images with
ring-down or other artefacts were excluded and no
attenuation behind intraluminal echodense structures
was seen. Exclusion of other causes of relative echo-
lucency such as contrast[13], thrombus[14] or a lipid
lake[15] was performed. Lesions were discrete and readily
distinguishable from conventional neointimal hyper-
plasia. After radioactive stenting, all appeared to be
juxtaposed to stent struts.
We have performed atherectomy on four such lesions
detected at the 6-month follow-up after radioactive
stenting and found that they contain a hypocellular
matrix with areas of proteoglycan, similar to that seen
in the animal model[16,17]. The mixture of neointimal
hyperplasia and proteoglycan, which has a high water
content, may explain the echolucent tissue adjacent to
the stent struts noted in Fig. 5. Further pathological

Figure 4 Representative example of echolucent tissue (‘black hole’). (a) A transverse section. A black hole
is seen from 9 o’clock to 3 o’clock. (b) A longitudinal reconstruction. Arrowhead points to semi-circular
echolucent tissue seen adjacent to the stent struts.
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assessment is required before deﬁnitive comment can be
made on this interesting observation. Equally, the long-
term incidence of restenosis from such lesions is yet to be
determined.
Edge remodelling
This was similar to that seen after non-radioactive
stenting, whereby non-restenotic late lumen loss was due
to negative remodelling[5,18].
Implications for the future: dealing with the
edge eﬀect
If the edge eﬀect is the result of balloon-induced trauma
and low dose radiation then limiting the trauma to
outside the stent and expanding the irradiated area
beyond the injured area should be attempted. For radio-
active stents, conceivably the most practical approach
may be to extend the area of irradiation beyond the
injured area using a ‘hot-end stent’. This involves liter-
ally concentrating the greatest activity of the stent at
Figure 5 Photomicrographs (a) and (b) show neointima consisting of
arboryzing smooth muscle cells in a proteoglycan matrix. H&E stain;
bars=50 m.
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the stent edges; such stents are already undergoing
multicentre trials. A further therapeutic option is that of
hybrid treatment with radioactive stent implantation
followed by catheter-based therapy localized to the stent
edges only.
Conclusion
Cold-end stent implantation, a strategy devised to pre-
vent edge restenosis after radioactive stenting results in
migration of the restenotic edge from outside the stent to
within the stent at the edges of radiation. This adds
credence to the hypothesis that injury and low-dose
radiation stimulate neointimal hyperplasia[19].
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Radioactive Stents Delay but Do Not Prevent In-Stent
Neointimal Hyperplasia
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A.H. Marco Knook, MD; Attila Thury, MD; George Sianos, MD;
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Background—Restenosis after conventional stenting is almost exclusively caused by neointimal hyperplasia. -Particle–
emitting radioactive stents decrease in-stent neointimal hyperplasia at 6-month follow-up. The purpose of this study was
to evaluate the 1-year outcome of 32P radioactive stents with an initial activity of 6 to 12 Ci using serial quantitative
coronary angiography and volumetric ECG-gated 3D intravascular ultrasound (IVUS).
Methods and Results—Of 40 patients undergoing initial stent implantation, 26 were event-free after the 6-month follow-up
period and 22 underwent repeat catheterization and IVUS at 1 year; they comprised half of the study population.
Significant luminal deterioration was observed within the stents between 6 months and 1 year, as evidenced by a
decrease in the angiographic minimum lumen diameter (0.430.56 mm; P0.028) and in the mean lumen diameter
in the stent (0.550.63 mm; P0.001); a significant increase in in-stent neointimal hyperplasia by IVUS
(18.1612.59 mm3 at 6 months to 27.7511.99 mm3 at 1 year; P0.001) was also observed. Target vessel
revascularization was performed in 5 patients (23%). No patient experienced late occlusion, myocardial infarction, or
death. By 1 year, 21 of the initial 40 patients (65%) remained event-free.
Conclusions—Neointimal proliferation is delayed rather than prevented by radioactive stent implantation. Clinical
outcome 1 year after the implantation of stents with an initial activity of 6 to 12 Ci is not favorable when compared
with conventional stenting. (Circulation. 2001;103:14-17.)
Key Words: radioisotopes  restenosis  stents  angiography
Implantation of
32P radioactive stents with activities ranging
from 3.0 to 12 Ci in coronary artery lesions has been
reported to inhibit neointimal hyperplasia within the stent at
6-month follow-up.1,2 The major limitation of this therapy is
significant renarrowing at the stent edges, which is called the
“candy wrapper” or “edge effect.”1 Catheter-based radiation
significantly reduces the recurrence of restenosis 6 months
after percutaneous transluminal coronary angioplasty for
in-stent restenosis, but 3-year follow-up reveals greater lumi-
nal deterioration in -radiation–treated patients.3,4 Such find-
ings indicate the need for longer follow-up beyond the
traditional 6 months in patients treated with intracoronary
radiation. The purpose of this study was to assess late results
after the implantation of radioactive stents using repeat
catheterization with quantitative coronary angiography and
3D intravascular ultrasound (IVUS) at 1 year.
Methods
Patient Population
The European 32P Dose-Response Trial was a nonrandomized mul-
ticenter trial evaluating the safety and efficacy of implanting radio-
active stents with activity levels of 3 to 12 Ci in single, native
coronary artery lesions. All stents were implanted in de novo lesions,
except for 1 case of in-stent restenosis. For the purposes of this
analysis, this case was excluded. Other inclusion and exclusion
criteria, as well as immediate and 6-month results, were previously
reported.1,2 Only patients undergoing 6-month angiographic and
IVUS follow-up who did not experience major adverse cardiac
events during the first 6 months were included. The study was
performed in accordance with the Declaration of Helsinki and the
European Guidelines for Good Clinical Practice. Ethical approval
was provided by the Medical Ethical Committee of the University
Hospital Rotterdam. All patients gave written, informed consent.
Radioactive Stent
The BX Isostent (32P) (Isostent Inc), which is 15 mm in length and
3.0 or 3.5 mm in diameter, was used. The initial activity of the stents
was measured and, thereafter, the date at which the radioactivity
would have decreased to 6 to 12 Ci was calculated.
Procedure and Clinical Follow-Up
Procedural details have been published previously.5 All patients
received either 250 mg of ticlopidine BID or 75 mg of clopidogrel
per day for 3 months after stent implantation and 80 mg of aspirin per
day indefinitely. Revascularization was performed on the basis of
clinical symptoms and/or evidence of ischemia on exercise testing.
Clinical end points were death, Q-wave myocardial infarction,
non–Q-wave myocardial infarction (creatine kinase-MB rise 2
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times normal upper limit), target vessel revascularization, non–target
vessel revascularization, and early and late thrombotic occlusion of
the target vessel.
Angiographic and IVUS Procedures
Angiography in multiple projections was performed before the
procedure, after stenting, and at 6-month and 1-year follow-up. The
stented vessel segments were examined with quantitative coronary
angiography (CAAS II analysis system,6,7 Pie Medical BV) and
mechanical IVUS (CardioVascular Imaging System). IVUS images
were acquired to coincide with the peak of the R wave by using an
ECG-triggered pullback device with a stepping motor at 0.2 mm/
step. This system eliminates the artifacts caused by the movement of
the heart during the cardiac cycle.8 The ECG-gated image acquisition
and digitization was performed by a workstation designed for 3D
reconstruction (EchoScan, Tomtec). A Microsoft Windows-based
contour detection program was used for the volumetric 3D analysis.8
Core Laboratory Analysis Procedures
Quantitative coronary angiography using at least 2 orthogonal
projections was performed. For analytical purposes, the following 3
regions of interest were defined: (1) stent, (2) target lesion, and
(3) target vessel. The stent included only the radioactive stent. The
target lesion was defined as the stent and 5 mm proximal and 5 mm
distal to the edge. The target vessel was defined as the target lesion
and the remaining segments of the treated vessel. Target lesion
restenosis was defined as 50% diameter stenosis, located within
the target lesion, at follow-up.9 Edge restenosis was defined as
50% diameter stenosis, located at the proximal and/or distal edge,
at follow-up.
Quantitative IVUS analysis of the stent and 5 mm proximal and
distal to the stent was performed. Lumen and stent boundaries were
detected using a minimum cost algorithm. Total stent and lumen
volumes were calculated as previously described.8 Neointimal vol-
ume was calculated as stent volume minus luminal volume. Feasi-
bility, reproducibility, and interobserver and intraobserver variability
of this system have been validated in vitro and in vivo.8
Statistical Analysis
Data are presented as meanSD. Continuous data were compared
using repeated measures ANOVA or a 2-tailed Studentst test as
appropriate.
Results
Baseline demographics and lesion characteristics are shown
in Table 1. Between 6 months and 1 year, target lesion
revascularization and target vessel revascularization were
performed in 4 patients (18%) and 5 patients (23%), respec-
tively. No late occlusion was seen. No patient died or
experienced myocardial infarction. In total, 21 of 40 patients
(53%) were event-free through the 1-year follow-up.
Quantitative Coronary Angiography and
IVUS Measurements
Quantitative coronary angiography data, presented as a sub-
segmental analysis of the stent area and the edges, are shown
in Table 2. A significant decrease in the minimum and mean
lumen diameters was noted between 6 months and 1 year
(P0.028 and P0.001, respectively) compared with both
edges. The late loss of mean lumen diameter was significantly
larger after 6 months than before 6 months. Furthermore, in
11 patients (50%), the minimum lumen diameter at the edge
at 6 months was detected within the stent at 1 year (“migra-
tion” from the stent edge to within the stent). Lesion progres-
TABLE 1. Baseline Characteristics of the 22 Patients Studied
Male sex 20 (91)
Age, y 57 (38–73)
Risk factors
Previous MI 12 (55)
Diabetes mellitus 3 (14)
Hyperlipidemia 18 (82)
Hypertension 9 (41)
Smoking 8 (36)
Family history 7 (32)
CCS class 3/4 15 (68)
Treated vessel
LAD 12 (55)
LCx 5 (22.5)
RCA 5 (22.5)
Lesion type
A 2 (9)
B1 10 (45.5)
B2 8 (36.5)
C 2 (9)
Lesion length, mm 103
Values are n (%), mean (range), or meanSD. MI indicates myocardial
infarction; CCS, Canadian Cardiovascular Society; LAD, left anterior descending
coronary artery; LCx, left circumflex artery; and RCA, right coronary artery.
TABLE 2. Subsegmental Quantitative Coronary Angiography Analysis
Baseline 6 Months 1 Year
Late Loss
Baseline to 6
Months
6 Months to
1 Year Total
P Between
Periods
Minimum lumen diameter, mm
Proximal edge 2.920.53 2.230.73* 2.080.50 0.690.80† 0.150.51‡ 0.84 0.060
Stent 2.500.47 2.360.47* 1.930.52* 0.140.52† 0.430.56‡ 0.57 0.16
Distal edge 2.290.61 2.170.58 2.080.49 0.360.49† 0.090.49‡ 0.45 0.9
Mean lumen diameter, mm
Proximal edge 3.190.56 2.730.57* 2.500.40* 0.390.62§ 0.220.51 0.61 0.33
Stent 3.120.42 3.090.58 2.540.41* 0.030.62§ 0.550.63 0.68 0.041
Distal edge 2.640.56 2.510.56 2.360.50 0.120.49§ 0.160.52 0.28 0.9
*P0.05, †P0.0041, ‡P0.025, §P0.028, P0.001 by ANOVA.
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sion to 50% diameter stenosis was observed in 5 patients.
This was due to a progression of in-stent restenosis in 4
patients and a progression of a proximal stent-edge lesion in
the other.
IVUS was completed in 19 patients; omissions were due to
equipment failure2 or patient clinical instability.1 IVUS anal-
ysis demonstrated a significant increase in neointimal hyper-
plasia between 6 months and 1 year (18.1612.59 mm3 to
27.7511.99 mm3; increase of 52.8%; P0.001), mainly in
the mid and distal portions of the stent (Figure 1). An increase
in neointimal hyperplasia 25% (range, 25% to 360%)
occurred in 12 cases (63%), as shown in Figure 2. No change
in lumen volume was noted at the stent edges between 6
months and 1 year.
Radiation Doses
The radioactive stents had a mean activity of 8.61.6 Ci at
implantation and delivered 5810 Gy to a depth of 1 mm
from the stent at 100 days, with a dose rate of 15cGy/h.
There was no correlation between stent activity or delivered
dose and changes in minimum or mean lumen diameter at
6-month or 1-year follow-up.
Discussion
A worrying late progression of in-stent neointimal hyperpla-
sia was observed between 6 months and 1 year after the
implantation of radioactive stents, leading to target vessel or
lesion reintervention in 5 of 26 patients (19%) who had been
event-free at 6 months. The event-free rate at 1 year after the
implantation of 6 to 12 Ci radioactive stents was 21 of 40
patients (53%), which compares poorly to the expected
outcome after the implantation of a nonradioactive stent.10
In contrast to the tissue growth seen in malignancy, the
DNA synthesis that occurs after nonradioactive stenting in
experimental models terminates after 6 weeks.11 At this time
point, the activity of the radioactive stent used in this study
would have been sufficient to inhibit cellular proliferation.
Thereafter, the majority of lumen deterioration occurs in the
first 3 months after conventional stent implantation, with
minimal change between 6 months and 1 year,12–14 and actual
regression of neointimal hyperplasia between 1 and 3 years
after stenting.15 This latter phenomenon has been attributed to
a reduction in the proteoglycan content of hyperplastic
tissue.16 Accordingly, the findings reported here of “break-
through” or “rebound” hyperplasia causing further lumen
deterioration between 6 months and 1 year must be inter-
preted as being specific to the effects of radioactivity,
presumably due to a fall- off in radiation levels. The obser-
vation that the radioactive stent may provide a substrate for
atherosclerosis may well have been predicted by Carter et als
porcine model.17
Because no significant stenosis progression was observed
at the stent edges among our patients, the candy wrapper
effect may be considered a short-term healing response to
vessel wall injury beyond the stented vessel segment com-
bined with the effects of low-dose radiation.18,19
Unexpected late luminal deterioration has also been re-
ported between 6 months and 3 years among patients treated
by catheter-based -radiation after repeat intervention for
in-stent restenosis (mean loss of 0.37 mm with 4 of 17
patients [26%] progressing to restenosis [diameter stenosis
50%]), compared with no major changes in the placebo
group.4 The difference in the time frame of this virtual
“rebound hyperplasia” between radioactive stenting and
catheter-based -radiation therapy may be a function of the
biological effects of and response to the type and dosage of
radiation administered. Alternatively, late loss may also have
Figure 1. Mean neointimal area in stent at 6 months () and 1
year (‘) using IVUS.
Figure 2. Cumulative distribution curve of
percent changes in late neointimal growth
after 6 months, as measured by IVUS.
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occurred between 6 months and 1 year and remained subclin-
ical in the catheter-based study.
Conclusions
Neointimal hyperplasia is delayed rather than prevented by
radioactive stent implantation. The combination of this phe-
nomenon of rebound hyperplasia with the established phe-
nomenon of edge restenosis calls into question the clinical
applicability of radioactive stenting using current approaches.
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Abstract 
Purpose: To determine the long term outcome of patients after radioactive stent implantation. 
Background: Radioactive stent implantation has been proposed as a modality to prevent 
restenosis. Its unfavourable short term outcome, due to edge restenosis prohibited its 
therapeutic use and the long term outcome of patients who underwent radioactive stent 
implantation is evidently a cause of concern. 
Methods and Results: The rate of major adverse cardiac events (MACE) was retrospectively 
determined in 133 patients who underwent successful radioactive stent implantation. MACE 
were defined as death, myocardial infarction, and any re-intervention. Long term clinical 
outcome was obtained from an electronic database of hospital records and questionnaires to the 
patients and the referring physicians. Long term survival status was assessed by written 
inquires to the Municipal Civil Registries. The mean follow up was 3.85±0.75 years. The target 
lesion revascularisation (TLR) at six months was 30%, mainly due to edge restenosis, and at 
one year 36.8%. It did not significantly changed up to 4 years; 41.3%, p=0.45. The incidence of 
a second TLR was 9%. The incidence of MACE at six months was 30.8% and at one year 
39.1%. There was no significant increment up to 4 years; 48.9%, p=0.1. At 4 years the 
cumulative incidence of death was 3%, of myocardial infarction was 6.8%, of CABG was 
10.5%, and of total occlusions was 7.5%, with the majority of events observed during the first 
year. 
Conclusion: A high incidence of MACE and re-intervention was observed during the first year 
following radioactive stent implantation, mainly related to TLR for edge restenosis. After the 
first year the clinical outcome of these patients remained stable indicating that there are no late 
adverse effects related to low dose-rate intracoronary radiation therapy 
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Introduction
Radioactive stents were evaluated as a treatment for restenosis prevention. Preclinical 
evaluation in two animal models showed discordant results with reduction of neointimal 
formation in a dose related manner in the rabbit iliac artery but more complex dose relationship 
in the pig coronary artery (1-3). Initial human studies with low activity (0,75-1.5 µCi) 
radioactive stents, showed that their use was feasible and safe but ineffective for the prevention 
of in-stent restenosis (4). Dose finding studies with intermediate activity (3-12 µCi) radioactive 
stents, proved their efficacy in preventing intra-stent restenosis but simultaneously revealed 
their major limitation related to the development of stent edge restenosis, the so-called “edge 
effect” or “candy wrapper” (5,6). Efforts to eliminate edge restenosis with high activity 
radioactive stents (12-21 µCi) (7), stent edge activity modification (cold-end, hot-end 
radioactive stents) (8-10) or the use of dedicated, edge non-traumatic square shouldered 
balloons (11), failed. 
The aim of the present study was to describe the long term clinical outcome after radioactive 
stent implantation. Although no longer in clinical use, these results might improve our 
understanding on the, potentially long lasting, interaction between localised radiation therapy 
and vascular response in humans. 
Methods 
Patient population 
Between November 1997 and July 2000, 133 patients received one or two radioactive stents, in 
our institution. The baseline characteristics of the patients are presented in Table 1. The 
patients were parts of five different studies. The design and short term outcome of the studies 
has been previously reported. An overview of the studies is presented in Table 2. Briefly the 
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IRIS 1 (4) study was a safety and feasibility study and IRIS 2 (5) was a European dose finding 
study. The cold end (8,9), the hot end (10) and the square shouldered balloons (11) were 
studies with dedicated radioactive stents and balloons to overcome the problem of edge stent 
restenosis observed with this therapeutic modality. In all studies follow up angiography was 
performed at six months and one year as mandated by protocol. 
Follow up 
Baseline clinical and procedural data were entered prospectively in a dedicated database. Long 
term clinical outcome was obtained from an electronic database of hospital records. The 
Thoraxcenter is a tertiary cardiology center, serving a group of 14 local hospitals for 
percutaneous coronary interventions in the region of Rotterdam. As required by the local 
medical system organisation all baseline procedures were performed in this tertiary facility, as 
well as the vast majority of re-interventions. 
Long term survival status was assessed by written inquires to the Municipal Civil Registries. 
Questionnaires were sent to all living patients focusing on the occurrence of MACE such as, 
myocardial infarction, and repeat intervention (surgical and percutaneous). The referring 
physician and institutions as well as the general practitioners were directly approached 
whenever necessary. Complete follow-up was obtained in all patients. 
Definitions 
MACE were defined as: 1) death, 2) non-fatal myocardial infarction, 3) repeat 
revascularisation. This order was used for the hierarchical ranking. TLR was defined as any 
surgical or percutaneous re-intervention due to restenosis within the radioactive stent or in the 
5mm proximal or distal peri-stent segments (edge restenosis). TVR was defined as any re-
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intervention driven by lesions located in the treated vessel beyond the target lesion limits. Non 
TLR-TVR was defined as any re-intervention in vessels other than the target vessel. By 
protocol, in all studies, radioactive stent implantation in more than one vessel was prohibited. 
For the hierarchical ranking presentation of re-intervention TLR was regarded as the more 
serious and non TLR-TVR as the less serious one. CABG was not considered as separate event 
but was regarded as a type of re-intervention (TLR, TVR or non TLR-TVR). 
Total occlusion was defined as radioactive stent occlusion documented by coronary 
angiography. Subacute thrombosis was defined as angiographically documented total occlusion 
≤ 30 days. Late total occlusion was defined as angiographically documented total occlusion > 
30 days post intervention. Late-late total occlusion was applied for patients who had a patent 
artery at six months follow-up and subsequently presented with total occlusion at the same site. 
Thrombotic occlusion was defined as any late or late-late occlusion that resulted in an acute 
coronary syndrome (myocardial infarction or unstable angina). (12). 
For the determination of the length of the follow up, the start day was the day of the index 
procedure with radioactive stent implantation between November 1997 and June 2000. The last 
day for the follow up was the 31
st
 March 2003. 
Statistical analysis 
Data are expressed as mean value ± SD. Survival and event-free survival were estimated by 
Kaplan-Meier curves. Continuous variables were compared by Student’s t-test, categorical 
variables by chi-square-tests. Statistical significance of all tests was defined at the p<0.05 level. 
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Results 
MACE
In hierarchical ranking the incidence of MACE at six months was 30.8%, and at one year 
39.1%, p=0.15. A non-significant increment was observed up to 4 years. 48.9%, p=0.1, Table 3. 
The total count of events is presented in Table 4. The MACE free survival rate at 4 years was 
51.1%. The MACE free survival curve is presented in Figure 1. At 4 years the cumulative 
incidence of death was 3%, and of myocardial infarction 6.8%. One death was cardiac in origin 
and in the other 3 cases the aetiology is unknown. Nine patients suffered a myocardial 
infarction. Four were referred for primary PTCA. Angiographic total occlusion of the 
radioactive stent was documented in two (in one 1276 days after the index procedure) and 
severe in-stent restenosis in the third. In the fourth patient the infarction was due to occlusion 
of a vessel other than that in which the radioactive stent was implanted. The remaining five 
patients were initially treated with thrombolysis; elective angiography showed edge restenosis 
of the radioactive stent in four and in-stent restenosis in the fifth. All patients were treated 
successfully (one referred for CABG). 
Re-intervention
The majority (90%) of re-interventions were TLRs. Low rates of TVR and non TLR-TVR were 
observed at 4 years (3% and 1.5% respectively). In hierarchical ranking the TLR at six months 
was 32.3% directly related to the first angiographic follow-up. A second wave occurred at one 
year related to the second angiographic follow up (36.8%, p=0.25). A non-significant 
increment was observed up to 4 years (41.3%, p=0.45), Table 5. The total count of re-
interventions is presented in Table 4. The re-intervention free survival curve is presented in 
Figure 1. 
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CABG 
In total 10.5% patients underwent CABG, Table 4. In eight patients surgery was the first TLR. 
In four patients it was the second TLR (recurrence after an initial percutaneous TLR). In one 
patient CABG was a TVR and another one non-TLR-TVR. 
Total occlusions 
The incidence of total occlusions up to 4 years was 7.5%, Table 6. No sub-acute thrombosis 
was observed. The incidence of late total occlusion was 3.8% and that of late-late total 
occlusion was also 3.8%. In three patients (2.2%) the occlusion was resulted in an acute 
coronary syndrome (late thrombotic occlusion). Two patients underwent TLR for edge 
restenosis, with bare stent implantation, before the vessel finally occluded.  
Outcome after first TLR 
In total 61 patients underwent a repeat intervention; 55 (90%) of them were TLRs, mainly due 
to edge restenosis (69%). The average time to the first TLR was 279±235 days. Clinical and 
angiographic characteristics related to the first TLR are presented in Table 7. Among patients 
who had a first TLR, a second TLR was performed in 21.9% (12 patients). The average time 
between implantation of the radioactive stent and the second TLR was 413±234 days. Clinical 
and angiographic characteristics related to a second TLR are presented in table 8. The MACE 
and re-intervention free survival rate was 76.3%. The event free survival curve of patients after 
a first TLR is presented in Figure 2. There was only one patient who underwent TLR for a third 
time. 
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Discussion 
Edge effect 
Radioactive stents were proposed as a therapy for restenosis prevention. During safety-
feasibility and dose finding studies they proved to be efficient for preventing in-stent restenosis 
but the edge restenosis, called the edge effect, became clearly apparent as their limitation (13). 
Intravascular ultrasound studies demonstrated that this effect is a combination of negative 
remodelling and plaque progression at the stent edges (6). The fall of the dose at the stent edges 
in combination with balloon injury which systematically occurs was regarded to be the cause. 
This is a well established phenomenon in catheter based brachytherapy, called geographical 
miss, responsible for development of edge restenosis (14,15). Animal studies with half 
radioactive stents confirmed this hypothesis (16). 
Attempts to resolve the problem, by making the edges of the stents non-radioactive (cold-end 
radioactive stents), for prevention of negative remodelling, or by increasing the activity at the 
edges (hot-end radioactive stents) to avoid under-dosage, failed (8-10). A last attempt with the 
use of square shouldered balloons aiming to minimize injury outside the stent edges was also 
not successful (11) and radioactive stents never found a place in routine clinical use (17,18). 
Effect of the angiographic control 
The event-free rate at 4 years after the implantation was 51% which compares poorly to the 
expected outcome after the implantation of a non-radioactive stent (19). The angiographic 
control at six months and one year affected the re-intervention rate since 20% of the TLRs 
were performed in asymptomatic patients. This probably influenced the time distribution of the 
re-interventions and the relative composition of the MACE rather than the event free survival 
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rate. All these patients had severe angiographic restenosis, and it is highly likely that they 
would have developed symptoms if they remained untreated. 
Comparison with non-radioactive stents and catheter based brachytherapy 
The main of lumen deterioration after conventional stent implantation occurs in the first 3 
months, with minimal change between 6 months and 1 year (20) and actual regression of 
neointimal hyperplasia between 1 and 3 years after stenting (21). A non-significant increase in 
the incidence of MACE and re-intervention was observed in our population between six 
months and one year. This might well be attributed to the second angiographic control, 
although there is evidence that radioactive stents, in contrast with the promising results 
observed at 28 days, promote the formation of “atheromatous” neointima in a porcine 
atherosclerotic coronary model at six months (22). Our group reported a significant increment 
in the in-stent neointimal hyperplasia between six months and one year (13-26 half-lifes of the 
P32 isotope) in radioactive stents with activity 6 to 12 µCi, by means of intravascular 
ultrasound (23). These results may indicate that the TLRs between 6 and 12 months were a 
result of late neointimal formation (delayed healing response). After the first year the clinical 
outcome following radioactive stent implantation is stable and comparable to non-radioactive 
stents indicative that there are no long term adverse effects after low dose rate irradiation 
(17,24). 
The long term outcome after brachytherapy for de-novo lesions has not yet been reported. 
Angiographic analysis from the SCRIPPS trial (gamma radiation for in-stent restenosis) at 3 
years showed a reduction of the MLD in irradiated patients but not in the placebo group (25) 
with further increase in the TLR rate in the irradiated patients only, between 3 to 5 years (26). 
Increase in the revascularization rate between 6 months and 3 years in the irradiated group only 
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of the WRIST trial (gamma radiation for in-stent restenosis) was also observed (27). The 
difference in the time frame of the restenosis process between radioactive stenting and catheter-
based gamma-radiation therapy may be a function of the biological response to the type and 
dosage of radiation administered.  
Type of failure in clinical trials with or without irreversible sequealae 
Radioactive stents represent an example of a technology whose premature application in 
humans was based only on preliminary and short term results in animal models. Results of 
long-term animal experiments, published when clinical trials in humans were already at an 
advanced stage, revealed the problem of late restenosis (22) and proved that the edge effect 
was unavoidable and without solution (16). Fortunately it resulted only in an increased rate of 
re-intervention without further consequences such as death and myocardial infarction. In the 
era of drug eluting stents, actinomycin (ACTION trial) is another example of failed treatment 
that did not result in irreversible clinical events (28). The latest example of 7-hexanoytaxol 
polymer sleeve eluting stents, that reached human application (SCORE trial) without proper 
animal documentation, unfortunately led to an unacceptable 21% incidence of myocardial 
infarction during the first year (29). Concern was raised recently that the safety-feasibility and 
the potential efficacy of new technologies should be based on firm animal data of at least six 
months before human trials (30). 
Conclusions 
A high incidence of MACE and re-intervention was observed during the first year after 
radioactive stent implantation that led to this technique being abounded. After that period the 
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long term clinical outcome is stable and comparable to non radioactive stents, indicating that 
there are no late adverse cardiac effects related to low dose-rate intracoronary radiation therapy. 
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Table 1 
Baseline and procedural characteristics 
Age (years) 58.75±10.8 
Male sex 95 (71.4%) 
Medical history 
Previous myocardial infarction 60 (45.1%) 
Previous CABG 18 (13.5%) 
Previous PTCA 4 (3%) 
Current medical condition 
Stable angina 83 (62.4%) 
Unstable angina 50 (37.6%) 
Risk factors 
Hypercholesterolemia 71 (53.4%) 
Hypertension 48 (36.1%) 
Diabetes 13 (9.8%) 
Smoking 33 (24.8%) 
Family history 31 (23.3%) 
Ejection fraction 
Normal >50% 112 (84.2%) 
Moderate 35-50% 14 (15.5%) 
Poor <35% 7 (5.3%) 
Lesion type †
A 23 (17.2%) 
B1 41 (30.9%) 
B2 65 (48.9%) 
C 4 (3%) 
Vessel treated 
LAD 59 (44.4%) 
RCA 28 (21.1%) 
LCx 46 (34.5%) 
IIb-IIIa inhibitors 37 (27.8%) 
Two radioactive stents 7 (5.3%) 
Bare stent 
Other vessel 14 (10%) 
Same vessel 16 (12%) 
Follow-up (range) in days 1384 (985-1917) 
CABG denotes coronary-artery bypass grafting, PTCA percutaneous transluminal coronary an-gioplasty, LAD left 
anterior descending artery, RCA right coronary artery, and LCX left circumflex coronary artery. 
† The type of lesion was classified according to the American Heart Association–American College of Cardiology 
classification, with A denoting a short focal lesion, and C the most complex type of lesion. 
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Table 2 
Study characteristics 
Study patients stent 
length
(mm)
dose
(Gy)
activity 
(µCi)
IRIS 1 26
32
P Palmaz-Schatz 
32
P BX Isostent 
15 7.5±1.6 0.75-1.5 
IRIS 2 40
32
P BX Isostent 15 58.1±10.4 6-12 
Cold ends 21
32
P BX cold-ends 25 47.2±13.5 6-24 
Hot ends 17
32
P BX hot-ends 18 89.8±20.8 18.5 
Square shouldered balloons 29
32
P Multi-Link DUET 23 64.8±22.1 15-23 
IRIS denotes Isostents for Restenosis Intervention Study. 
Table 3 
MACE hierarchical ranking  
<6m <1y <2y <3y <4y 6m vs 1y 1y vs 4y 
Death  1 (0.75%) 1 (0.75%) 2 (1.5%) 4 (3%) p=0.3 p=0.2 
MI 5 (3.8%) 5 (3.8%) 7 (5.3%) 8 (6%) 9 (6.8%) p=1 p=0.3 
Re-intervention 36 (27.1%) 46 (34.6%) 48 (36.1%) 49 (36.8%) 52 (39.1%) p=0.2 p=0.45 
Total MACE 41(30.8%) 52 (39.1%) 56 (42.1%) 59 (44.3%) 65 (48.9%) p=0.15 p=0.1 
Hierarchical ranking scale considers only the worst event; i.e. if a patient required repeat intervention and later 
suffered a MI the ranking scale would reflect only the worst event. The MACE were ranked as follows: death, 
non-fatal MI, and re-intervention  
MI denotes myocardial infarction, and MACE denotes major adverse cardiac events. 
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Table 4 
Total count of events 
<6m <1y <2y <3y <4y 
Death  1 (0.75%) 1 (0.75%) 2 (1.5%) 4 (3%) 
MI 5 (3.8%) 5 (3.8%) 7 (5.3%) 8 (6%) 9 (6.8%) 
TLR 43 (32.3%) 56 (42.1%) 63 (47.3%) 66 (49.6%) 68 (51.1%) 
TVR 4 (3%) 6 (4.5%) 7 (5.3%) 7 (5.3%) 7 (5.3%) 
Non TLR-TVR 13 (9.8%) 14 (10.5%) 16 (12%) 16 (12%) 18 (13.5%) 
Any re-intervention 59 (44.4%) 76 (57.1%) 86 (64.6%) 89 (66.9%) 93 (69.9%) 
Any MACE 64 (48.2%) 82 (61.6%) 93 (69.9%) 99 (74.4%) 106 (79.7%)
CABG 8 (6%) 10 (7.5%) 13 (9.8%) 13 (9.8%) 14 (10.5%) 
Total occlusion 5 (3.8%) 6 (4.5%) 6 (4.5%) 8 (6%) 10 (7.5%) 
All events reflects the total count of events i.e. if a patient required repeat intervention and later suffered a MI the 
total count would reflect both events and not just the worst occurred. For the MI, CABG and the total occlusions 
the total count of events is the same as the hierarchical ranking since there were no patients with repeated such 
events. CABG was not considered as separate event but was regarded as a type of re-intervention. 
MI denotes myocardial infarction, TLR denotes target lesion revascularisation, TVR denotes target vessel 
revascularisation, MACE denotes major adverse cardiac events and CABG denotes coronary artery bypass graft 
operation. 
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Table 6 
Total occlusions 
incidence 10 (7.5%) 
timing 
<30 days 0 (0%) 
<6months 5 (50%) 
6m-1years 1 (10%) 
1y-2years 0 
2y-3years 2 (20%) 
3y-4years 2 (20%) 
clinical presentation
asymptomatic 2 (20%) 
angina 5 (50%) 
unstable angina 1 (10%) 
MI 2 (20%) 
treatment 
CABG 3 (30%) 
Stent implantation 4 (40%) 
medical (failed re-intervention) 3 (30%) 
TLR before the occlusion 2 (20%) 
average time (range) in days 524 (144-1276) 
average dose 59.5 Gy 
CABG denotes coronary artery by pass surgery and TLR denotes target lesion revascularisation. 
Table 5 
Re-intervention hierarchical ranking 
<6m <1y <2y <3y <4y 6m vs 1y 1y vs 4y 
TLR 40 (30%) 49 (36.8%) 52 (39.1%) 53 (39.8%) 55 (41.3%) p=0.25 p=0.45 
TVR 3 (2.3%) 4 (3%) 4 (3%) 4 (3%) 4 (3%) p=0.7 p=1 
Non TLR-TVR 0 0 0 0 2(1.5%)  p=0.2 
Any re-intervention 43 (32.3%) 53 (39.8%) 56 (42.1%) 57 (42.8%) 61 (45.8%) p=0.2 p=0.3 
Hierarchical ranking scale considers only the worst event; i.e. if a patient required repeat TLR and later TVR 
ranking scale would reflect only the worst event. Events are given ranked as following: TLR, TVR, non TLR-
TVR.
TLR denotes target lesion revascularisation, TVR denotes target vessel revascularisation. 
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Table 7 
First TLR 
Any re-intervention 61 (45.8%) 
First TLR 55 (41.3%) 
Additional intervention during first TLR 
TVR 1 (1.8%) 
Non TLR-TVR 8 (14.5%) 
Other re-intervention before first TLR 2 (3.6%) 
Angiographic appearance 
In-stent restenosis 9 (16.4%) 
Bilateral edge restenosis 11 (20%) 
Proximal edge restenosis 26 (47.3%) 
Distal edge restenosis 1 (1.8%) 
Total occlusion 8 (14.5%) 
Device used †
Balloon 11 (20%) 
Cutting balloon 4 (7.3%) 
Stent 34 (61.8%) 
Atherectomy 5 (9.1%) 
CABG 8 (14.5%) 
Sonotherapy 1 (1.8%) 
Clinical presentation 
Angina 35 (63.6%) 
Unstable angina 6 (10.9%) 
MI 3 (5.4%) 
Asymptomatic 11 (20%) 
Average time (range) in days 279 (70-1276) 
TLR denotes target lesion revascularisation, TVR denoted target vessel revascularisation and CABG denotes 
coronary artery bypass surgery. 
†Not mutually exclusive 
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Table 8 
Second TLR 
Re-intervention after first TLR 13 (9.8%) 
Second TLR 12 (9%) 
Third TLR 1 (0.75%) 
Additional intervention during second TLR 
non TLR-TVR 1 (8.3%) 
Other re-intervention between first and second TLR 2 (16.6%) 
Angiographic appearance 
In-stent restenosis 5 (41.7%) 
Bilateral edge restenosis 1 (8.3%) 
Proximal edge restenosis 2 (16.6%) 
Distal edge restenosis 2 (16.6%) 
Total occlusion 2 (16.6%) 
Device use †
Balloon 2 (16.6%) 
Stent 3 (25%) 
CABG 4 (33.3%) 
PMR 1 (8.3%) 
Conservative (failed intervention) 2 (16.6%) 
Clinical presentation 
Angina 8 (66.7%) 
Unstable angina 4 (33.3%) 
Average time (range) in days 413 (148-835) 
TLR denotes target lesion revascularisation, TVR denoted target vessel revascularisation, CABG denotes coronary 
artery bypass surgery, PMR denotes percutaneous myocardial revascularisation. 
† Not mutually exclusive. 
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Figure 2 
MACE and re-intervention free survival curves (Kaplan-Meier) after first TLR. 
MACE denotes major adverse cardiac events, TLR denotes target lesion revascularisation. 
Figure 1 
MACE and re-intervention free survival curves up to four years (Kaplan-Meier). Since the majority of events were 
re-interventions the two curves are almost identical. These curves have four distinct segments. Up to six months a 
relapse is clearly visible followed by a sharp decrease related to the first angiographic control. From six months up 
to one year the curve remains stable. Around one year a second sharp decrease occurs related to the second 
angiographic control. From one year and up to four years the curve remains reasonably stable. MACE denotes 
major adverse cardiac events. 
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SUMMARY 
   Balloon angioplasty was the first non surgical treatment of coronary artery disease but it was 
limited by a high incidence of complications and restenosis. Stents almost eliminated the 
problem of acute complications but they also created the most challenging problem of in-stent 
restenosis. After a decade of failures to solve the problem of in-stent restenosis with 
mechanistic and pharmacological approaches intracoronary radiation therapy was introduced 
both with catheter based systems and radioactive stents. This thesis addresses issues central to 
both of these therapeutic modalities. 
Catheter based Intracoronary Radiation Therapy
   New observations such as positive remodelling, relocation of the minimal luminal diameter, 
edge restenosis and geographical miss have been associated with intracoronary brachytherapy. 
They created confusion in the interpretation of the results of the first brachytherapy trials with 
a discrepancy between a “good” angiographic outcome in the irradiated segment and a “bad” 
clinical outcome related to restenosis that developed in the adjacent segments. This systematic 
change in vessel response after vascular radiation therapy prompted us to adopt new 
quantitative angiographic approaches aimed at optimal interpretation of the results of 
brachytherapy trials. The incidence of restenosis was determined in sequentially longer 
segments termed as injured segments, effectively irradiated segments, irradiated segments and 
total analysed vessel segments. The quantitative assessment of geographical miss became also 
possible (chapter 3). This type of analysis became the gold standard for all the new therapeutic 
modalities that followed brachytherapy including drug eluting stents. 
   The Beta Radiation In Europe (BRIE) registry introduced beta radiation therapy in Europe in 
a multicenter fashion for the treatment of de-novo lesions using the non-centred 90Sr/90Y 
source. Despite the fact that it was a safety and feasibility study with a limited number of 
patients significant observations were made. First the problem of edge restenosis became 
obvious by the significant increment in binary restenosis observed between the target segment 
and the total analysed vessel segment. The second significant observation was the high 
incidence of late vessel, silent or thrombotic, occlusion. It was the first study to prove that 
prolonged use of antiplatelet medication can eliminate this problem at least in the short term. 
Finally the incompatibility of brachytherapy with the use of stents was also documented as 
expressed by the increased late loss observed in patients in whom stents were implanted 
compared to those that were treated with balloon angioplasty and brachytherapy (chapter 4). 
   By careful and detailed retrospective angiographic analysis in the same cohort of patients we 
proved that edge restenosis was related to geographical miss. This was a term invented in 
radio-oncology to define a cause of treatment failure due to low-dose, and translated in 
interventional cardiology to define those coronary segments which were injured but received 
low-dose radiation. It was the first study indicating that the elimination of geographical miss 
can improve the results of beta radiation therapy for de-novo lesions (chapter 7). Interestingly 
the randomised trial (Beta-Cath trial), conducted in USA, was launched prematurely without 
awaiting the results of our registry. The lessons learned were not awaited and taken into 
account and the trial had a negative outcome, mainly because the same mistakes in the 
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application of beta-radiation were repeated. This had a drastic negative impact in the use of 
beta radiation for primary prevention of restenosis globally. 
   This initial experience was followed by the implementation of brachytherapy in routine use 
as part of the multicenter surveillance RENO registry. Although the application of 
brachytherapy is more complex compared to standard angioplasty procedures a high success 
rate was achieved proving that its application is feasible in routine practice. However the mid 
term outcome was hampered by the delayed occurrence of major adverse cardiac events 
between 6 and 12 months after the index procedure (chapter 6). 
   The Dose Finding study was a European multicenter dose finding study with the use of the 
centered 90Yttrium source for de-novo lesions, published in the New England Journal of 
Medicine. Using the same angiographic analysis performed in the BRIE trial, no association 
between geographical miss and edge restenosis was documented in this study (chapter 8). The 
differences in the sources, the delivery devices (centering vs non-centering), and in the design 
of the studies, in addition to the small number of patients enrolled were possible causes for this 
differential outcome. For this reason the two studies were analysed together aiming to increase 
the statistical power. From this analysis it became obvious that geographical miss is strongly 
related to the development of edge restenosis particularly at the proximal edge and when 
caused by stent injury. For the first time a correlation of geographical miss with restenosis in 
the total vessel segment was documented (chapter 9). 
   Hypoechoic tissue, dubbed the ‘black hole’ was first described at 6-month follow-up after 
radioactive stenting and catheter based brachytherapy. Such tissue was difficult to diagnose 
initially due to its echolucency. Atherectomy specimens demonstrated that the echolucent 
tissue was predominantly proteoglycan with a paucity of collagenous tissue. Concern was 
raised that such a tissue may be the precursor of atherogenic tissue, explaining the late lumen 
loss (> 6 months) in patients that have undergone radioactive stenting (chapter 10). 
   In the long-term follow-up of our patients following catheter based intracoronary beta 
radiation an incremental adverse cardiac event rate was documented beyond the first 6 months 
and up to 4 years. A low dose (<18 Gy) was the most significant predictor of target lesion 
revascularisation in the long term indicating that higher doses are required. We concluded that 
brachytherapy delays rather than abolishes cardiac events in the long-term and that patients 
treated with this therapeutic modality require longer follow-up evaluation than those treated 
with standard techniques (chapter 11). Further to that, high incidence (12.3%) of late vessel 
silent and thrombotic occlusions was observed, mainly in patients treated for de-novo lesions 
with new stent implantation and more importantly, after the cessation of double antiplatelet 
medication. This was another indication of the incompatibility of intracoronary radiotherapy 
with stents for the treatment of de-novo lesions and indicative that life long treatment with 
aspirin and clopidogrel may be required in these patients to avoid this complication (chapter 
13). 
   The treatment of brachytherapy failures with conventional percutaneous techniques is safe 
and feasible, with a reasonable outcome, up to three years follow up, but a residual risk of 
development of late vessel occlusion (chapter 14). The sirolimus eluting stents were proven 
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less effective in treating brachytherapy failures compared to other clinical situations (chapter 
15). 
Radioactive stents 
   Conventional radioactive stents are limited by a high incidence of edge restenosis at 6 
months follow up. The implementation of cold-end radioactive stents did not prevent the edge-
effect. Instead of restenosis occurring outside the stent, it appeared in-stent, always at the edges 
of radiation (chapter 16). 
   Further to that although inhibition of neointimal hyperplasia was successful within the body 
of the radioactive stent at six months at the activity levels 6-12 µCi this was not the case at 1 
year. Here there was evidence of late restenosis, which was unprecedented after conventional 
stenting. Consequently there was an excessive amount of patients who underwent late 
revascularisation. (chapter 17). These observations led to the early abandonment of this 
therapeutic modality. 
   Longer term follow-up, up to 4 years, after radioactive stent implantation revealed that 
beyond the first year where high incidence of MACE and re-intervention was observed, the 
long term clinical outcome of these patients is stable, indicating that there are no irreversible 
late adverse cardiac effects related to low dose-rate intracoronary radiation therapy (chapter 18). 
CONCLUSIONS 
1. Intracoronary radiation therapy is safe and feasible in de-novo lesions, but not effective for 
the primary prevention of restenosis especially when combined with the use of stents. 
2. Edge restenosis is a major limitation of intracoronary beta radiation therapy. Geographical 
miss, defined as low dose irradiation administered in treated segments, accounts for this 
phenomenon. 
3. Intracoronary beta radiation therapy is limited by the development of delayed restenosis 
which results in an unfavourable long term clinical outcome of patients treated with this 
therapeutic modality both for the treatment of de-novo as well as restenotic lesions 
4. Repeat percutaneous intervention is a reasonable therapeutic option for patients after failed 
intracoronary beta radiation therapy. 
5. Late vessel occlusion (silent or symptomatic) is a major limitation of intracoronary beta 
radiation therapy. Increasing the duration of double antiplatelet medication simply delays 
its appearance but it cannot prevent it. Presently there is no solution to this limitation. 
6. Radioactive stents are limited by the development of edge restenosis in the short term and 
delayed restenosis in the mid term follow up. The long term clinical outcome after 
radioactive stent implantation is not associated with further irreversible clinical sequealae. 
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SAMENVATTING 
   Ballonangioplastiek was de eerste niet-chirurgische behandeling van kransslagaderziekte. 
Het werd echter beperkt door het hoge percentage complicaties en hervernauwingen 
(restenose). Door de introductie van stents verdwenen de acute complicaties, echter een nieuw 
hardnekkig probleem was het optreden van hervernauwingen in de stent. Na een decade van 
mislukte pogingen  om dit probleem op te lossen met mechanische middelen of medicijnen, 
werd de intracoronaire bestralingstherapie (brachytherapie) geintroduceerd. Dit is mogelijk 
door middel van het inbrengen van catheterbronnen of door middel van radioactieve stents. 
Bestralingstherapie met catheterbronnen 
   Nieuwe observaties zoals positieve remodelering, het zich verplaatsen van de kleinste 
vaatdiameter, hervernauwing aan de rand van het behandelde gebied (edge restenose) en 
geografisch incorrecte positionering (geographical miss) zijn in verband gebracht met 
intracoronaire bestralingstherapie. 
   Zij hebben gezorgd voor verwarring in de interpretatie van de resultaten van de eerste 
brachytherapie trials met een discrepantie tussen de goede angiografische resultaten in de 
bestraalde coronairsegmenten en de slechte klinische uitkomsten door het ontstaan van 
restenose in de aangrenzende segmenten. Deze systematische veranderingen in vaatreactie na 
bestralingstherapie, hebben ons gedwongen om nieuwe kwantitatieve angiografische 
benaderingen te kiezen om de resultaten van brachytherapie trials goed te kunnen 
interpreteren. De incidentie van restenose werd bepaald in steeds langere segmenten, n.l. de 
beschadigde segmenten, de effectief bestraalde segmenten, de bestraalde segmenten en de 
totale geanalyseerde segmenten. Hierdoor was het mogelijk een kwantitatieve analyse te 
verrichten van de geographical miss (hoofdstuk 3). Dit type analyse is de gouden standaard 
geworden voor alle nieuwe behandelmogelijkheden die geintroduceerd werden na de 
brachytherapie, inclusief de met medicijnen bedekte stents (drug-eluting stents). 
   De Beta Radiation In Europe (BRIE) studie was een multi-center registry die de beta-
bestralings therapie in Europa introduceerde voor de behandeling van de-novo vernauwingen. 
Er werd gebruik gemaakt van een niet-gecentreerde 90Sr/90Y bron. Ondanks het feit dat het 
een veiligheids- en haalbaarheids-studie was met slechts een beperkt aantal patienten, werden 
toch belangrijke observaties gedaan. Door het grote verschil in restenosepercentage van het 
behandelde segment en het totaal geanalyseerde vaatsegment werd het probleem van de edge 
stenose (aan de randen van het behandelde gebied) duidelijk. Daarnaast was het hoge 
percentage late vaatocclusie (trombotisch of asymptomatisch) opvallend. Het was de eerste 
studie die aantoonde dat langdurig gebruik van plaatjesaggregatieremmers dit probleem 
tenminste op de korte termijn kon voorkomen. 
   Tot slot bleek dat de combinatie van stenting met het gebruik van brachytherapie resulteerde 
in meer “late loss” (afname van vaatlumen diameter) dan ballonangiopastiek en 
brachytherapie (hoofdstuk 4).
   Door middel van gedetailleerde retrospectieve angiografische analyse in hetzelfde cohort 
patienten hebben we aangetoond dat “edge restenosis” gerelateerd was aan “geographical 
miss”.  Deze term werd voor het eerst gebruikt in de radio-oncologie om het falen van 
therapie door te lage dosering te beschrijven. In de interventiecardiologie werd deze term 
geintroduceerd om die coronaire segmenten te beschrijven, die beschadigd werden door de 
ballon maar slechts een lage doses bestraling ontvingen. Het was de eerste studie die 
aanwijzigingen opleverde dat eliminatie van “geographical miss”de resultaten van beta-
256
Chapter 19
radiatie therapie kan verbeteren voor de-novo stenosen (hoofdstuk 7). Het is opvallend dat de 
gerandomiseerde trial ( Beta-Cath trial), uitgevoerd in de USA, gestart werd voordat de 
resultaten van onze registry bekend waren. De geleerde lessen werden niet afgewacht en 
geimplementeerd met als gevolg een negatieve uitkomst van de trial. Dit had een dramatisch 
negatief effect op het gebruik van beta-straling voor primaire preventie van restenose 
wereldwijd. 
   Deze eerste ervaring werd gevolgd door het routinegebruik van brachytherapie in het kader 
van de multicenter observationele RENO registry. Hoewel het gebruik van brachytherapie 
ingewikkelder is dan standaard behandelingen werd een hoog succespercentage gehaald, 
hiermee bewijzend dat gebruik van brachytherapie in de praktijk haalbaar is. Helaas bleken de 
middellange termijnresultaten minder gunstig door het verlate optreden van “ major adverse 
cardiac events (MACE)“ tussen 6 en 12 maanden na de interventie (hoofdstuk 6).
   De Dose Finding studie was een Europeese multicenter studie waarin gebruik gemaakt werd 
van een gecentreerde 90 Yttrium bron voor de-novo lesies, gepubliceerd in de NEJM. Gebruik 
makend van dezelfde angiografische analyse als in de BRIE trial, werd geen verband 
gevonden tussen “geographical miss”en “edge restenosis” in deze studie (hoofdstuk 8). De 
verschillen in de bronnen, de transportcatheters (gecentreerd vs. niet-gecentreerd), het 
studiedesign tezamen met het geringe aantal  geincludeerde patienten waren de mogelijke 
oorzaken voor deze andere uitkomst. Wegens deze discrepantie werd een analyse uitgevoerd 
van de twee studies samen om de statistieke power te vergroten. In deze analyse bleek een 
sterke correlatie tussen “geographical miss” en “edge restenosis”, met name ter hoogte van de 
proximale edge en wanneer gerelateerd aan beschadiging door een stent. Voor het eerst werd 
een correlatie gedocumenteerd tussen “geographical miss”en restenose in het  totale 
vaatsegment (hoofdstuk 9).
   Echolucent weefsel, waaraan de naam “black hole” gegeven werd, werd voor het eerst 
beschreven tijdens analyse van de 6 maanden follow-up intravasculaire echo van patienten die 
behandeld waren met radioactieve stents of brachytherapie met catheterbronnen. Wegens de 
echolucentie was dit weefsel in het begin moeilijk te karakteriseren. Uit onderzoek van  
weefsel verkregen met atherectomie  bleek dat dit weefsel vooral bestond uit proteoglycanen 
met een geringe hoeveelheid collageen weefsel. Er ontstond de vrees dat dergelijk weefsel de 
voorloper zou kunnen zijn van atherogeen weefsel. Dit zou een verklaring kunen zijn voor het 
onstaan van de late hervernauwing (late lumen loss) meer dan 6 maanden na radioactieve 
stenting (hoofdstuk 10). 
   De lange-termijn follow-up van onze patienten na behandeling met intracoronaire beta-
stralingsbronnen liet een toename zien van de MACE tussen de eerste 6 maanden en 4 jaar 
follow-up. Lage stralingsdosis (< 18 Gy) was de belangrijkste voorspeller voor target lesie 
revascularisatie op lange termijn, implicerend dat hogere doses noodzakelijk zijn. We 
concludeerden dat brachytherapie “cardiac events”niet voorkomt echter slechts uitstelt. Dit 
impliceert dat deze patienten langer vervolgd dienen te worden dan patienten die met 
standaardtechnieken behandeld worden (hoofdstuk 11). Bovendien werd een hoog percentage 
(12.3%) late stille en trombotische occlusies gezien, m.n. in patienten die behandeld werden 
wegens de-novo lesies met een stent en vooral na het stoppen van dubbele 
plaatjesaggregatieremmende medicatie. Dit was weer een aanwijzing dat de combinatie van 
brachytherapie met implantatie van stents niet verstandig is voor de behandeling van de-novo 
lesies en mogelijk zouden deze patienten levenslang behandeld dienen te worden met aspirine 
en clopidogrel om deze complicatie te voorkomen (hoofdstuk 13).
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   De behandeling van gefaalde brachytherapie met conventionele interventietechnieken is 
veilig en mogelijk, met een redelijke uitkomst tot 3 jaar follow-up, echter met een 
persisterend risiko op een late vaatafsluiting (hoofdtuk 14). De sirolimus-eluting stents (SES) 
bleken minder effectief bij deze patienten met gefaalde brachytherapie dan in andere 
patientengroepen om restenose te voorkomen (hoofdstuk 15). 
Radioactieve stents 
   Gebruik van conventionele radioactieve stents resulteerde in een hoog percentage edge 
restenose na 6 maanden follow-up. Het gebruik van “cold-end”radioactieve stents voorkwam 
dit edge-effect niet. In plaats van net buiten de stent ontstond de restenose nu in de stent, altijd 
op de rand van het bestraalde gebied.(hoofdstuk 16).
   Hoewel er in stents met een stralingsactiviteit van 6-12 mcCi een reductie van neointima 
hyperplasie aanwezig was na 6 maanden, bleek dit effect niet meer aanwezig na 1 jaar. Deze 
late restenose werd nooit gezien na implantatie van conventionele niet-radioactieve stents. Het 
gevolg hiervan was dat een groot aantal patienten een late revascularisatie onderging. 
(hoofdstuk 17). Dit leidde al vroeg tot het stoppen van het gebruik van deze stents. 
   Langere follow-up tot 4 jaar liet zien dat na het eerste jaar met een hoge incidentie van 
MACE en reinterventie, de klinische uitkomst stabiel is. Hieruit kan geconcludeerd worden 
dat er geen irreversibele late negatieve effecten zijn, gerelateerd aan lage doses intracoronaire 
bestralingstherapie (hoofdstuk 18).
CONCLUSIES 
1. Intracoronaire bestralingstherapie is veilig en mogelijk voor de-novo lesies, maar niet 
effectief in de primaire preventie van restenose, met name wanneer gecombineerd met 
stents.
2. Edge restenose is de meest belangrijke beperking van intracoronaire beta-
bestralingstherapie. Geographical miss, gedefinieerd als lage dosis straling op 
behandelde segmenten, is verantwoordelijk voor dit fenomeen.
3. Het bebruik van intracoronaire beta-bestralingstherapie wordt beperkt door het 
optreden van late restenose. Dit resulteert in een ongunstige lange-termijn uitkomst 
zowel voor de-novo als voor restenose lesies.
4. Herhaalde percutane interventie is een redelijke therapeutische optie voor patienten 
met gefaalde bestralingstherapie.
5. Late vaatocclusie (stil of symptomatisch) is de belangrijkste beperking van 
intracoronaire beta bestralingstherapie. De lange termijn toediening van dubbele 
plaatjesaggregatieremmende medicatie vertraagt, maar kan deze occlusie niet 
voorkomen. Op dit moment is er geen oplossing voor dit probleem.
6. Het gebruik van radioactieve stents wordt beperkt door edge restenose op korte termijn 
en verlate restenose op de middellange termijn. De lange termijn klinische uitkomst 
wordt niet verder negatief beinvloed door irreversibele klinische events. 
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